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Abstract 
The research presented in this thesis aims to assess the capacity of metal organic frameworks 
for potential applications as drug delivery systems and novel vaccine adjuvants. 
The opening chapter (Chapter 1) provides a reader with a background to the field, metal 
organic frameworks synthesis routes and their potential applications in medicine and insight 
into the basics of immunology and biological assays as well as the anti-cancer drugs 
mechanisms and how it can be used to target the tumour cells. 
Chapter 3 describes the experimental techniques used in this research combining biological 
with chemical testing. 
Investigation of Zr-MOFs (UiO66 and UiO66-NH2) and CPO – 27 (CPO Mg and CPO Ni) for 
their potential application as drug delivery systems for cisplatin is presented and compared in 
Chapter 4, as well as two different drug incorporation techniques (conjugation and physical 
encapsulation) in the case of UiO66-NH2. The route proved to be more efficient when 
compared with encapsulation for the same MOF, and overall the most promising candidate for 
a drug delivery system for cisplatin, due to its large pores, was UiO66. 
 
Chapter 5 focuses on the potential application of Zr-MOFs and CPO-27 (Mg and Ni) as a 
drug delivery system for 5-Fluorouracil, a drug which because of its sparse solubility in water 
is challenging when it comes to its administration in the human body. Chapter 7 investigates 
the possibility to design multiple drug delivery systems utilising MOFs that contain cisplatin 
and fluorouracil in their framework, loading them with nitric oxide to increase the anti-cancer 
action and also to prevent thrombosis that may pose a danger to patients who undergo anti-
cancer therapies. Chapter 6 describes the new concept of investigating MOFs (Zr-MOFs and 
Al-MOFs) as potential candidates as vaccine adjuvants. The research concluded that the 
performance of Al-MOFs, was better when compared to commercially available adjuvants. 
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Chapter 1. Introduction 
1.1. Metal-organic frameworks for biological applications 
The development of new materials is crucial for industry as well as for everyday 
life. Metal–organic frameworks (MOFs) are a relatively new class of materials 
that offers great potential in many applications
1-3
 e.g. in gas storage
4-11
, gas 
purification and separation
12
, heterogeneous catalysis
13-15
, imaging
16-18
, 
luminescence
19
 and biomedicine
20-24
. For more than 20 years, MOFs have been a 
hot topic in terms of their superb properties: large surface areas with pore sizes 
that can be adjusted depending on the usage and adsorption capacities as well as 
the fact that their density is low
25, 26
. These properties play a great role in the 
applications in catalysis, gas storage and gas separation. Their exceptional 
properties (e.g. swelling of the crystallographic network in the presence of 
different guest molecules
26
), are very interesting for some applications in which 
zeolites cannot be used and offer easy and non-complicated synthesis. In 
comparison with the zeolite materials, an inorganic or organic template must be 
used and its removal may cause the structure to collapse
1
. In contrast to zeolites, 
MOFs are easier to synthesise and do not require the generation of a template, as 
they have an organic linker and a metal in their structure. It is important to 
mention that a lot of names have been given to these porous materials (e.g. porous 
coordination networks, porous coordination polymers, metal-organic frameworks 
etc.). These materials are highly attractive to research as well as the industrial 
world and the number of publications is remarkable
1, 2
. Especially important 
applications are in gas storage, drug storage and delivery
27
. There is a question 
left to answer, how many MOFs structures are there. This depends on how the 
MOF is defined. Well, if we take the provisional recommendations on MOF 
terminology from IUPAC that says a MOF is a coordination polymer with an 
open framework containing potential voids
28
 then our search will be based on a 
transition metal that is bonded to a nitrogen or an oxygen via a polymeric bond. It 
does not require a 3D framework only that it will be repeated. According to 
CCDC data base, there are 38 062 structures up to the 1
st
 of Dec 2012
29
.  
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Number of publications regarding MOFs sky-rocketed over the years as depicted 
in Figure 1-1 below. 
 
Figure 1-1 Number of publications on MOFs
30
. Source: Web Science. 
Discovered by Robson in 1989
31
, metal-organic frameworks are a relatively 
young group of advanced porous materials that consists of a metal ion, the 
inorganic part and the organic linker. The number of possible combinations is 
infinite. The most commonly used linkers are depicted in the Figure 1-2 below. 
 
Figure 1-2 Some example of linkers that are used to synthesise MOFs. 4,4-bipyridine 
(1),1,3,5-Tris(4-pyridyl)-2,4,6-triazine (2), hexamethylenetetramine (3), tetra(4-
cyanophenyl)methane (4). Terephthalic acid BDC 1,4- benzene dicarboxylate (5), 
benzene-1,3,5-tricarboxylic acid (6), 1,3,5-Tris(4-carboxyphenyl)benzene (7), 
Hexamethylenetetracarboxylic acid (8), 4-Pyridinecarboxylic acid (9)
2
. 
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One of the key properties of MOFs is the tuneable size of the pores that can 
sometimes adjust their porosity upon the loading with gases or molecules; or also 
as easily by exchanging the metal atom or the linker forming new structures
20
. A 
quite interesting property for MOFs as recently reported, is the so-called 
reversible breathing or swelling effect, which gives rise to flexible pore size 
depending on the guest molecules hosted by the porous structure
26, 32
. To give an 
example, the cell volume of the dry structures increases by 50-230% in case of the 
MIL-53 (Cr) and (Fe) isoreticular family
33
. The term isoreticular was introduced 
by Yaghi
34
 to describe the structure formed with “the same preferred topology” 
with the only difference in the metal ion and the size of the links. In the same 
framework it is possible to exchange the metal ions and keep the topology of the 
material the same. This is not the case with the rigid bonds found in zeolites. The 
cages and tunnels of MOFs are larger and thus, so are the specific surface areas of 
500 – 6000 m2/g BET35 or even 6240 reported for MIL-20036, with low densities, 
generally 0.2-1 g/cm
3
 (density of Li metal 0.56 g/cm
3
)
37
 and with the 
exceptionally low density of 0.126 g/cm
3
 and big pores 8–43.2 Å21, 22, 30, 33, 34 
recently reported for MOF-399
34
. Just recently, the reported surface areas of 
MOFs are about 10000 m
2
/g which makes them the materials for special missions 
and in this matter superior to zeolites and carbons
38
. These features give MOFs an 
edge in a variety of applications such as gas storage, catalysis, separation and 
recently drug and bioactive gases loading with a controllable release
39, 40
. Also, 
thanks to the open metal sites of the inorganic part of the MOF, bioactive gases 
such as NO, CO and H2S can be successfully loaded inside the molecule as a 
result of their chemical nature
41
.  
For bio-applications, the following criteria must be fulfilled – the MOFs should be 
non-toxic, which requires both the linker and the metal to be inert; the release of 
the drug or the bioactive gas must be controllable; and also the excretion of the 
MOF after the drug administration should be possible
24
. That is why the 
endogeneous linker is the most preferable candidate, as it could have bioactive 
functionality in the human body. What is meant by “endogeneous” is the fact of 
being the part of or produced by the human body. An example of such a linker is 
Niacin (vitamin B3) that together with non-toxic iron molecules (50% of lethal 
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dose LD50=30g/kg) builds BioMIL-1 (Figure 1-5). Nicotinic acid that controls the 
blood pressure and can control cholesterol and has antilipemic properties
42
. 
Figure 1-3 gives an overview how we cluster MOFs, and Figure 1-4 shows the 
variety of MOF structures comprising of endogeneous linker, that may make them 
more biocompatible. Coordination polymer is the most general term and MOFs 
are best described as 3-dimentional coordination networks, IUPAC set the 
recommendations for nomenclature of coordination polymers and MOFs
43
. 
 
Figure 1-3 Variety of the coordination polymer, the 3D ones are referred as 
MOFs
44
 
 
Figure 1-4 View of some of the MOFs structures based on the endogenous 
linkers. The colourful polyhedra are metal ions and carbon is in black
20
. 
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Figure 1-5 A view of some MOFs with endogenous linkers. Here from the 
left: CPO-27 (Zn, Mg), MIL-100 (Fe), Bio-MOF-1
20
. 
1.2. Nitric oxide – a friend or a foe? 
Nitric oxide is a very interesting molecule thanks to its antithrombotic and 
antibacterial properties, the discovery of which brought a Nobel Prize in 1998 for 
Robert F Furchgott, Louis J Ignarro and Ferid Murad. It became the “molecule of 
the year” six years earlier after the discovery of a wide spectrum of its bio-
properties like relaxation of the smooth muscle, prevention of platelet clotting and 
neurotransmission
45
. The nitric oxide molecule has got 11 valance electrons, in 
which 5 electrons of Nitrogen [2s
2
2p
3
] and 6 of oxygen [2s
2
p
4
] are responsible for 
bonding that emerges from sp-orbitals mixing leading to π-bonding. Figure 1-6 
illustrates a schematic diagram of the molecular orbital in nitric oxide. The bond 
order defined as the difference between bonding electrons and anti-bonding 
electrons divided by two, for nitric oxide is 2.5. 
 
Figure 1-6 Molecular orbital diagram of nitric oxide
46
. 
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This free radical molecule (it has an unpaired electron in the 2π orbital) can 
interact with transition metals and an unpaired electron could accept an electron 
and thus acting as an anti-oxidant
47
. NO is an important gas-transmitter in a human 
body and has a positive impact on blood platelet adhesion and cell division and is 
responsible for vasodilation (relaxation of the blood vessels) and control of blood 
pressure
48, 49
. It has been stipulated that  biologically active amount of nitric oxide 
for certain applications may vary and for example to offer anti-thrombosis action, 
only a small dose is necessary (4 ppm), however, for anti-bacterial protection - a 10 
times higher dose of nitric oxide is required50. Antibacterial, wound healing and anti-
blood-clotting properties of NO have already been tested in vitro and in vivo to assess 
its efficacy51. Several studies shown that NO assists with wound healing and 
prevents forming of the blood clots
35, 50, 51
. NO – donor therapy is based on the 
generation of the accurate amount of NO in the right spot in the human body
52
. 
Not only have MOFs recently been used for NO delivery but also zeolites
53
 and 
functionalised nanoparticle silica
54
 and polymers
55, 56
. MOFs can deliver pure gas 
without any other oxides and the release of the gas can be controlled and triggered 
by exposure of the MOF-powder to water. For example CPO-27: Ni showed the 
exceptional uptake of NO up to 7 mmol/g, prolonged release under H2O over time 
up to 3 weeks and after 2 years the loaded material showed no loss in NO 
storage
24, 41
, which compared to HKUST-1 of 2 μmol/g at 298 K, gives the value 
2500 times higher. This level of loading (HKUST-1) is still sufficient for 
biological applications, but for antibacterial would not be enough
57
. The 
mechanism of action is still unknown and the NO dose that would suppress the 
tumour growth must be yet identified, it is stipulated that above certain threshold 
NO is carcinogenic
58
. 
Not only anti-thrombotic and anti-bacterial properties of nitric oxide are of 
interest but also its potential application as anti-cancer agent that may show higher 
efficacy when compared to conventional therapies involving anti-cancer drugs
59
. 
In the human body, nitric oxide is produced by nitric oxide synthases (NOSs), a 
family of enzymes with catalytic properties, in the process of L-Arginine 
oxidation. This biological reaction needs to be supported by NADPH enzyme 
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complex (nicotinamide adenine dinucleotide phosphate-oxidase) and oxygen and 
as products, generates L-citrulline and NO
60
.  
There are three forms of nitric oxide synthase enzyme: NOS-II, whose the main 
function is cytotoxicity and defence of the host, and its primary site of action is 
either in macrophages or tumour cells, NOS-I responsible for 
neurotransmission/relaxation of smooth muscle and finally NOS-III, in charge of 
smooth muscle proliferation control and minimising clotting of blood platelets. 
NOS-II action can be regulated when stimulated by variety of cytokines and 
ligands: TNF-α, interferon, IL-1 and endotoxins61 and is induced in different cell 
types for example macrophages and dendritic cells
62
.  
Some research conducted, showed that NO can cause apoptotic death of cancer 
cell at elevated concentrations
63
 or can lead to suppression of tumour early 
development
64
 and also of its growth and metastasis
65
 
66
, which could potentially 
open another avenue for therapies other than radio – and chemotherapies45. 
1.3. Anticancer drugs and drug delivery systems. 
The interest in pharmaceuticals and therapies is seeing a substantial growth every 
year with a lot of new drugs being approved by FDA (Food and Drug 
Administration). Despite the fact that research is aided with computational 
chemistry and biology helping in drug discovery immensely, drug development 
that leads to successful commercialization is still a very time-consuming and 
expensive process, taking between 10-15 years of development, clinical trials and 
ca. $1.8 bn of cost per drug before it lands on the shelves of a drug store
67, 68
. 
Figure 1-7 depicts the total market sales in billion of $ and its growth over years. 
The trend shows that starting from 2012 there is a growth potential over the last 2 
years. Table 1-1 depicts the top 5 drugs that had quite an influence on the sales 
revenues of the companies who made discoveries, however, the expiration dates 
of patents is alarming, which is pushing the companies to maximize their revenues 
within the time frame of an existing patent. As it is really tricky and time-
consuming to successfully come up with new drugs every time, there is a 
paradigm that by preparing the formulations of these drugs and working on drug 
delivery systems instead, would result in therapeutics of much higher efficacy. 
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Figure 1-7 Total market sales in pharmaceuticals/drugs sector according to 
IMS Health (American company providing information services and 
technology for the healthcare industry). 
 
Table 1-1 Top 5 Medicines worldwide and the percentage of company sales as 
of 2010 that it generated
68
. *)the patent expired in 2010 in the US and in 
Europe in 2012. 
The application of biocompatible and non-toxic polymers has contributed a lot to 
modern medicine as it impacts on a vast field of biosciences including the areas 
such as: tissue engineering, diagnostics and therapeutic strategies. Different 
naturally-occurring and synthetic polymers are used to develop state-of-the-art 
drug delivery systems, just to mention a few: chitosan, alginate, gelatin, dextran, 
albumin. These polymers may help chemotherapy be more selective as it offers a 
secure platform for controlled release that does not lead to overdose in some 
human body regions
67
. Metal organic frameworks have found wide applications in 
many fields, but there is still one which needs to be more developed and further 
research should be carried out in order to give satisfying results – it is the bio-
application of MOFs
27
. There is a challenge to navigate the cargo in the region 
invaded by cancer by using different targets in the cancer tissue
69
. These could be 
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Lipitor Pfizer 12657 22.8 2011
Plavix Sanofi-Aventis/BMS 8817 17.3 2012
Seretide GSK 8469 25.2 2013
Nexium Astra Zeneca 8362 23.5 2014
Seroquel Astra Zeneca 6816 19.2 2012*
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the changed mitochondria
70
, leaky cellular walls and lower pH values in the 
tumour tissue. Normal physiological conditions have a pH value of 7.2-7.4, 
however, it becomes more acidic (5.0-6.5) in the extracellular space in the 
endosomes and drops further to pH 4.0 in lysosomes (primary and secondary), in 
the tumour cells the pH values are lower by 0.5-1.0 units than in the healthy tissue 
as it is reported by non-invasive techniques
55, 71
. That feature could be used for 
selective targeting. 
 
Figure 1-8 Endocytic pathway with different pH regions (left). To the right, 
the scheme that illustrates the normal cell and the one touched by the cancer 
with the possible ways for the drug delivery system migration shown 
55
. 
As of now, only between 10-100 ppm of administered antibodies may reach their 
targets in vivo
72
. Therapeutics that are available now, are quite limited with their 
non-selective distribution in the human body that leads to high administration 
doses, fast excretion, poor pharmacokinetics (very fast release also called “burst 
effect” that may lead to the overdose at certain spots) and side effects which in 
case of anti-cancerous drugs might be very severe causing damage to the healthy 
cells
73, 74
. Nanotechnology offers some ways to overcome these challenges and 
has received a lot of attention in the past 20 years
72
. The nano-carriers such as 
polymeric structures, micelles, liposomes, iron oxide and gold encapsulated with a 
drug have been used for advanced therapies e.g. Abraxane and Doxil
21
. Research 
focused on encapsulation Fe3O4 nano-carriers with cisplatin and coated with 
Poly(D,L-Lactide) showed the ability of iron oxide to absorb the drug and release 
it within 70 hours from activation in PBS (phosphate buffer saline)
75
. Only 
recently MOFs, thanks to their interesting properties – large pores and porosity 
with impressive surface areas (BET) up to 6240 m
2
/g
36
 (MOF 210) or reported 
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7140 m
2
/g for NU-110
76
 (NU – Northwestern University), theoretically predicted 
to go as high as 10 000 m
2
/g or greater
77, 78
 and coordinative unsaturated sites 
upon dehydration, has turned the research world into converting them into drug 
delivery systems.  
MOFs offer the possibility to incorporate the Mn or Gd cations in the framework 
that can work as imaging agent with an encapsulated cargo that the agent will 
enable tracing to allow for a better understanding of the targeting and delivery 
mechanisms. The Lin Group developed imaging agents – a nano-MOF containing 
Manganese with a linker terephthalic acid (BDC) or trimesic acid (BTC)
17
.  
A gas or small molecules can serve as a drug. Some of the gases are highly toxic 
in high amounts but paradoxically when dosed in a controllable way, are crucial 
for life processes: NO, CO and H2S. The most recognised for its vasodilating 
properties is nitric oxide but the two other gases recently have caught interest with 
more research done on their controlled delivery
35
. The pores of MOFs are big 
enough to host small molecules of drugs, e.g. CPO-27 Ni (11Å). The presence of 
nickel makes the entire structure quite toxic for bioaplications
23
 , however, it can 
still be used for anti-tumour drugs as they are very toxic
20. Christian Serre’s group 
tested their MIL materials family (MIL-53, 88A, 88B, 89, 100, 101-NH2) for drug 
loading: doxorubicin, cidovir, busulfan, caffeine, azidothimidine triphosphate 
(antiviral for HIV)
79
. For better drug storage, derivatives of 2,5- 
dihydroxyterephthalic acid linkers were used that introduced different functional 
groups in the framework which had great impact on the size of pores leading to 
the formation of flexible iron (III) dicarboxylates
22, 26, 33
. This group also 
accomplished to synthesize a BioMOF called BioMIL based on a bioactive linker 
which is nicotinic acid and a non-toxic iron (LD50 = 30g/kg). It is important to 
mention that nicotinic acid is responsible in the human body for lowering LDL-
cholesterol and triglyceride levels and keeping HDL-cholesterol levels high and 
also shows antibacterial and vasodilating properties
42
, and is a precursor for 
NADH coenzyme in living cells. Some other MOFs based on the nicotinic acid as 
a linker were already reported but they all had a toxic cation in the framework 
(Cu)
80
. 
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The anti-cancer drugs can be simply divided into 4 groups in regards with the 
mechanism they present to fight the cancer cells, these are alkylating agents, 
antimetabolites, anthracyclines and hormones. In this thesis, MOFs were 
researched as potential drug delivery systems for two drugs representing 
alkylating agent group – cisplatin and antimetabolites – 5- fluorouracil. 
Alkylating agents have chemical groups capable of forming a covalent bond with 
nucleophilic substances in the cell, and such a substance is DNA. Nitrogen in 
guanine in the position N7 is strongly nucleophilic and as such a perfect target for 
alkylation, nitrogen molecules in adenine (N1, N3 positions) and in cytosine (N3) 
may also be a target of attack for the alkylating agents. These can bond in the 
intra- or inter- chain positions, leading to cross-linking, which disturbs 
transcription and replication of DNA, and ideally, the DNA-chain of the tumour 
cells. In this group, we can list the following agents cisplatin, carboplatin, 
busulfan hydroxycarbamide and carmustine
81
.  
1.3.1. Cisplatin 
Already in 1968
82
 cytotoxicity against cancerous cells presented by cisplatin 
was recognized and in numerous intensive research projects over subsequent years 
showed efficacy against several cancers in clinical trials
83
. Finally in 1978, it was 
approved by the FDA, although it  has been known since 1845
74
 in the world of 
chemistry. The mechanism of action of cisplatin is based on forming intrastrand 
and interstrand cross-links with nucleic acids, which causes damage because by its 
binding to the bases of DNA, the multiplication of DNA is impaired, leading to 
cell death (apoptosis) caused by inability of DNA to proliferate
84, 85
.  
Looking at the variety of cancers where cisplatin is used as a drug -  the treatment 
of head, neck, ovarian, cervical
86
, testicle, breast and bladder tumours
87-89
, one can 
state that cisplatin is the most commonly used anti-cancer drug. There are some 
shortcomings of cisplatin therapy, as the drug affects all cells because it cannot 
distinguish between cancerous and healthy cells. Even though its efficacy is quite 
high, it comes with many side-effects: these include nephrotoxicity (kidneys 
damage) and neurotoxicity (toxicity in the nervous system); drug resistance of 
tumours also develops over time as well as may cause an acute thrombosis in 
patients receiving chemotherapy based on cisplatin
90, 91
. As a result, research is 
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ongoing in order to circumvent the drug’s side-effects by introducing new ways in 
which cisplatin is delivered
88, 92, 93
. This is achieved by the use of a variety of drug 
delivery systems, designed to release the drug inside the tumour cell and to leave 
healthy cells untouched. Carbon nanotubes
94
, liposomes
88, 95-99
, polymers
88, 100
 and 
nano-sized metal phosphates
87
, oxides
75
 and hyaluronic acid nanoparticles
101
 are 
all under investigation. Recently MOFs have also begun to be explored in this 
regard
23, 102, 103
.  
Below, in the Figure 1-9, reader may find the representation of different 
derivatives of cisplatin that will follow the same mechanism of action in the 
tumour cells, namely intrastrand cross-linking of DNA.  
 
Figure 1-9 Different derivative of cisplatin reproduced from
104
 (left) and
74
 
(right). 
Only cis-platin is active in cancer treatment, as its geometric isomer trans-platin 
did not show this feature in the clinical trials
74
. What makes the drug efficient, it 
is its affinity to DNA which acts here as a target to which cisplatin is bound which 
causes damage to the helical structure followed by the inability for further 
replication and transcription. That leads to the cell apoptosis
104
. Recently it was 
discovered that cisplatin does not enter the tumour cells by passive diffusion but a 
copper transporter CTR1, which is a cell membrane protein and influences 
cisplatin uptake. At the same time cisplatin causes degradation of CTR1 and in 
this way introduces a limitation for its accumulation in the cancer tissue. The 
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resistance of the tumour cell against cisplatin that occurs over the course of time is 
linked to lack of the membrane protein in the cancer cell
105
.  
1.3.2. 5-Fluorouracil 
Fluorouracil (5-FU) is an example of another mechanism of action which aims to 
replace uracil in purine biosynthesis. In contrary to uracil, 5-FU cannot be 
converted to thymidylate and because of this blocks DNA synthesis and cell 
proliferation. 5-FU is widely used mainly in topical applications to treat solid 
tumours, however, some drawbacks e.g. variable efficacy and toxicity limit its 
usage and FDA recommends not to administer 5-FU to patients with 
dihydropyrimidine dehydroglenase deficiency (DPD metabolic disorder).  
The structure of 5-FU is depicted in Figure 1-10. 
 
Figure 1-10 Structure of Fluorouracil, which is a derivative of uracil. 
The drug was patented by Charles Heidelberg, who carried out research that 
showed that 5-FU was capable to stop the propagation of cancer in mice
106
.  
5-Fluorouracil is a hydrophilic drug what makes it challenging for preparations of 
formulations as its solubility in water is very sparse, and can only be enhanced in 
acidic or basic environments. It is though widely used as a part of therapies to 
treat colorectal, bladder, head and neck and breast cancers
107, 108
. Likewise 
cisplatin, therapies comprising 5-FU are toxic to the healthy cells and the short 
half-life (16 min) makes the therapy not very long-lasting with repetitions of 
administered doses being necessary and as such these have to be well adjusted 
depending on the individual
109
.  
A new Zn-MOF (Zn-BDC) was reportedly synthesised of a surface area of  
600 m
2
/g that was then used for 5-FU encapsulation with the loading achieved at 
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the level of 0.42 g/g. 5-FU release was monitored
110
. This piece of research did 
not provide any information on the drug delivery system efficacy in the in vitro 
environment. ZSM-5 zeolite has been recently investigated for its potential 
application as a drug delivery system for 5-FU
111
. 
Another approach has been presented by researcher at School of Pharmacy, UCL, 
to encapsulate 5-FU, by applying electro-spinning method. This technique 
involved a preparation of a formulation for production of electrospun fibres
112
 that 
contained 5-FU. It has been shown that pH values had tremendous effect on the 
speed of drug release and at pH =1, between 40% and 80% of cargo was released 
and only increasing the pH value to 6.8 resulted in 100% release of the drug. The 
ideal drug delivery system would keep the cargo intact at pH 7 and only allow for 
a release at lower pH values to target the areas touched by cancer. 
1.4. Adjuvants – integral part of every vaccine 
First vaccination procedure that was ever reported was the one performed by 
Edward Jenner and this was 220 years ago. He realized that people whose job was 
to milk cows, were not vulnerable to smallpox. Based on this observation he 
inoculated a boy with a cowpox and as a result this gave him immune protection 
against smallpox
113, 114
. Years later, it has been researched that the protection 
against disease can be provided by vaccination in a form of administration live-
attenuated virus, inactivated virus or a vaccines. The latter was the safest way of 
offering a full protection, however the immune response induced was quite 
insignificant. Live attenuated vaccines have a live form of the pathogen that was 
modified so that it is in its non-virulent form, which can still multiply in the living 
organism without causing the full form of the disease. The immune response is 
very strong and the lifetime immunity to the virus can be achieved by 
administration of only two doses (rubella, measles)
115, 116
. However, there is a risk 
associated with this type of the vaccines as the pathogen can reverse to its virulent 
form which would pose a danger of the infection with the disease following 
vaccination. The other possibility is to administer the inactivated vaccine, in 
which the pathogen is dead and is unable to reproduce in the body as once dead, it 
cannot reinstate its virulence. Inactivation is realized by use of heat, radiation or 
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chemicals to inactivate the pathogen and it is of great importance to monitor such 
a process to make sure that no live strains of pathogen was left in the vaccine. As 
a result, such vaccines are much safer than live attenuated ones and just to name 
an example is Salk polio vaccine. This type, however, can only induce relatively 
weak immune response when compared to the former type, and in order to 
achieve a long-term immune protection an administration of multiple doses is 
necessary
117
.  
Subunit vaccines contain only a part from the antigen, such as sugar of a virus 
which would be something the immune system would respond to and record the 
immune event. The antigen is either modified in a chemical or mechanical way, 
that damages the cellular structure or by genetic engineering where the genomic 
material has been removed from the pathogen
118
. Administration of such a non-
virulent vaccines does not cause any infection in the organism and can be given to 
patients with HIV or these undergoing chemotherapy. It is worth noting that 
subunit vaccines as well as inactivated ones, to be efficient need to paired with an 
adjuvant, which is a second component added to the formulation containing 
antigen. “Adiuvare”, the verb in Latin means to help or to aid and is where the 
word adjuvant originates from. It was observed and then reported by Alexander 
Glenny nearly 100 years ago, that the antigen (toxoid) that was precipitated with 
aluminium potassium sulfate was able to stimulate much stronger immune 
response than the antigen itself and resulted in much higher number of antibodies 
produced
119
. This experiment was performed “in vivo” on guinea pigs and proved 
that aluminum is capable of working as a powerful adjuvant and remained for 
many years the only vaccine adjuvant one approved by FDA in the USA and 
referred as alum and by far most widely used. Its role is to enhance the immune 
response, by stimulating the production of the antibodies that was initially 
triggered by the administration of antigen and would not reach the desired 
threshold to be effective
120
. It has been researched that Al-containing adjuvants 
induce strong immune responses
121
. So far, there is no explanation to the 
mechanism of such action and trials are made in order to develop other adjuvants 
that would contain other metals, or salts like calcium phosphate, which is used in 
diaphtheria/pertussis/tetanus vaccines
122
.  
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Special cells like dendritic, macrophages, B cells and T cells are involved in 
creating an immune response. Dendritic Cell (DC) presents antigen to T cells 
which activates a specific immune response that would be conveyed by a T cell 
(pre-programmed by DC) to this particular pathogen that the antigen came from. 
What happens is the following: if an antigen is detected in the body, dendritic cell 
will travel to the lymph node in order to present the antigen to the T cell. 
Activated T cells secrete cytokines and chemokines to recruit other immune cells 
to fight the pathogen. By monitoring the response from the stimulated DCs, we 
can predict how effectively DCs will activate T cells to respond to pathogen. T 
cells assist other cells by speeding up the process of B cell-maturation, and are 
called a T-helper (CD4+) and ascribed as Th. In an event of infection, the T and B 
cells are “naïve”, meaning that they are not efficient to fight the infection and 
need to adapt numerous cell proliferations must occur in the body to produce a 
certain number of effectively working cells, which are able to produce cytokines 
(protein mediators) or differentiate to cells able to secrete antibody to fight the 
infection (B cells). The other type of T cells, CD8+ (cytotoxic T lymphocytes) 
will act as a warhead to destroy infected cells, as well as tumour cells. The last 
type of cells, important for this thesis are the B cells, which are able to produce 
antibodies that are specific to the pathogen.  
Generally, vaccine will stimulate one or both immune responses, recognized as 
Th1 and Th2. Th2 is observed during cell stimulation by alum – coordination of 
humoral response which is responsible for production of antibodies, and very 
common in case of bacterial infections 
123
. Th1 response is cell-mediated and 
follows through activation of cytokines, which is promoting viral termination. 
This kind of response involves mainly T cells that displays major 
histocompatibility complex including cells infected by pathogens, tumour cells or 
transplanted cells. The function of the vaccine is to create a supply of specific B 
and T cells with the memory to the pathogen causing a disease, but in this case 
without infecting the body. Th1 cells synthesise cytokines: IL-2, IL-18, IFN-γ also 
promote cellular defence and inflammatory response. Th2 cells secrete the 
cytokines: IL-4, IL-5, IL-6 and IL-13 as well as TNF-α (tumour necrosis factor). 
The perfect adjuvant would be able to activate T cells to give rise to Th1 and Th2 
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responses in order to cover a wider spectrum of immune response and hence be 
universal for bacterial and viral infections.  
Cytokines are small proteins playing a pivotal role in signalling to the cells the 
state of inflammation arising from the state of infection. Cytokines term, includes 
interleukins, interferons, chemokines and tumour necrosis factors. These proteins 
are secreted by B and T cells (lymphocytes), mast cells and macrophages. It is 
worth noting that each cytokine may be produced by any of the cells. They are 
important for immune system as they regulate cell population and maturation by 
keeping in balance immune responses coming from humoral (Th2) and cell-
mediated (Th1) immune responses. Some can influence the way other cytokines 
act and as such important to host immune responses to infection, inflammation 
and  tumour cells. Just to introduce some of the cytokines, IL-2 and IL-6 are 
believed to treat cancer
124
, IFN-α found application to treat multiple sclerosis and 
hepatitis C. IL-4 activates T cells into Th2 cells. TNF-α is produced mainly by 
macrophages and plays crucial role in regulating the immune cells, responsible for 
triggering inflammatory response (fever) or capable of inducing apoptotic death. 
The latter action is believed to give some hope in the cancer therapies
125-127
.  
Many materials come to interest when it comes to search after the potent adjuvant. 
There was some research done, dedicated to the potential usage of Zinc oxide as 
an adjuvant formulated in a nanoparticles form, where after 21 days after 
vaccination performed on mice elevated amounts of IL-17, IL-4 and IL-5 were 
reported
128
. Another study performed later, where nano-sized ZnO with particles 
smaller than 50 nm were used, confirmed these findings especially on enhanced 
secretion of the following cytokines: IL-2, IL-4, IL-6, IL-17, however the 
production of IL-10 and TNF-α decreased129. Also, an interesting study was 
performed in the 90’ to investigate the role of the surface area of the materials 
used. This investigated SiO2, ZrO2, Fe-oxides (III and II+III), SnO2, Al2O3. Silica 
was reported to promote antibody production, Aluminium and Iron oxides 
triggered small response and others proved to be not effective
130
.  
Au-nanoparticles came to interest of researchers as potential drug carriers for 
Pt(IV) warheads in the cancer therapy
131
. And yet as a potential candidate for 
novel adjuvants especially for vaccines against HIV-1 with their modified surface 
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132
. These studies showed that there are some cases for which the immune 
response triggered is not sufficient and as research suggests the best results, to 
stimulate the immune response, are obtained by introducing the second adjuvant 
which is alum
133
.  
The human immune system is highly complicated and this introduction does not 
aim to describe it fully and the goal is to give the reader an overview to follow the 
concepts of this thesis. For more detailed outlook into immunology, the reader is 
advised to consult the textbooks
115, 134-136
.  
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Chapter 2. Aims 
The main objective of this thesis was to research and investigate the potential 
applications of MOFs as drug delivery carriers for anticancer drugs: cisplatin and 
5-Fluorouracil (5-FU). The potential double-functionality will be looked into, 
obtained thanks to NO (nitric oxide) loading, as the former has shown to play an 
important role in the human organism particularly its beneficial anti-cancer, anti-
thrombotic and anti-microbial properties. It is important for anti-cancer therapies 
in which the treatment may suppress immune system and an extra anti-bacterial 
protection is crucial.  
Also, this thesis will investigate several MOFs for their potential to be candidates 
for its use as adjuvants in novel vaccines, replacing “alum” that is commonly used 
in today’s vaccination formulations. 
The aim of this project was to synthesise MOFs which would be non-toxic to cells 
and able to allow for drug encapsulation or incorporation and its release in the in-
vitro conditions for possible use in medicinal applications.  
In the context of anti-cancer drug delivery systems research project, MOFs were 
chosen on the basis of their bio-compatibility, pore sizes and the availability of the 
functional groups to allow for incorporation of selected drugs: cisplatin and 5FU.  
In terms of the selection of MOFs for candidates for adjuvants, these were 
selected due to the bio-compatibility criteria as well as their porosity and in the 
first instance the MOFs containing Al-metal were given preference as their 
composition be closely related to alum. In the second instance, the search would 
expand for MOFs with other metal centres. It is worth noting that till now the 
mechanism of action for alum is unknown which makes research for novel 
vaccines challenging. 
Each chapter of the thesis gives the aims separately, to help the reader to follow 
the thesis.  
Chapter 3 contains Experimental Section, where the experimental methods used in 
this thesis are described. Chapter 4 focuses on MOFs as drug carriers for cisplatin 
encapsulation or incorporation in the framework and viability studies of such drug 
carriers. Chapter 5 describes the investigations made into variety of routes to 
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successfully encapsulate Fluorouracil, its release up to the viability and 
cytotoxicity studies. Chapter 6 investigates the potential application for MOFs as 
adjuvants in the novel vaccines with necessary biological testing to assess the 
immune response signals triggered in the macrophages and dendritic cells by their 
stimulation with a selection of MOFs (Al- and Zr-MOFs). Chapter 7 describes the 
research that was conducted in order to synthesise the multifunctional drug carrier 
systems, capable to perform drug delivery of the anti-cancer drug coupled with 
the release of nitric oxide. Chapter 8 gives some indications into the future work 
that could follow up the investigations for medical applications of MOFs 
conducted in this thesis.  
Appendix 1 contains the cell parameters refinements performed in CELCheck 
program and Appendix 2, the x-ray patterns of the Al-MOFs synthesised to test 
their immune response properties. It also contains the x-ray patterns from the CIF 
files (simulated patterns). 
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Chapter 3. Experimental Methods 
3.1 Solvothermal and Microwave-assisted synthesis 
Both methods allow to synthesise solid material. These are often crystalline 
materials if the conditions for crystal growth are met, which is the case for 
solvothermal synthesis performed in an autoclave. Such an approach gives more 
adjustable parameters like heating and cooling rate, dwelling time etc. that can be 
refined in much better way than during microwave (MW) – assisted route. The 
advantage of MW – assisted approach is its speed. Microwave radiation can 
significantly speed up reactions, and so while the control present in solvothermal 
is lost, the advantage of speed can compensate. For obvious reasons obtaining a 
crystalline material is the goal of the synthesis. If an unknown structures are 
predicted to result, the obtained single crystal diffraction would allow to solve this 
structure (that is determining its unit cell, crystal symmetry and atom 
coordinates). Both methods can be used to prepare single crystals or at the very 
least, crystalline powders.  
The principle of the solvothermal synthesis method is as follows: the reagents are 
mixed in solvents and then heated above their normal boiling point in a closed 
autoclave that can withstand high pressure. The viscosity of the solvent decreases 
under such conditions that leads to faster mass transfer and promotes diffusion 
according to Fick’s law. This opens up the possibility to synthesise quite a huge 
number of materials which would not emerge in normal conditions. The routine 
step is to pre-weigh a desired amount of reactant, dissolve it in the solvent (or 
partially) and place in a Teflon-lined autoclave which is then placed in a stainless 
steel paar-bomb in an oven at the desired temperature for a chosen period of time 
usually being a matter of hours or days. Over the recent years microwave heating 
has become popular due to its dramatically improved reaction times allowing to 
achieve results from normally time-consuming reactions, in a much shorter time. 
The method is based on the fact that high dielectric momentum of the polar 
solvents leads to locally superheated spots thanks to the efficient thermal 
conversion of energy resulting in fast and homogenous nucleation preferred over 
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the crystal growth. This method will be often used for the synthesis of 
biocompatible MOFs of MIL series (MIL-53, MIL-100, MIL-88A, MIL 101-
NH2)
1
. Nevertheless, this synthesis route is not best choice if a single crystal is the 
goal as it yields only very fine powder solids, also the equipment is quite 
expensive as a flow set-up and scale-up only possible if a microwave with a big 
vessel is in operation. This method was useful for investigations the influence of 
the reaction times on the material structure, and by far the best for a quick-
synthesis
2
. 
3.2 X-ray diffraction 
The crystal structure is unique for every substance and this feature gives a 
wide window to characterise and then identify the materials. To define the crystal 
structure, the smallest building unit, with the lattice parameters: length of the 
edges (a, b, c) and the angles between them is necessary to be determined. This 
unit is called the unit cell. The unit cell is the smallest unit in the crystal that 
contains all the symmetry elements of that structure and through translational 
symmetry the structure of the crystal can be obtained. The unit is defined by 3 
non-planar axis a, b, c and 3 angles α, β and γ (Figure 3-1).  
Figure 3-1 A unit cell, edges a, b and c, and angles α, β and γ. 
If we added to it the symmetry of the cell then the outcome of such an operation 
would be the Bravais unit cell which describes the geometric arrangement of the 
lattice points. There are four arrangements possible: P-primitive, C-base centred, 
F-face-centred and I-body centred. If we repeated the unit cell in all directions, a 
crystal lattice will be formed. There are 7 crystallographic systems and 14 Bravais 
unit cells.  The powder x-ray diffraction method allows for determination of the 
crystallinity of the material and then describes its structural properties of the 
sample such as inter and intra-molecular distances and the atom distribution in the 
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unit cell. This will lead to structure solution if single crystal material is available. 
If the crystals are small, a synchrotron X-rays are required to record the X-ray 
reflections and this will be used for solving the structure. X-rays, which are 
electromagnetic waves, can interact with the electrons in the specimen and the 
diffraction will only take place if the wavelength of the X-ray is of approximately 
the same size as the object they diffract on. The X-ray detector records the 
intensity of the X-rays being scattered by the electrons in atoms. The picture 
below explains what happens when X-rays are incident on a sample. 
 
Figure 3-2 Depiction of Bragg’s law
3
. 
X-rays are scattered by the electrons in the atoms. Figure 3-2 shows two planes of 
atoms that are separated by a distance d. If we consider X-ray beam numbers 1 
and 2 that came in from the X-ray source, they are scattered (reflected) by the 
atoms to produce the diffracted beams 1’ and 2’. If beams 1’ and 2’ are in phase 
there will be constructive interference and a detector will measure a large 
intensity. If 1’ and 2’ are out of phase then there will be a destructive interference 
and the detector will measure nothing. The condition for destructive interference 
is that the distance travelled by 1’ and 2’ must be related by a half of whole 
number of wavelengths, this happens when two waves are a half cycle out of 
phase. For example, in Figure 3-2 beam 2’ travels further than 1’ by a distance 
equal to AC+BC. Simple trigonometry means that AC+CB =2d sinθ. For 
constructive interference this distance must be a whole number of wavelengths 
giving nλ = 2d sinθ, this is achieved when two waves are in phase. The second 
beam will travel longer because the path is longer AC+CB. If Pythagorean 
Theorem is applied, the path can be expressed in lattice parameters d and the 
incident angle as diffraction angle θ in the equation (3-1). 
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AC+CB = 2dsinθ = n λ   (3-1) 
The distance AC+CB is called the path difference and must be equal, for in-phase 
interactions are allowed, to the wavelength (λ) multiplied by integer (n). The 
diffraction is described by Bragg’s law: nλ=2dsinθ. 
3.3  Microwave-Plasma – Atomic Emission Spectroscopy (MP-
AES)  
A liquid sample is exposed to high energy generated by microwave plasma (MP) 
in order to excite electrons in atoms into excited electronic states (Figure 3-3). 
These can then return to a lower energy state emitting energy at a characteristic 
set of wavelengths corresponding to the energy difference between the two levels. 
The portion of energy (quantum) depends on the electronic structure of that 
element. During the decay, photons can only transit from a high energy state to a 
low energy state emitting permitted wavelength and the detection of this emitted 
energy leads to elements’ identification - both qualitatively and quantitatively. 
The sample is injected into the nebuliser and then sprayed in the microwave 
plasma chamber where electrons of the element will be excited to higher energy 
levels.  
 
Figure 3-3 Excitation of electrons (ground state) in the atom to the excited 
electronic levels and the emission of the photons in a form of light (permitted 
wavelengths). 
The MP-AES and ICP-AES (Inductively coupled plasma atomic emission 
spectroscopy) techniques were used to quantify the amounts of platinum 
encapsulated in MOF powders as well as the amounts released over time (MP-
AES). The wavelength of the emission spectrum of Pt was chosen to be λ = 
265.945 nm line because of its high intensity
4
. This wavelength corresponds to 
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emission of a quantum of energy by a photon returning from its excited state 
[Xe]6s
0
4f
14
5d
9
6p
1
 to the ground state [Xe]6s
1
4f
14
5d
9
. The orbital energy diagram 
for Pt atom is depicted in Figure 3-4 below. 
 
Figure 3-4 Orbital energy diagram for an Pt atom in a ground state before its 
excitation to 6p
1
 and the following emission of quant of energy. 
In the experiments Agilent MP4100 microwave plasma – atomic emission 
spectrometer was used. The instrument is supplied with nitrogen from a nitrogen 
generator and synthetic air would only be used for an equipment start-up, making 
the technique more affordable than ICP, where Argon of high purity is used (min. 
99.999%). 
3.4. High Performance Liquid Chromatography (HPLC) 
HPLC is the most broadly used analytical method in the pharmaceutical sector as 
it allows the separation of almost any compounds in a mixture, excluding solids. 
The technique is not an assay on it is own but only separates substances that can 
be then measured via a detector that must be carefully chosen depending on the 
property of the compound that will be used for characterisation (mass 
spectrometric, fluorescent or UV). The method relies on the fact that molecules 
have different retention times when they travel through different mobile phases. 
Here, a sample that is in a liquid form (Gas Chromatography deals with a gaseous 
phase) is transported in a mobile phase through a column which in this case is the 
stationary phase.  
The analyte that is injected in the mobile phase is pumped through the column at 
high pressure (ca. 6000 psi = 43MPa)
5
. The retention time can be altered 
depending on their affinity to mobile phase, and how fast the compounds can be 
eluted too, high affinity of the analyte to the stationary phase is not recommended 
as it will make the separation impossible and will poison the column (blockage). 
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High-performance liquid chromatography is often used in chemical and 
pharmaceutical laboratories in order to separate and determine the quantities of 
species in a variety of materials. It uses two phases, one which is mobile and a 
stationary phase that is finely divided. In its humble beginnings, the method 
would only use solid particles as a column packing material and these were larger 
than 150-200 μm in order to keep the flow rate at the reasonable level. The goal of 
the optimisation is to separate each of the compounds in the analyte mixture 
giving one clear peak for each. Once the two phases are optimally selected then 
the separation of the species of the sample contents into the bands can be seen, 
with the retention times allowing for their characterization and quantity 
determination. The most important part of the instrument is a column and once 
this is damaged the measurements cannot be completed
6
. Only in the 1960’ much 
smaller diameters of packings 3-10 μm were used, this however, required elevated 
pressures (200-800 atmospheres) and thus an application of a pump
7
. The purity 
of solvents used as a mobile phase is paramount in obtaining reliable results due 
to polar impurities and H2O may seriously damage the column, also UV-
absorbing impurities may lead to erroneous results when using UV-detectors
8
. 
The quantification method (reverse-phase HPLC) to detect 5-Fluorouracil (5-FU), 
was developed by Upulitha Illangakoon and performed using an Agilent 1260 
Infinity instrument (Agilent Technologies) under isocratic conditions (the mobile 
phase consisted of 80% v/v methanol and 20% v/v acetic acid) with C18 column 
(00G-4326-60, Phenomenex, silica gel beads of size 3, 5, 10 μm, Pore size 100 Å, 
surface area 440 m
2
/g, carbon load 19 %). During the measurements temperature 
of the column was set to 40°C, and the flow rate 1 mL/min with sample injection 
quantity of 10 µL for each sample and chromatograms were recorded for 10 min 
with UV detection at the wavelength of 266 nm, which is where the 5-FU 
maximum of absorption falls.  
Retention time for 5-FU is ca. 3 min, however due to stabilisation of the 
instrument the longer run-time was required.  
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Figure 3-5 Schematic depiction of HPLC functionality 
3.5 Biological Assays 
3.5.1 Flow Cytometry 
 
Apoptosis/ Necrosis and viability  
The method of flow cytometry was first patented in 1953 by Mack Fulwyler
9
, and 
is widely used for cell counting or detecting the biomarkers by measuring the 
fluorescence signal rising from the excited states of the organic dyes that the cells 
in question are labelled with. The suspended cells are passed through a nozzle that 
is flushed with a sheath fluid and then as they go through one by one, a laser beam 
is then scattered by the passing cells. The scattered light is detected by detectors 
and on this principle the cells are counted. The laser beam can excite the 
fluorescent dye on the stained cell that will emit a certain amount of energy in a 
form of fluorescence at a given wavelength that can be quantified by a 
fluorescence detector and analysed. The emitted photons are collected by sensors, 
the fluorescent light is filtered so each of the sensors catches only the specific 
wavelength. There are some channels able to detect wavelengths characteristic to 
fluorescence of organic dyes, these are FITC (Fluorescein isothiocyanate - a 
derivative of fluorescein functionalized with an isothiocyanate reactive group 
(N=C=S)) at 519 nm, PE (Phycoerythrin – a red protein-pigment, fluorochrome) 
at 575 nm and TR (Texas Red - fluorophore) at 620 nm. Fluorescence-activated 
cell sorting (FACS) is a special type of flow cytometry, the method was broadly 
developed by Len Herzenberg
10
. It provides a method for sorting a heterogeneous 
mixture of cells, that contains useful information to analyse the cell size and 
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volume. The method allows one to measure the intensity of fluorescence that 
arises from cell surface protein – specific monoclonal antibodies that were 
labelled with fluorescent dyes
11
. As such, it is quite complicated and time – 
consuming method,  used for screening cancer cells. In the research presented in 
this thesis the FACS method was applied to set up a viability assay to determine 
apoptotic and necrotic death and the % of live cells. By labelling of cells with 
FITC-Annexin V, which is a biomarker for early apoptosis (a protein with a 
directly conjugated fluorochrome), it was possible to measure the signal on the 
detector. Apoptosis and necrosis are two types of cell death, the former is the 
programmed cell death. Cells that undergo apoptosis have their membranes 
changed and do not show phospholipid asymmetry that is the case for a normal 
cell. The human anticoagulant protein like Annexin V can bind to phospholipids 
in the environment rich in calcium. This can be used for determination of number 
of cells that are early apoptotic. At the same time using positively charged nucleic 
acid probe Ethidium homodimer III, the staining of necrotic cells can be 
realised
12
. The membrane of the live cells does not allow for binding to either of 
the proteins and as such offers a straight forward way of analysing live, necrotic 
and apoptotic cells. The cells stained with both dyes are considered and count as 
late apoptotic ones. This is a very important principle for anti-cancer drug 
delivery systems and studies of their efficacy, as not only it is important to 
measure viability but also the nature of the cell death because the mechanism of 
action should aim to induce apoptosis. Necrotic death leads to cell bursting that 
may contaminate other cells with the cancerous genetic material
13
.  
In addition, the method allows one to measure the signal on the receptors on the 
dendritic cells in order to assess the immune response induced by application of 
different stimulants, and in this research project is broadly used to verify the 
potential candidates for new adjuvants for novel vaccines
14
.  
The kit for Apoptosis/Necrosis was bought from Biotum and contained FITC-
Annexin V biomarker, Ethidium Homodimer and Annexin Binding Buffer. 
Phosphatidylserine (PS) is translocated from the inner to the outer surface of the 
cell during apoptosis, which allows the dying cell to be surrounded by phagocytic 
cells. These cells are to protect the body by removing any harmful objects like 
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bacteria or dead or dying cells digesting them. Biomarker Annexin V is a Ca
2+
 - 
dependent phospholipid binding protein with high affinity to PS and it is labelled 
with fluorescein FITC (EX/EM 492/514 nm), which stains PS on the surface of 
apoptotic cells. Ethidium Homodimer III is a positively charge nucleic acid stain 
that does not show any fluorescence until bound to DNA, then it emits a 
fluorescence (EX/EM 528/617). It does not bind to the live or early apoptotic cells 
and thus stains only necrotic or late apoptotic cells. Necrosis is a result of a severe 
damage of the cell in which internal organelle and plasma membrane integrity are 
lost making it possible to be stained by the dye of high affinity to DNA. This dye 
is a superior alternative to PI (Propidium Iodide) or Ethidium Homodimer I as it 
shows much higher affinity to DNA and fluorescence quantum yield is much 
higher, which allows for more precise quantification. The cells stained with the 
dyes can be observed in the light of a fluorescent microscope as well as quantified 
in the flow cytometry
15
.  
Cytokines  
Some of the immuno-assays, for accuracy and alignment with a better model, 
were performed on dendritic cells and Flow Cytometry was used for 
quantification of the signal for the protein expressed on the antigen-presenting 
cells providing signals for T-cells activation (CD40
+
, CD86, CD1a
+
).  
Macrophages that in this thesis were obtained by stimulation of cancer cells  
THP-1 with PMA (phorbol myristate acetate) are also antigen presenting cells. 
This differentiation is much faster than the differentiation from monocytes to 
dendritic cells, and takes 3 days vs. 8 days in case of dendritic cells (DC) to obtain 
mature form of DC. Monocytes will be separated from blood cells and then 
stimulated with cytokines IL-4 and antibodies GM-CSF for 4 days in order to 
obtain immature DC, then stimulation with other cytokines (IL-4,  TNF-α, IL6) 
and antibodies (GM-CSF, PGE2) will transform them to mature DCs that could be 
stimulated with potential adjuvants and able to activate T cells, the maturation 
leads to increased surface expression of CD86 molecules, that would signal the T 
activation. The monocytes separation from the blood samples, as well as 
stimulation to obtain dendritic cells that were used in this thesis was performed by 
Dr Ilona Kubajewska. 
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Dendritic cells were differentiated from monocytes by incubation with polarising 
cytokines (rhIL-4 and rhGM-CSF) for 6 days. Monocytes were separated from 
PBMC (peripheral blood mononuclear cells) by magnetic sorting using EasySep 
Human Monocyte Enrichment kit (STEMCELL Technologies). PBMCs were 
isolated from human peripheral blood using gradient centrifugation method. 
Dendritic cells were cultured in complete RPMI 1640 medium (Roswell Park 
Memorial Institute). After stimulation with relevant experimental conditions 
(MOFs, alums: ALO(OH), ALPO4, LPS (endotoxin – Lipopolysaccharides), PBS 
(Phosphate-buffered saline)) in 96 well plates, cells were washed with PBA buffer 
(PBS w/o Ca/Mg ions + 2% FBS) and stained with fluorochrome-conjugated 
antibodies (PE anti-human CD86 and APC anti-human CD40 by Miltenyi Biotec, 
PerCP-Cy5.5 anti-human CD1a by BioLegend) for 30 mins at 4°C, then fixed 
with 2% formaldehyde and washed 3 times with PBA. Cell suspension was 
resuspended in 200ul PBA and acquired by MACSQuant flow cytometry machine 
measuring fluorescent signal in relevant channels. Analysis was performed in 
MACSQuantify flow cytometry software. The dendritic cells used in the 
experiment were prepared by Dr Ilona Kubajewska. 
3.5.2 Viability by Alamar Blue 
Alamar Blue is a commercial name for a solution of rezasurin, a non-toxic 
compound which if applied as an assay enables pharmacokinetic studies. To 
contrary, assays performed with MTT (3-[4, 5-dimethylteazol-2-yl]-2,5-diphenyl 
tetrazolium bromide), are endpoint assays and cells are lost during the 
measurements. Rezasurin solution is blue in color and non-fluorescent, which 
upon entering cells’ membrane, is reduced to resorufin by mitochondrial enzymes 
during cells activity, a compound that is red in color and highly fluorescent
16
. The 
more live cells there are, the more can convert more rezasurin into its fluorescent 
form resulting in a higher FL signal. The principle of the method is depicted in 
Figure 3-6. 
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Figure 3-6 Schematic depiction of a mechanism of action of Alamar Blue 
viability assay and the change in colour resulting from the conversion of 
Resazurin (blue) into Resorufin (purple) indicating high viability of the cells. 
Alamar Blue assay was performed to measure the cell viability on two different 
cell lines: monolayer culture A549 lung cancer cells and suspension THP-1 
human leukemia (blood cancer). The incubation time for each of the two cases 
was optimised. Alamar Blue Assay was used to quantify the viability of A549 
cells and viability of THP-1 was measured using Flow Cytometry and 
Necrosis/Apoptosis kit. For the viability experiments the following seeding 
densities were used: 500 000 cells /ml for THP-1 and 40 000 cells/ml for A549. 
The optimisation curves are presented below in Figure 3-7 and Figure 3-8. For 
A549 the incubation time based on the optimisation curve was adjusted to 4 h for 
all of the viability bioassays for A549 cell line and for THP-1 the optimised 
incubation time was 6.5 h. The incubation times were included in the drug 
stimulation experiments and accounted for the exposure time. Briefly, the 96-well 
plate with stimulated cells containing 10% by volume of Alamar Blue solution  
(5 mM resazurin solution in a non-completed RPMI) are incubated in the cell 
incubator at 37°C and environment containing 5% of CO2. Then the plate is read 
in the Multiplate Reader instrument by Molecular Devices UK model m2e and the 
fluorescence of the product of cell activity monitored (Excitation at 555 nm and 
Emission at 585 nm). Fluorescence is linearly proportional to cell viability. 
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Figure 3-7 Alamar Blue bioassay optimisation for A549 cell line. 
 
Figure 3-8 Alamar Blue bioassay optimisation for THP-1 cell line. 
Cell culture of A549 monolayer cell line: 
Cells were cultured in a T75 flask and incubated at 37°C (5% CO2) and passaged 
once they reached the confluence level at 85-90%. The cell confluence was 
observed by an inverted microscope EVOS. As the cells are adherent, in order to 
passage them, they need to be harvested with the TrypLE Express Enzyme (1x; 
Life Technologies), which is a derivative of trypsine enzyme that is harmless to 
cells and detachment from the flask bottom takes only 10 minutes. Briefly, the 
media was discarded from the flask and the flask rinsed with 5 ml of PBS that 
does not contain Ca, Mg ions. To such prepared flask 3 ml of Trypsin (TrypLE 
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Express) was added and the flask placed in the incubator for 10 min, after which it 
was removed and examined in the microscope if the cells detached from the 
bottom. Then trypsin would be deactivated by an addition of 6 ml of complete 
growth media. The growth media for cell culture was Gibco RPMI 1640 
supplemented with penicillin (100 μg/mL), streptomycin (100 μg/mL),  
L-glutamine (292 μg/mL), all from Life Technologies supplier and 10% v/v heat-
inactivated fetal bovine serum (FBS, Gibco). This is hence referred to as 
“complete RPMI” or 10% RPMI. The cell suspension (9 mL) was transferred with 
a serological pipette and placed in the 15 ml tube and then centrifuged for 5 min at 
1000 rpm so the cells would form a pellet. The cells were re-suspended in 10% 
RPMI 1640 growth media for cell counting and splitting. For cell seeding, cells 
were resuspended in 2% RPMI media, i.e. 2% FBS v/v was added instead of 10% 
FBS. This serves as a growth limiting step for the seeded cells. The cells were 
seeded on the 96-well plate. For all the experiments performed in this thesis the 
seeding density was 4000 cells/well (40 000/mL) which corresponded to 100 μL 
of cell suspension volume per well. Cell counting was accompanied by Trypan 
Blue exclusion test. Trypan Blue is a blue dye that permeates membranes of dead 
cells and thus stains them in blue and does not enter the viable cells. Therefore, 
live and dead cells can be distinguished. 
Cell culture of suspension THP-1 cell line: 
The steps for subculturing the suspension cell line are similar to above, only there 
is no need to use trypsin for cell passage. The growth media for subculturing and 
seeding was 10% completed RPMI 1640 and the seeding density was 100k/well 
(500 000 cells/mL) which corresponded to 200 μL of cell suspension volume per 
each well. Such subcultured cells were used in the cell stimulation experiment 
with cisplatin and 5-Fluorouracil to determine apoptosis/necrosis cell death. 
3.5.3 Cytokines’ secretion by ELISA 
The enzyme-linked immunosorbent assay is a technique based on antibodies and a 
colour change arising from enzyme linking performed in a plate and designed for 
detection of antigen (peptides, proteins, hormones) or antibodies and their 
quantification. It relies on a basic concept that any antigen will bind to its specific 
antibody. Measurement of the absorbance at the maximum of the characteristic 
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wavelength of the dye and constructing a calibration curve allows for 
quantification of secreted cytokines.  
For the purpose of this thesis the ELISA assays were performed to quantify 
cytokines: IL-6 and TNF-α, using commercially available kits purchased from 
BioLegend. In this work Sandwich ELISA method was used for detecting and 
quantifying cytokines that were secreted by macrophages and dendritic cells
17, 18
.  
For the sandwich ELISA, the 96-well plates were used. The plate was coated by a 
capture antibody solution (60μL in 11.94 ml of Coating Buffer – 8.4 g NaHCO3, 
3.56 g Na2CO3 in 1L of deionised H2O, 100μL per each well), specific to the 
antigen of interest and incubated overnight at 4°C. Then the plate was washed 
with a wash buffer (9.6g PBS in 1L deionised H2O and 0.5mL of Tween 20 
added) from excessive amount of coating antibody and nonspecific binding sites 
were blocked with assay diluent (0.5 g bovine serum albumin in 50 ml deionised 
H2O). This step also helped reducing the background. The plate prepared in this 
way was then sealed and incubated for 1 hour. Thereafter, it was washed again on 
the plate washer and to as prepared plate, the antigen-containing samples were 
added. This included the reference protein standards  which were then used for a 
standard curve. Then the plate was sealed and incubated for 2 hours. A cytokine -  
IL-6 or TNF-α, was bound to the immobilised capture antibody if any was 
secreted by the macrophages. A specific primary antibody (detection antibody) 
was added to the samples and followed by the labelled horseradish peroxidise 
enzyme (Avidin HRP), producing an antibody-antigen-antibody sandwich. Then 
the plate was again sealed and incubated for 1 hour. Unbound antibody–enzyme 
conjugates were washed off. This step was quite important as any excessive 
amounts of enzyme-conjugates could corrupt the results. Next, TMB substrate 
(3,3′,5,5′-Tetramethylbenzidine) was added and enzymatically converted to a 
substance that  can be quantified and was proportionate to the concentration of IL-
6 or TNF-α present in the sample, the plate was sealed and incubated for 30 min. 
TMB developed a blue reaction product whose absorption was quantified at 370 
or 655 nm. The reaction followed according to the scheme (Figure 3-9), colourless 
TMB is transferred to 3,3',5,5'-tetramethylbenzidine diimine yielding a product, 
blue in colour as it is a hydrogen donor for the reduction of hydrogen peroxide 
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upon detecting HRP and catalysed by HRP-enzyme
19
. Because this reaction can 
proceed with no limits, for endpoint assays, it is important to add, a so called 
“stop solution” (e.g 0.16 M sulphuric acid) that would denature the enzyme in the 
pH value, forming a yellow product with maximum of absorption at 450 nm.  
 
Figure 3-9 TMB oxidation process. A blue charge transfer product is formed 
with diamine and diimine oxidation products, an addition of a stop solution 
shifts the equilibrium into formation of diimine. 
Differentiation of the human monocytic cell line THP-1 into macrophage-like 
cells was performed by stimulation with PMA (phorbol myristate acetate,  
100 nM, purchased from Sigma Aldrich).  
It is worth noting that differentiation of THP-1 cells to macrophages is sometimes 
not 100%, however serves as a model for antigen presenting cells to T-cells. The 
mechanism of action of ELISA kit by Biolegend is depicted in Figure 3-10 below. 
 
Figure 3-10 Mechanism of ELISA assay. Left image was adopted from 
Biolegend commercial materials. Right image is an outcome of the ELISA 
assay prepared by the author of this thesis. 
Stimulation THP-1 cells with PMA for macrophages differentiation 
For the PMA stimulation a cell suspension prepared contained 500 000 cells/mL 
and the seeding volume of 200 μL of cell suspension (Seeding density 100 000 
cells/well). Concentration of PMA used for stimulations was 2.5 μL per well 
(100nM/well) and 12.5 μL/mL. Differentiation continued for 72 h and after this 
time the cells were stimulated with MOF powders (10 μL of a dispersion 
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10 mg/mL, corresponding to 500μg/mL). Lipopolysaccharides (LPS) – gram-
positive bacteria and used as a positive control (5 μL, an eq. of 100 ng/mL), PBS 
– used as a negative control (w/o Ca, Mg ions 10 μL) and commercially used 
alums: Al-OH and Al-PO (10 μL per well of each). The macrophages were 
exposed to stimulants for 24 h after which time the plate was centrifuged and 
aliquots harvested on other two plates, for quantification of the cytokines IL-6 and 
TNF-α by ELISA (100 μL taken up from each well). 
3.6. Nitric Oxide chemiluminescence 
NO release measurements were performed in order to quantify the amount of NO 
being released by the MOF samples loaded with anti-cancer drugs: 5-Fluorouracil 
and cisplatin. Briefly, NO loading was performed in a schlenk tube in the 
experiment very similar to procedure for powder dehydration. In order to activate 
(remove solvent from) the MOF powders (0.015 g per glass vial), they were first 
placed under vacuum (2.3 ×10-3 bar) during which time ca. 30% of the mass was 
lost. They were then heated to 120°C while still under dynamic vacuum and held 
at this temperature overnight, leaving a fully activated material accessible for NO 
adsorption. The samples were subsequently cooled to room temperature and 
exposed to ca. 2 atm of dry NO (99.5%, Air Liquide) for 45 min. The vials were 
next evacuated and exposed to dry argon, before being flame sealed. This cycle of 
evacuation and argon flushing was repeated three times in order to remove any 
residual physisorbed NO from the surfaces of the MOF and glassware. To 
measure the release, the Sievers 280 i chemiluminescence NO analyser was used. 
This instrument is equipped with high-sensitivity detector that measures nitric 
oxide content based on chemiluminescent reaction between ozone and nitric 
oxide, equations 3-2 and 3-3. 
NO + O3 →NO2
*
 + O2     (3-2) 
NO2
*
 → NO2 + hν        (3-3) 
The signal comes from the excited NO2
*
 that is in the near-infrared and is 
measured by the photomultiplier tube detector sensitive in the red. The calibration 
of the instrument was made by setting up a zero for NO signal by letting air pass 
and then 93.2 ppm NO calibration gas (Air Products, balance nitrogen) was 
Chapter 3 Experimental Methods 
46 
 
passed. The nitrogen flow was set up at 200 ml/min with a cell pressure of 8.5 torr 
and an oxygen pressure of 6.1 psig. The nitrogen supply, before it enters the 
sample chamber is flowing through the flask containing LiCl saturated solution 
which provides relative humidity at the level of 11 % (15 mg in 12 ml of H2O)
20
, 
to replace NO bound to the metal open sites with H2O molecules coming from the 
moisture passed through the nitrogen gas. Below (Figure 3-11), there is a picture 
of the experimental set-up. 
 
Figure 3-11 Nitric Oxide analyser experimental set up. 
3.7 Fourier transform infrared spectroscopy (FTIR) 
Molecules have vibrational modes, which are associated with vibrations of 
functional groups and bonds. This property of compounds is very useful for their 
identification and widely used with developed spectroscopic methods, one of 
which is Fourier Transform Infra Red Spectroscopy. In this method, light 
(polychromatic radiation) that covers full range 4000-400 cm
-1
 is produced by a 
light source e.g. a high pressure mercury lamp, (wavelengths from 2.5 to 25μm) is 
split into two beams, one of them always travels a longer path than the other. This 
is achieved by installing a set of mirrors, one in a fixed position and the other 
moving and a beam-splitter (Michelson interferometer), see (Figure 3-12) for 
FTIR instrument scheme. Ideally the beam-splitter would transmit half of the 
radiation to the stationary mirrors and another half would be reflected to hit the 
moving mirror, this allows to generate an optical path difference. The recombined 
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beams would pass through the sample and some of the radiation will be absorbed 
by the sample. The signal of the recombined beams, which would vary in optical 
path length will be transferred onto detector, which measures a difference of 
intensities as a function of difference of optical paths
21
.  
 
Figure 3-12 Simplified diagram of an FTIR spectrometer. 
If a mathematical operation - Fourier transform (FT) is now applied to this 
spectrum, which is called interferogram and contains all the frequencies as a plot 
of their intensities versus time, it will be transferred into a new function, which is 
a commonly known as a plot of absorption against a wave number. The relation 
between the function of time f(t) and a function of wave number F(ν) that is 
changing in time, is described by the equation (3-4): 
     
 
   
                
 
  
  (3-4) 
The FTIR instrument is capable of acquiring an interferogram in seconds and as 
such allows to plot results with much better signal-to-noise ratio as many scans 
can be taken in a very little time. Spectra allow to analyse vibrations of the bonds 
and functional groups that are characteristic for chemical compounds
22
. Not all of 
the molecules would absorb infra red radiation but only these with bonds having a 
diapole moment
23
. Region below 1500 cm
-1
 is called a fingerprint region and 
contains spectra of many bending vibrations from within the molecule, which are 
quite complex to analyse due to the fact of complicated series of absorptions, 
however this region is very unique to every compound and allows to identify the 
substance, once we have a known spectra of this compound. 
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Chapter 4. MOFs as drug delivery carrier for 
cisplatin 
4.1. Aims 
Cisplatin, cis-[Pt(NH3)2Cl2], is one of the most successful and researched anti-
cancer drugs with its use accounting for nearly 50% of all anti-cancer therapies for 
a variety of cancers
1, 2
. Despite its high toxicity (the first generation drug), 
cisplatin is used in the treatment of head, neck, ovarian, cervical, testicle, breast 
and bladder tumours
3-5
. The toxicity of cisplatin against cancerous cells was first 
recognized in 1968
6
. Over subsequent years of intensive research, it showed high 
efficacy against many cancer types in clinical trials
7
 and was finally approved as 
an anti-tumour drug by the FDA (Food and Drug Administration) in 1978
8
. 
Cisplatin is capable of forming intra- and inter-strand cross-links with nucleic 
acids of DNA. This leads to cell death (apoptosis) due to the resultant inability of 
DNA to replicate
9
. Cancer is one of the most feared diseases known to mankind. 
Therefore, the development of new and more efficient drugs has continuously 
attracted a great deal of attention. This chapter will explore MOFs (CPO-27 Mg, 
CPO-27 Ni, UiO66 and UiO66-NH2) for their potential application as drug 
delivery systems for cisplatin. This is thanks to utilising their high surface areas, 
high porosity and non-toxic character. It should be mentioned that CPO-27 Ni 
shows toxicity, however, as anti-cancer drugs are much more toxic than Ni, this 
MOF was qualified for the testing phase. Different encapsulation strategies: 
physical encapsulation and conjugation, will be presented, and these assessed in 
terms of their efficacy by a variety of bio – assays in vitro (Alamar Blue and Flow 
Cytometry) and resulting in the choice for the best strategy for cisplatin delivery. 
Encapsulation of a variety of active pharmaceutical ingredients is a broadly 
known way of developing drug carrier systems and some MOFs with their 
relatively large voids have been investigated. A good example was given by 
Christian Serre’s group with their range of MIL materials10-13. Zr-MOFs have 
been previously researched for their potential application as drug delivery carriers 
for caffeine
14
. According to the literature, conjugation technique has been 
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successfully applied to some MOFs, by activating an amine group on the organic 
ring of the MOF framework, this including Mn-MOF and MIL-101
15, 16
. Due to 
the fact that the MOFs listed have not yet been approached for their applicability 
for cisplatin, and that encapsulation and conjugation proved to be a good way of 
obtaining particles showing cytotoxic character, this chapter will describe the 
research conveyed. 
4.2. Synthesis 
Four MOFs were chosen to serve as the best candidates because of their relatively 
non-toxic character (excluding CPO-27-Ni), simplicity of synthesis and large 
cages that could accommodate a molecule of cisplatin. Each of the materials was 
prepared in a large batch in order to reduce heterogeneity of different batches and 
stable parameters of the powders. Briefly the synthesis was the following: 
UiO66 
A mixture of zirconium (IV) chloride (82 mg, 0.35 mmol) and 1,4-
benzenedicarboxylic acid (58 mg, 0.35 mmol) in dimethyl formamide  
(DMF; 5 mL) was acidified using HCl (37 wt%, 805 μL, 9.7 mmol). The solution 
was sealed inside a 23 ml Teflon-lined steel autoclave and heated at 220°C under 
autogenous pressure for 24 hours
17
. The UiO66 product was collected by vacuum 
filtration, washed with DMF and dried in vacuum. The reaction has been scaled 
up in order to obtain ca. 4 g of the MOF powder and the reaction was carried out 
in a 600 mL autoclave
18
. 
UiO66 –NH2  
A mixture of zirconium (IV) chloride (82 mg, 0.35 mmol) and 2-amino-1,4-
benzenedicarboxylic acid (63 mg, 0.35 mmol) in DMF (5 mL) was acidified using 
HCl (37wt%, 805 μL 9.7 mmol) and acetic acid (concentrated, 605 μL, 10.57 
mmol). The solution was sealed inside a 23 ml Teflon-lined steel autoclave and 
heated at 120°C under autogenous pressure for 24 hours. The UiO66-NH2 product 
was collected by vacuum filtration, washed with DMF and then with MeOH and 
dried in vacuum. The yield was 130 mg, efficiency 90%.of The reaction was 
scaled up, in order to obtain enough powder to cover all of the experiments once 
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the material has been characterised. The amounts obtained were 1.774 g, 87.7%, 
scale up of the reaction was 14 times according to the procedure in literature
17, 19
. 
Successful preparation of the MOFs was confirmed by X-ray diffraction, with the 
patterns of the obtained materials being identical to those reported in the 
literature. The particle size of the Zr-MOFs was assessed by SEM to be around 
250-300 nm (Figure 4-1).  
 
Figure 4-1 SEM images of UiO66-NH2 (left) and UiO66 (right). 
CPO-27 MOFs have been synthesised in the hydro-solvothermal process in 
autoclaves
20
. In this synthesis, which eliminates toxic organic solvents like DMF, 
the reactants (metal salt and an organic linker) are dissolved in a solution which is 
a mix of 50:50 (v/v) of water and THF for CPO-Ni and 3:10 (v/v) for CPO-Mg. 
The solvothermal reaction is carried out at 110 ºC. The synthesis time according 
to Dietzel et al. recommendation should be 3 days
21
. The MOF powder after its 
synthesis was kept in a water bath in order to perform the ion exchange and 
remove THF from the pores of the material. It was noted that the formation of the 
final product can be achieved in 24 hours in the autoclave, even in case of a 25-
times scale-up. Some trials were made to apply microwave assisted synthesis 
process as this method offers a rapid formation of the MOF powders, in just 60-
120 min versus 24-hour cycle. The only drawback of following this method being 
the size of the vials which in our case, only allowed for preparing small quantities 
of the powder that is 58 mg if small vials (5ml) are used or 115 mg yield 83% if 
larger vials are used (12 ml). The microwave-aided syntheses enables to verify the 
reaction conditions quicker before dedicating longer time intervals if the 
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solvothermal process is used (reaction in the autoclave). The aim for this thesis 
was to use the same batch for all of the experiments to avoid any batch-related 
discrepancies in the surface properties: porosity, BET which are crucial for 
development of drug delivery systems. The method originally published by 
Dietzel et al. was adapted and it was observed that it gave satisfying results
22
.  
Briefly: 
CPO-27-Mg 
A mixture of an organic linker 2,5-dihydroxyterephthalic acid (99 mg, 0.5 mmol) 
and metal salt Mg(NO3)2•6H2O (257 mg, 1.0 mmol) were dissolved in a solution 
of THF (7 mL), NaOH (2 mL, 1 M), and water (3 mL) under stirring. The given 
above quantities were scaled up 25 times to 6.425 g (25 mmol) of 
Mg(NO3)2•6H2O, 2.475 g (12.5 mmol) of dhtp and volume of solvent: 175 ml of 
THF, 75 ml of H2O and 50 ml of 1M NaOH, in order to obtained higher yield of 
the MOF powder. The mixture was then sealed in a 600 mL Teflon-lined 
autoclave and heated in an oven at 110 °C for 24 hours. The product 
Mg2(dhtp)(H2O)2•8H2O was collected by filtration as a light-yellow substance. 
Ca. 2 g was obtained, 38 %. The reaction is depicted in Figure 4-2 below. 
 
Figure 4-2 Simplified equation of the reaction of synthesis of CPO-27 Mg. 
CPO-27-Ni  
2,5-dihydroxyterephthalic acid (2.972 mg, 15 mmol) was dissolved in THF  
(50 mL), [Ni(OCOCH3)2] •4H2O (7.466 mg, 30 mmol) was dissolved in H2O (50 
mL), both solutions were mixed together
23
 and stirred until homogenous. The 
amounts were scaled up 3 times, which gave 22.398 g of [Ni(OCOCH3)2] •4H2O, 
8.916 g of dhtp and 150 ml of THF and 150 ml of H2O. After being stirred, all the 
reactants were transferred to a 600 ml Teflon-lined autoclave and heated in an 
oven at 110°C for 24 h. Dark yellow powder Ni2(C8O6H2)(H2O)2•8H2O was 
collected after filtering and dried under vacuum. 4 g was obtained, 54.3%. 
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Figure 4-3 SEM images of CPO-27 Mg (left) and CPO-27 Ni (right). 
The size of particles of CPO-27 Mg was assessed to be ca. 10 μm and CPO-27 Ni 
between 400-600 nm. 
4.2.1 One pot synthesis 
A one-pot route was pursued to synthesise the MOF powders with cisplatin that 
would be already entrapped in the pores and cages of the materials. 
For Zr-MOFs, two syntheses were performed: in 50 ml autoclaves (solvothermal) 
and in 12 ml glass vials (microwave-assisted synthesis), the protocols were 
adopted and the amounts of cisplatin were added according to the Table 4-1. The 
reaction time for a synthesis in autoclaves was set to be 24 hours at 120°C for 
UiO66-NH2 and 220°C for UiO66, for microwave-radiation aided synthesis, 
reaction time was shorter and set to be 40 min, same temperature conditions 
applied. 
For CPO Mg and CPO Ni only a hydro-solvo-thermal method was exploited, and 
the reaction time was set to be 24 hours and temperature 110 °C for both MOFs. 
The quantities of cisplatin added to the mixture of the reagents were adjusted 
based on cisplatin’s solubility in a solvent at the level of 80% (2.53 mg/mL of 
H2O)
24
. 
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MOF Linker [mg] Metal-Salt [mg] Solvents [mL] Cisplatin [mg] 
CPO-27 
Mg 
99 (0.5 mmol) 257 (1 mmol) 7 THF, 3 H2O, 2 1M 
NaOH 
10 (0.033 mmol) 
CPO-27 
Ni 
594 (6mmol) 1493 (6mmol) 10 THF, 10 H2O 20 (0.066 mmol) 
UiO66 58 (0.35mmol) 82(0.35mmol) 5 DMF, 0.807 HCl, 0.6 
acetic acid 
52 (0.17 mmol) 
UiO66-
NH2 
63(0.35mmol) 82(0.35mmol) 5 DMF, 0.807 HCl, 0.6 
acetic acid 
52(0.17 mmol) 
Table 4-1 Synthesis summary of the chemicals used in the MOF synthesis. 
4.2.2 Encapsulation  
The high surface areas and quite big cages of 11-12 Å23 for CPO -27 (Mg and Ni) 
and 11 Å and 8.5 Å in case of Zr-MOFs (UiO66)25, 26 are a foundation for the idea 
of exploiting a method of physical entrapment of an anticancer drug. The 
procedure was as follows: MOF powders (ca. 350 mg) were dehydrated under 
dynamic vacuum overnight and then immersed in a solution of cisplatin, cis-
[Pt(NH3)2Cl2], (35 mL, saturation with cisplatin at 80%, 2mg/mL, (6.66 mM) in 
deionised water). This corresponded to a theoretical loading of 30 mg of cisplatin 
per 100 mg of dehydrated MOF. The encapsulation continued for 48 hours under 
stirring at room temperature. The samples were centrifuged and allowed to dry in 
air. There was an effort made to measure the quantity of cisplatin that did not 
migrate into the pores of materials, however, the signal coming from cisplatin was 
masked by the one coming from the MOF (UV-VIS spectroscopy). 
4.2.3. Conjugation 
An alternative route to encapsulation, conjugation, was explored. According to 
this strategy, a war head attached to the MOF via functionalised amine group into 
a “peptide bond” could release its cargo “on demand” when in the proximity of a 
cancer cell where oxygen concentration is lower and hence would reduce Pt(IV) 
to Pt(II) allowing for a more targeted action as all the cargo is kept intact and only 
realised at its destination. In order to create such a drug delivery system, a 
modified version of cisplatin was synthesised. The prerequisite for this route is 
presence of available amine groups in the framework, which then could be 
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functionalised in an amide coupling reaction. Thus, this method cannot be applied 
to just any MOF.  
A prodrug of cisplatin, cis,cis,trans,-[Pt
IV
(NH3)2(Cl)2(O2CCH2CH2CO2H)(OH)] 
(see Figure 4-2), was synthesised in the following procedure (schematic reaction 
depicted in Figure 4-5). A suspension of cisplatin (0.4 g, 1.33 mmol) in H2O (12 
mL) at 60 °C was oxidized with H2O2 (20 mL) added dropwise. The reaction was 
kept running for 4 hours, and then the resultant bright yellow solution left to cool 
overnight. Yellow crystals (yield: 234 mg, 53%) were recovered by filtration and 
washed with ice cold water. A more detailed procedure can be found in the 
literature
1, 27
. The product (Complex 1, 202 mg, 0.6 mol) was then reacted with 
succinic anhydride (60 mg, 0.6 mol) at 70°C in a DMF (5 mL) suspension for 24h 
under stirring and then cooled to room temperature. DMF was removed under 
vacuum and the residual suspension (1 mL) was dissolved in acetone, and 
precipitated with diethyl ether to give a pale yellow solid with yield: 180 mg, 70% 
(Complex 2). 
 
 
 
 
Figure 4-4 The structure of the cisplatin prodrug used in this work. 
The prodrug was conjugated to UiO66—NH2 using the EDC/NHS method in an 
aqueous solution. A detailed procedure can be found in the literature 
28, 29
. In brief, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl 0.038 g, 0.20 mmol) 
and N-hydroxysuccinimide (NHS 0.023 g, 0.20 mmol) were dissolved in de-
ionized water (15 mL) under stirring. Next, the prodrug (0.70 g, 0.16 mmol) was 
added into the aqueous solution. After the solution became clear, UiO66-NH2 
(0.140 g, 0.0798 mmol) was added and the reaction mixture (ratio 1 mol Pt to 3 
mol amine groups) stirred at room temperature for 24 hours. Finally, the solid 
product was recovered by vacuum filtration, washed with water and left to dry in 
air. 
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Figure 4-5 Schematic depiction of cisplatin modification 2-step reaction to 
obtain the non-toxic derivative of cisplatin Pt (IV) able to be reduced “in 
vitro”. 
4.3. Results 
4.3.1 Quantification of cisplatin content 
In order to quantify the amount of Pt in the MOF powders EDX (Energy-
Dispersive X-ray Spectroscopy) technique was used in the first instance. The 
EDX method is a good estimate for metal concentration in the sample, however, it 
is not analytical and quantitative. A high number of scans must be taken from the 
samples to provide good statistical distribution and more precise results. Two data 
sets have been discarded from analysis – max and min read-outs to provide better 
averaging. This dramatically changed results, which are shown in Table 4-2 also 
including Pt:Zr ratios. For each analysis, the number of scans was no smaller than 
8 for MOF samples encapsulated with cisplatin and 6 for UiO66NH2-prodrug. 
This limitation was due to the time constraints. For the simplicity of calculations 
of the content of cisplatin expressed in %wt, the molecular weights of MOFs used 
are following, CPO-27 Ni (491.5 g/mol), CPO-27 Mg (422.7 g/mol) for 
M2(dhtp)(H2O)2 •8H2O, UiO66 (1664 g/mol) and UiO66NH2 (1754 g/mol) and an 
assumption that perfect crystals with no defects in their structure are obtained. 
For Zr-MOF with a conjugated prodrug, the estimation of Pt content was made 
based on the EDX read-outs for weight% of Pt in the sample. Looking at the range 
of the results for Pt content estimates based on EDX data, it is not sufficient to 
conclude regarding cisplatin and another analytical method for Pt quantification 
was necessary to be applied. 
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MOF Pt: Metal 
ratio (Mol) 
All data sets 
Corresponds to Cisplatin 
loading wt.% 
Value in brackets 
corresponds to data with 
discarded data 
Pt: Metal ratio 
(Mol) max 1data 
set discarded 
UiO66-NH2-prodrug 1:1.76 21 Pt wt % (17 Pt wt%) 1:2.50 
UiO66-NH2 encapsulated 1:15.9 7.0 (6.1) 1:13.6 
UiO66 encapsulated 1:17.4 5.9 (1.6) 1:66.1 
CPO Mg encapsulated 1:24.4 5.5 (5.4) 1:25.1 
CPO Ni encapsulated 1:20.4 5.7 (5.8) 1:19.7 
Table 4-2 Summary of the estimation of cisplatin contents utilizing EDX 
measuring technique. 
The digested powders of CPO-Mg, CPO-Ni, UiO66 and UiO66-NH2 loaded with 
cisplatin in the encapsulation method and UiO66NH2 with a conjugated prodrug 
were analysed by ICP-AES/MP-AES. The digestion of CPO-Mg and CPO-Ni 
with 37% HCl overnight, was successful, whereas the other MOFs were stable in 
HCl solution and digestion must have been carried out using aqua regia 3:1 vol. 
HCl:HNO3. Despite a lot of attempts made to digest the powders – an amount of 4 
ml of the acid solution has been added to each volumetric flask containing 1.5 - 6 
mg Zr-MOF powders, and treated for an hour before diluting up to 100 mL with 
deionised water, there were no signs of reaction and powders were seemingly left 
unchanged. Nevertheless, the aliquots were taken for analysis under assumption 
that aqua regia solution should be penetrating the pores of material bringing Pt 
amounts stuck in the pores into the analyte solution. The prodrug that is 
conjugated to the amine group of the UiO66-NH2 MOF is a derivative of cisplatin, 
and as such with a different structure, however it is stipulated that “in vivo” 
conditions Pt(IV) will be reduced to release Pt(II), a cytotoxically active part of 
cisplatin as the peptide bond will be cleaved 
27
. The results are shown in Table 
4-3. Surprisingly, the amount of cisplatin encapsulated in the pores of UiO66 was 
very low when compared with those encapsulated in UiO66-NH2. 
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Table 4-3 Summary of results obtained using MP-AES and ICP techniques. 
In order to measure the cisplatin content encapsulated and conjugated in Zr-MOF 
powders, which were very robust and hard to digest, a quantification on ICP-MS 
has been performed at University of Warsaw, that included a novel method of 
samples mineralisation in School of Chemistry in Prof. Ewa Bulska Lab, which is 
dedicated to spectroscopic techniques of elements quantification. The method 
applied by Warsaw University group was based on mineralisation of the samples 
(ca. 5 mg) with 1mL of the solution obtained by mixing two acids HNO3:HCl (vol 
1:3) and then the samples were digested aided with a microwave radiation 
(Milestone UltraWave). The following program was applied: both, temperature 
and pressure were gradually increasing to values 270°C and 140 bar respectively 
over the time of 15 minutes. The microwave-aided heating program has been 
repeated twice. This method has been developed by Prof. Bulska’s group and used 
to mineralise samples obtained by e.g. NASA – this was communicated to me 
when meeting in person Prof. Bulska during World Chemistry Congress in Busan, 
Aug 2015. The digested samples were then diluted with deionised water by 
weight, and the proportions for dilutions were adjusted based on the quantity of Pt 
in the sample to match the range of the calibration curve. The quantification of the 
Pt content in the samples was performed on ICP-MS NexION 300D (Perkin 
Elmer) with the following parameters: Cyclonic Spray Chamber, Plasma Power 
1200 W, Argon gas flow rate 18 L/min, zero gas flow rate 1.2 L/min. Calibration 
curve has been constructed by measuring the signal of 3 points in the range 0-100 
μg/L (blank, 10 μg/L and 100 μg/L), the standard used was Multi-element Ultra 
Scientific ICP MS Calibration Standard #3, with Pt content 10 mg/L. The Pt 
contents is shown in the Table 4-4 below.  
 
MOF Pt content wt%±SEM Cisplatin content 
wt%±SEM 
Method 
CPO-27 Mg-encapsulated 1.64±0.016 2.53±0.03 ICP-AES 
CPO-27 Ni-encapsulated 0.91±0.004 1.39±0.01 ICP-AES 
UiO66-encapsulated 1.00±0.01 1.54±0.02 MP-AES 
UiO66-NH2-encapsulated 2.32±0.03 3.58±0.04 MP-AES 
UiO66NH2-conjugated 4.40±0.04 6.77±0.06 MP-AES 
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Table 4-4 Pt and cisplatin quantification by ICP-MS, with an application of a 
microwave aided digestion method. 
The cisplatin content in the sample was calculated according to the equation 4-1.  
                    
              
      
                4-1 
These results show that digestion with cold aqua regia was not efficient and the 
MOF porous structure withheld cisplatin quantities in its framework as there is 
still some Pt retained in the MOF structure and not in the solution with aqua regia. 
Especially, striking is the difference in Pt-content in UiO66 accounting for  
5.59 %, and 6.92 % for UiO66-NH2 but only 3.23 % for UiO66-NH2 with 
conjugated prodrug which may be due to the fact that the peptide bond connecting 
a prodrug to the amine group, may be broken by aqua regia. For EDX estimates, if 
one of the read-outs in a data set is discarded then based on the same calculations, 
we find 1.3 wt% and 5.2 wt% for UiO66 and UiO66-NH2 respectively, which by 
far is close to the MP-AES analysis.  
TGA analysis of the unloaded and loaded samples was performed to estimate the 
cisplatin content. The cisplatin will decompose at 270 °C in the thermal process to 
Pt, which is indicated in the TGA plot showing a weight loss of 65 % of the mass. 
The composition of MOF that underwent the thermal process may be affected and 
in a result a mixture of oxides can be formed, and this composition is not stable in 
time, which is leading to uncertainty of the cisplatin/ Pt content that was initially 
incorporated in the sample. However, the attempt was made to estimate the 
amount of cisplatin by comparing the differences in the solvent content between 
loaded and unloaded MOFs based on the TGA plots. The free space in the pores 
of the framework should be filled up by H2O/DMF and in the encapsulation 
process will be taken and is occupied by cisplatin molecules instead. 
The water content in the MOF-cisplatin loaded samples was read out from the 
TGA plots (weight loss at 110°C), and was found for CPO Mg to be 2.5 wt% 
(from 27.5 wt%), for CPO Ni by 1.5 wt% (from 24.6 wt%). In case of Zr-MOFs, 
MOF Pt content wt%±SEM Cisplatin content 
wt%±SEM 
Method 
UiO66-encapsulated 4.6 ± 0.2 7.07 ±   0.4 ICP-MS 
UiO66-NH2-encapsulated 6.8 ± 0.3 10.46 ± 0.5 ICP-MS 
UiO66NH2-conjugated 6.5 ± 0.3 10.00 ± 0.5 ICP-MS 
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as for their synthesis DMF is used, which is then partially exchanged with water 
in the solvent exchange process, the solvent content (water + DMF) was read out 
from the TGA plots as a weight loss at the 160 °C. The following changes were 
noticed loaded vs. unloaded samples: a drop by 6.6 wt% (from 23.1 wt%) in case 
of UiO66 and by 8.2 wt% (from 21.7 wt%) in case of UiO66NH2, this is based on 
TGA results obtained in St Andrews, the feed gas used was air. The amount of 
solvent content for each of the MOFs that drops after the encapsulation may be a 
good estimate of the cisplatin quantity that was successfully encapsulated in the 
porous framework, as the TGA results match closely the results of ICP/MP. 
MOF “Drop” in a solvent content Cisplatin content by ICP/MP 
CPO Mg 2.4 wt% 2.53 wt% 
CPO Ni 1.5 wt% 1.39 wt% 
UiO66 6.6 wt% 7.07 wt% 
UiO66-NH2 8.2 wt% 10.5 wt % 
Table 4-5 Comparison between results obtained in ICP-MP analysis and 
TGA solvent losses. 
It should be noted that comparing the differences in a weight loss between loaded 
and unloaded MOFs can be misleading as to the cisplatin or Pt content emerging 
from the fact that Pt is a very heavy molecule (Mmol = 195.084 g/mol) when 
compared to metal molecules in MOFs: Mg (24.305 g/mol), Ni (58.693 g/mol) or 
Zr (91.224 g/mol) that are the remaining product or their oxides of the combustion 
process, the composition of these product may not be stoichometric and may vary 
depending on many conditions. For simulation purposes the Table 4-6 was 
compiled to depict probable outcomes for combustion products based on the 
assumption that there will be a preference for oxide formation (NiO, MgO, ZrO2), 
no oxide formation or half oxide formation (eg. 3 Zr + 3 ZrO2). This is due to the 
fact of a limited knowledge of the product composition once their combustion is 
completed. MOFs can absorb various amount of solvents in their pores depending 
on the conditions, some of the pores may remain empty. During the combustion 
process different products are formed, depending on the framework. Thus, it is 
very challenging to predict the drug content in the situation that the drug will not 
be completely burned out, and in the case of cisplatin, most probably Pt or PtO are 
formed. 
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Remaining product in wt% 
(100% = dehydrated MOF compensated by 
solvent content from TGA plot) 
Remaining product in wt%  
100% = Structural MOF formula as given 
in literature 
Experimental 
results in wt% 
No oxides oxides Half oxides No oxides oxides Half oxides 
16% 26% 21% 11 % 19% 15% 20.7% 
30% 38% 34% 24% 30% 27% 26.2% 
26% 37% 32% 34% 44% 39% 33% 
27% 35% 31% 32% 42% 37% 31% 
Table 4-6 Simulation of the possible products forming during TGA 
combustion of MOFs. 
 
Figure 4-6 TGA of MOFs loaded and unloaded with cisplatin, cisplatin 
marked in black for a reference. 
By combining the results obtained from ICP/MP-AES analysis and TGA plots 
(weight loss of solvents), the calculations on the Pt:Metal ratio were conducted. In 
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the TGA process, the solvent evaporates first. Each of the samples contains a 
known amount of cisplatin. Let’s calculate the “dry” mass of the MOF: 100% – 
[solvent] % – [cisplatin] % = dry pure MOF. These masses are then calculated 
into mols of substance, for MOFs this will be the dehydrated structure with no 
water molecules (UiO66 = 1664 – 36 g/mol, UiO66NH2 = 1754 – 36 g/mol, CPO 
Mg = 242 g/mol, CPO Ni = 311 g/mol). Based on this assumption, we obtained 
the following ratio of Pt: Metal, CPO Mg [Pt:Mg = 1:68.4], CPO Ni [Pt:Ni = 
1:102.4], UiO66 [Pt:Zr = 1:10.7], and UiO66NH2 [Pt:Zr = 1:6.6]. 
For UiO66NH2 with a conjugated prodrug, the synthesis conditions will have 6 
amine groups available to be functionalised and only 2 prodrug groups (reaction 1 
mol of MOF on 2 mols of Pt-prodrug) based on the ICP result for Pt content of 6.5 
wt%, we can form an equation (Eq.4-2), describing the number of moles of Pt per 
1 mol of the MOF: 
         
              
           4-2 
Where x is the number of moles (prodrug or Pt) being conjugated to the amine 
group of Zr-MOF and a equals either 0 (unsuccessful), 1 or 2 (if all the available 
amine groups set by synthesis conditions are conjugated, every 3
rd
 amine group). 
Solving this equation, we obtain x = 0.6783±0.12%, by rounding it up 0.68. So the 
ratio Pt: Zr = 1:8.82, meaning that roughly every 8
th
-9
th
 amine group will be 
conjugated to Pt-prodrug. If the entire amount of Pt was successfully conjugated 
to the amine group, then the Pt wt% would be 15.09 wt% (Table 4-7). The max 
incorporation of prodrug functionalising all the 6 amine groups would require the 
dose of 210 mg per 140 mg of Zr-MOF. 
No. of functionalised amine groups 1 2 3 4 5 6 
Pt wt% 9 15 19 23 25 28 
Table 4-7 Pt wt% content in the MOF depending on the number of amine 
groups successfully functionalised. 
Some attempts were made to adapt UVVIS analysis for the purpose of cisplatin 
content determination. However, the MOF samples gave the signal at the cisplatin 
maximum of Absorbance at 301 nm masking it and setting up a new cut off at 
around 300 nm. This was noticed for CPO Mg and CPO Ni and UiO66 samples 
and made the application of this method for determination of cisplatin quantity, 
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impossible. MOFs’ own absorbance masks completely the spectra coming from 
cisplatin. Due to the fact that molar absorption coefficient for cisplatin for its 
maximum at 301 nm is 0.130 mM
-1
cm
-1
, giving A = 0.2 for the concentration of 
0.49 mg/ml, the further dilution of the samples would lead to reaching the 
undetectable limit of cisplatin concentration. In case of UiO66-NH2, this “feature” 
of the powder was only observed when a dissolution studies were performed on 
the control sample (pure UiO66-NH2) and the test sample (loaded with cisplatin). 
The control sample would give absorbance signal that would gradually be raising 
with higher t > 0 min, excluding the application for UV-VIS method (Figure 4-7). 
 
Figure 4-7 Results for the cisplatin quantification by application of UVVIS. 
A.) shows the release measured for UiO66NH2, over 180 min and after 15 and 
35 min on the test samples B.) release measured for UiO66. Experiment used 
the pelletised material.  
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4.3.2 Cisplatin Release 
The quantification of the cisplatin in samples was performed utilising ICP-AES 
and ICP-MS, and MP-AES technique was used to assess how much cisplatin 
(wt%) has been released over time from the drug – loaded MOF. 
For the release experiment, MOF powder (CPO Ni, CPO Mg, UiO66 and UiO66-
NH2) was prepared in a form of a pellet ca. 20 mg each, containing 25% of a 
drug-loaded MOF and the remaining 75% being Teflon. In each experiment, two 
pellets of 20 mg were added to 10 mL of TRIS buffer of pH 7.4, the release was 
carried out at 37 °C. TRIS buffer was prepared in a following way: 100 mL 0.1M 
TRIS (2-Amino-2-hydroxymethyl-propane-1,3-diol), 84 mL 0.1 M HCl, and 12 
mL deionised H2O), it is an organic compound widely used in biochemistry, here 
it was used in order to keep the solution free of Na
+
 and K
+
 ions, to protect the 
torch of MP-AES. Aliquots of 0.5 mL were removed in the following time points: 
15 min, 30 min, 1 h, 2, h, 3 h, 4 h, 5 h and 24 h. Cisplatin release was quantified 
as expressed in Pt amounts in solution and then the cisplatin content calculated 
based on Pt content. Experiments were performed in duplicate. All calculations 
for the extent of release are related to the amount of the active powder in a pellet 
and not to the mass of a pellet. Also, a pellet preparation technique was applied in 
order to examine the feasibility of adjusting the percentage of drug (active 
powder) in a pellet, replacing 75% of its weight with a non-toxic material such as 
Teflon (patient dependent dose). The results are shown in the Figure 4-8 below. 
 
Figure 4-8 Plot depicts cisplatin release from the MOF pellets (25wt% of the 
pellet is an active MOF-powder) over 24 hours. 
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The plot shows that the release of cisplatin from CPO Mg powder (cisplatin 
loading at the level of 2.53 wt% ) is reaching nearly 40 % of the incorporated 
cargo, and is the highest from the given MOF. UiO66-NH2 releases only above of 
5% of its cargo, which is the lowest, even though the ICP analysis showed that the 
cisplatin loading is the highest. It must be noted that the drug loading content for 
this diagram for CPO Mg and CPO Ni are based on the digestion in concentrated 
HCl and analysed by MP-AES and for the Zr-MOFs a special digestion technique 
was applied and analysis performed on ICP-MS, thus the comparison should be 
made between CPO Mg and CPO Ni, pointing out that CPO Mg is a better 
candidate for a drug delivery carrier for cisplatin than CPO Ni is. It should also be 
stressed that cisplatin content is expressed in weight units and CPO Ni is much 
heavier than CPO Mg which may lead to this conclusion. Conversely, analysis of 
the released cisplatin quantities by UiO66 and UiO66-NH2 points out that the 
former is a better candidate for drug delivery system for cisplatin. It should be 
noted that the release was carried out over a limited time which is 24 hours, and 
the curves are still far away from reaching a plateau, apart from performance of 
UiO66-NH2. The quantities of released cisplatin are reaching 38.6 % in case of 
CPO Mg, 31.8 % for UiO66, 21.6 % for CPO Ni and only 5.6 % for UiO66-NH2. 
The poor release of cisplatin obtained from UiO66-NH2, despite its high drug 
loading of 10.5wt %, may be linked to the interaction between the amine group 
and Pt in cisplatin, most probably ruled by the very same mechanism that is 
involved in Pt-binding at the N7 sites of Guanosine (Guo) and Adenosine in 
DNA. Cisplatin binds much more strongly to guanosine due to the fact of amine 
binding to the oxygen on guanosine 
30, 31
. The diagram Figure 4-9 below shows 
the release of a drug expressed in Pt quantities in μg per each mg of MOF powder. 
Chapter 4 MOFs as drug delivery carriers for cisplatin 
 
67 
 
 
Figure 4-9 Release of cisplatin from the MOF powders expressed in 
quantities of Platinum [μg] per MOF weight unit [mg]. The pellets used 
contained 25% wt of cisplatin loaded MOF powder. 
If we looked at the release of Pt expressed in μg per mg of MOF, the one carrying 
the highest amount of Pt is UiO66, with 14.66 μg/mg, Pt release of others is 
inferior with UiO66-NH2, carrying 3.82 μg Pt per each mg of MOF and CPO Ni 
with only 1.96 μg. This may be due to the poor loading achieved or blockage of 
the encapsulated quantities in case of amine-Zr MOF. The content of cisplatin in 
the samples was calculated based on the Pt concentration, by multiplying it by a 
factor 300.01/195.08, which corresponds to molecular weight of cisplatin to 
molecular weight of Pt. 
To normalise the results and accommodate the differences in molecular weight of 
the MOF compounds, Pt or cisplatin release profile and drug loading, were 
expressed in μg cisplatin per mol of MOF. This allows for a direct comparison of 
drug loading potential. The molecular formula of UiO66 is 
Zr6O4(OH)4(CO2C6H4CO2)6 and molecular weight 1664 g/mol thus one gram of is 
equivalent to 0.60 mmol 
32
, UiO66NH2 is Zr6O4(OH)4(CO2C6NH5CO2)6 and 
molecular weight 1754 g/mol and similarly 1 g an equivalent of 0.57 mmol. For 
CPO-27 the molecular formula is M2(C8O6H2)(H2O)2•8H2O 
23
 the molecular 
weights are: 491 g/mol and 423 g/mol, with 1 g equivalents of 2 mmol and 2.36 
mmol for CPO Ni and CPO Mg respectively. This approach is simplified and does 
not compensate for H2O and DMF presence in the pores of the material. The 
results are shown in Figure 4-10. 
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Figure 4-10 Release of cisplatin, depiction of a normalised release of cisplatin 
to mol of MOF, a.) g of cisplatin per mol of MOF and b.) mmol of cisplatin 
per mol of MOF. 
The same results were calculated to express the quantity of cisplatin per 1 mol of 
metal in the MOF. In all of the depictions UiO66 is the best performing MOF for 
the release of cisplatin and CPO Ni is not performing so well.  
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Figure 4-11 Cisplatin released quantities per 1 mol of Metal ion, a.) in g of 
cisplatin and b.) in mmol of cisplatin. 
In order to check if the Teflon content may have influenced the release profile of 
the drug, a pellet containing 100% active powder of CPO Ni was prepared. CPO 
Ni was chosen as it was the option with very low cisplatin release, the experiment 
was run in a duplicate and release carried over 48 h. Also, this was carried on the 
best performing MOF, UiO66, over 24 hours. The results are shown in the Figure 
4-12 below. All the calculations relate to mass of active MOF powder used in that 
experiment. 
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Figure 4-12 Cisplatin release profile from pellets containing 100% of active 
powder and only 25%, the rest being Teflon. 
The values obtained indicate a possible Teflon influence on the cisplatin release 
profile from pellets prepared with 25% of active powder (CPO-27 Ni, UiO66). 
The difference is 5.7 μg/mg active MOF, 3.00 μg/mg vs. 8.7 μg/mg (CPO-27 Ni). 
This is not the case for UiO66 though. This may be due to entrapment of cisplatin 
in the MOF structure when the pressure is applied to form a pellet and the Teflon 
presence may work as a release-block. The Zr-MOF with a conjugated prodrug of 
cisplatin has not been tested for the release profile as it is envisaged that the 
release mechanism will be activated by reducing environment in the cancer cells 
in which [Pt
IV
(NH3)2(Cl)2(OH)(O2CCH2CH2CO-NH-UiO66)] will be reduced to 
[Pt
II
(NH3)2]Cl2 which in the solution will form a radical [Pt
II
(NH3)]
2-
 that easily 
interacts with nitrogen (N7) of guanine on double-stranded DNA chain
3, 28, 33, 34
. It 
has been proven that Pt(IV) – prodrug compound does not have the ability to 
cleave the DNA chain by intercalation of Pt to guanine or adenine and only 
cisplatin Pt(II) moiety shows such a behaviour
35, 36
. 
4.3.3 Viability assays 
Viability assays were set up and performed in order to assess the efficacy of the 
two proposed methods for cisplatin incorporation in the MOF framework. One 
being physical encapsulation and the other conjugation of a modified cisplatin 
prodrug to an amine group of Zr-MOF. These assays used Resazurin dye (Alamar 
Blue assay) and Flow Cytometry (FACS) techniques. The latter method also 
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allowed to assess the kind of death, the cell undergoes by cell staining with the 
markers such as FITC-Annexin V to quantify early apoptosis and Ethidium 
Homodimer III (superior to Propidium Iodide) for necrosis. The mechanism was 
described in Chapter 3 Experimental Methods. 
4.3.3.1. Viability of cells : Conjugation vs. Encapsulation method 
Alamar Blue assays, as well as FACS, were used to quantify the viability of cells 
that were exposed to drug delivery systems, for 24 hours. Both viability assays 
were performed using different passage number and different cells, Alamar Blue 
tested viability on A549 lung cancer whereas FACS – THP-1 human leukemia 
cancer. The FACS instrument is designed to work with suspension cells and if 
adherent cell culture should be investigated, the cells must be treated with trypsin 
so they could flow freely and be counted. This may though influence the results 
and may block the instrument, this is why only THP-1 cells were tested with the 
FACS technique for the purpose of this thesis. The prodrug of cisplatin 
[Pt
IV
(NH3)2(Cl)2(OH)(O2CCH2CH2CO2H)] that was used in the conjugation 
reaction was analysed by Elemental Analysis showing that values found during 
the analysis, [C] 10.77 %, [H] 2.67 % and [N] 6.61 % agree with expected content 
11 wt%, 2.76 wt% and 6.45 wt% respectively. Cisplatin as well as two modified 
compounds, oxoplatin and prodrug were analysed using ATR spectroscopic 
technique showing the vibrations of characteristic bonds, this indicates that 2-step 
cisplatin modification reaction was successful. In a prodrug spectra a very broad 
band of O-H stretch can be seen in a range of 3300-2500 cm
-1
, C=O stretch 1760-
1690 cm
-1
 and C-O stretch 1320-1210 cm
-1
. ATR infrared spectroscopy (Figure 
4-13) shows bands at around 1580 and 1730 cm
-1
 corresponding to amide groups, 
proving a peptide bond formation between the Pt(IV) prodrug and the amine 
group of UiO66-NH2. Small bands corresponding to amine groups can also be 
seen, as not all available amine groups on the MOF were involved in the 
conjugation. The band at 1750 cm
-1
 in the MOF, completely disappeared after 
conjugation, which supports the hypothesis of a successful conjugation. 
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Figure 4-13 FTIR spectra of modified cisplatin products and Zr-MOF. 
TGA analysis of cisplatin, prodrug, UiO66-NH2 and Zr-MOF with a conjugated 
prodrug indicates that the compounds are different to cisplatin. Cisplatin TGA 
curve shows that this compound starts to decompose at 270 °C with a weight loss 
of 37.6 % which indicates that metallic Pt is a combustion product. The TGA 
analysis (Figure 4-14) was performed with nitrogen as a feed gas so no oxides can 
be formed. In case of prodrug, the weight loss amounts to 52.8 wt% which also 
indicates that a prodrug is burned to metallic Pt. The difference in weight loss 
between the Zr-MOF with conjugated prodrug and pure Zr-MOF is ca. 4 wt%, 
which is due to the Pt quantities in the burned material.  
 
Figure 4-14 TGA results for Zr-MOF, cisplatin and a prodrug. 
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The results obtained from TGA in oxygen free environment for the Zr-MOF 
encapsulated with cisplatin is not clear as it indicates the Pt content at the level of 
29.3 % wt and ICP-MS showed that Pt weight content is at the level of 6.5 %wt. 
This may be due the formation of an oxide product that is stable in temperatures 
of more than 800°C. In the MOF framework, there is oxygen available for this 
new compound formation. There was an idea to analyse the product that was left 
after TGA analysis with X-ray radiation, however, the quantities were very small. 
The amide-coupling reaction allows for the direct incorporation of a non-toxic 
Pt(IV) prodrug to the MOF amine group. The Pt(IV) prodrug can be easily 
reduced in an environment poor in oxygen, resulting in cytotoxic Pt(II)-containing 
cisplatin. This reduction can be realized by biological reducing agents such as 
glutathione
28, 37
. The MOF integrity was retained after the coupling process. No 
impurities are evident in the PXRD pattern, which is shown in (Figure 4-15). 
Some attempts were made to reduce the Pt(IV) prodrug with ascorbic acid
27
 and 
quantify the amount of cisplatin released by 
195
Pt NMR, however the signal to 
noise ratio was low and the results therefore inconclusive. 
 
Figure 4-15 PXRD of UiO66-NH2, phase pure (blue) and with a cisplatin 
prodrug conjugated (red). 
The lung cancer cell line A549 was stimulated with different MOF formulations 
and cell viability was examined after 24h exposure using the Alamar Blue assay. 
This cell line was selected for in vitro studies because cisplatin is commonly used 
to treat lung cancer. The data are presented as mean ± SEM (standard error of the 
mean) from two independent experiments, with each set of conditions run in 
triplicate for each experiment. Suspensions of the MOF formulations were 
Chapter 4 MOFs as drug delivery carriers for cisplatin 
 
74 
 
prepared with a concentration of 1mg/100µL and aliquots of 10, 30 and 50 L 
were used to stimulate the cells. MOF powders were ground in the mortar with a 
pestle before preparing the suspensions so to avoid big agglomerates of the 
powder. This corresponded to 100 g, 300 g and 500 g of MOF per well 
respectively. Complete RPMI was added to even up the volume in wells to 150 
L. A cisplatin solution was prepared as a positive control, with a concentration 
of 1 mg/ml (3.33 mM). The aliquots used for cell stimulations were the same as 
those for MOF powders: 10 L (cisplatin concentration 222 µM), 30 L (cisplatin 
concentration 666 M) and 50 L (cisplatin concentration 1110 M). Statistical 
analysis was performed by Repeated Measures ANOVA and Sidak’s multiple 
comparisons test using GraphPad Prism v6.05 software. Differences between 
means were considered statistically significant when P < 0.05 (*), P < 0.01 (**), P 
< 0.001 (***), or P < 0.0001 (****). “P” is the probability of obtaining the 
observed effect purely due to chance. P < 0.05 is the conventional threshold for a 
statistically significant result, and indicates that there is only a 5% of chance that 
the conclusion drawn is in fact false. Subsequent levels of significance commonly 
used in statistics are P < 0.01, P < 0.001, P < 0.0001, which denote 1%, 0.1% and 
0.01% chance, respectively. The lower the P value obtained, the higher the level 
of significance of the observed effect and, consequently, the greater our 
confidence that it is true. Statistical analysis was performed by Dr Ilona 
Kubajewska. The cytotoxic efficacy of UiO66-NH2 with encapsulated cisplatin 
and UiO66-NH2 conjugated with the cisplatin prodrug are compared in Figure 
4-16. It appears that the latter performed better in inducing cell death, particularly 
at higher concentrations where statistically significant outcomes were observed. 
This is expected to be a result of the higher drug accessibility “on demand” in the 
conjugated system, as well as the binding between cisplatin and the amine groups 
of UiO66-NH2 quenching the release. The conjugated UiO66-NH2 system shows 
approximately the same cytotoxicity as the cisplatin itself at higher 
concentrations, but is less effective at low concentrations. In all cases, there is a 
distinct dose-dependent effect observed of the drug-loaded MOFs on cell 
viability. It is clear that these systems are biologically functional, and thus have 
potential as drug delivery systems.  
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Figure 4-16 Cell viability (A549) after 24h exposure to UiO66-NH2 with 
encapsulated cisplatin and conjugated with the prodrug. Results are from 
two separate experiments, each of them conducted in triplicate, shown as 
mean ± SEM. *,** refer to the p values of statistical significance P<0.05 (*) 
and P<0.01 (**). 10, 30 and 50 μL are the volumes of aliquots added to the 
cell suspension correspond to a concentration of encapsulated cisplatin that 
can be found in Table 4-8 and 4-9. Cisplatin stimulating solution 1mg/ml was 
added as the same aliquot volumes with concentrations corresponding to 222, 
666 and 1110 μM respectively for 10, 30 and 50 μL added. 
The situation is pretty similar for THP-1 cells stimulated with Zr-MOF 
formulations. The volume of the cells being stimulated was 200 μL and added 
aliquots were 50 μL (1 mg / 100 μL). The results (Figure 4-17) show that prodrug 
stimulation induces much higher apoptotic death than cisplatin does. The Zr-MOF 
with a conjugated cisplatin prodrug is showing slightly higher efficacy (viability 
at the level of 76 %) than the formulation prepared in the encapsulation route 
(viability 81.5 %). The percentage of cells undergoing the necrotic death induced 
by drug delivery systems based on UiO66-NH2 with incorporated cisplatin, is very 
small and the result show that it is not a main mechanism for cell death. It is worth 
noting that no matter how diligently the powders were ground and milled before 
preparation of suspensions for cells stimulations, the formulation was not 100% 
homogenous. This may have caused a disruption and influenced the results 
obtained as it cannot be excluded that bigger or smaller chunks of material may 
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have been pipetted during cell stimulation experiment. The possible way to 
address this could be separation of MOF powders into the fractions using a sieve, 
however, it may not solve the problem and the sieve could retain cisplatin 
particles on its metal surface or making them in a nanoparticles size. 
 
Figure 4-17 THP-1 cell viability (blue) by FACS, differentiating between the 
cell death: apoptosis (green), late apoptosis (gray) and necrosis (red). The 
error bars are SD (standard deviation) of results taken from duplicates. 24h 
stimulation. Concentration of MOF stimulant 2 g/L (500 μg/250 μL). 
Amounts of encapsulated cisplatin may be bound to the amine group which would 
impair or even stop the drug release, the ICP (Inductively coupled plasma) 
quantified cisplatin loading is slightly higher (10.5 wt%) for a carrier with 
encapsulated drug, however, the efficacy is lower as shown by the results in the 
two viability assays. In case of a conjugation technique, the release of the prodrug 
is not influenced by the amine group. 
4.3.3.2. Viability of cells: Zr-MOFs (UiO66 and UiO66-NH2) and CPO-27 
(Ni and Mg) as an example of drug delivery carriers in 
encapsulation route 
Four MOF materials have been selected for carriers of cisplatin, and these systems 
were prepared by the encapsulation route. Their efficacy against cancer was tested 
on 2 types of cell lines: A549 lung cancer and THP-1 human leukemia. MOFs 
were chosen due to their non-toxic character, large pores and simplicity of the 
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synthesis route
22, 25, 26, 38
. Alamar Blue assay was used to assess viability of A549 
cells and the cells’ viability was monitored in two time points, after 24 and after 
48 hours. The FACS allowed assessment of viability and conclude the kind of cell 
death that the used formulation may induce. Table 4-8 presents the relations 
between added material and the concentration of MOF powder in the well. The 
cell concentration for both cell lines were not the same, and the seeding density 
adjusted to the type of the cells, in case of A549 cells in the given volume of  
100 μL, 4 000 cells were seeded and in case of THP-1, 200 000 cells were seeded 
per 200 μL (100 000 per 100μL).  
Aliquots added[μL], 
all MOFs 
MOF quantity added to 
cells[μg] 
A549 cell line 100 μL 
MOF concentration [g/L] 
THP-1 cell line 200 μL 
MOF concentration [g/L] 
10 100 0.9 0.5 
20 200 1.7 0.9 
30 300 2.3 1.3 
40 400 2.9 1.7 
50 500 3.3 2.0 
Table 4-8 Amount of aliquots of MOF suspension used for cell stimulations. 
The cisplatin concentration based on the ICP measurements has been found to be 
1.39 wt% for CPO Ni, 2.53 wt% for CPO Mg, 7.1 wt% for UiO66 and 10.5 wt% 
for UiO66-NH2. By multiplying the MOF powder quantities pipette in the well by 
these values, the cisplatin concentration can be found and expressed in [g/L], and 
this can be further calculated to express this concentration in mM, see tables Table 
4-9 and Table 4-10. Cisplatin solution 1 mg/mL used as a standard (aliquot of 50 
μL) corresponds to the concentration of 200 mg/L, 0.67 mM for THP-1 cells 
stimulation and 333 mg/L, 1.11 mM for A549. 
A549 cell line 100 μL 
MOF concentration 
[g/L] 
CPO Mg 
Cisplatin 
concentration 
(mg/L) [mM] 
CPO Ni 
Cisplatin 
concentration 
(mg/L) [mM] 
UiO66 
Cisplatin 
concentration 
(mg/L) [mM] 
UiO66-NH2 
Cisplatin 
concentration 
(mg/L) [mM] 
0.9 (23.0) [0.08] (12.6) [0.04] (64.5) [0.22] (95.5) [0.32] 
1.7 (42.2) [0.14] (23.2) [0.08] (118.3) [0.39] (175.0) [0.58] 
2.3 (58.4) [0.19] (32.1) [0.11] (163.8) [0.55] (242.3) [0.81] 
2.9 (72.3) [0.24] (39.7) [0.13] (202.9) [0.68] (300.0) [1.00] 
3.3 (84.3) [0.28] (46.3) [0.15] (236.7) [0.79] (350.0) [1.17] 
Table 4-9 Concentration of cisplatin (mg/L) and (mM), stimulated A549 cells. 
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THP-1 cell line 200 μL 
MOF concentration 
[g/L] 
CPO Mg 
Cisplatin 
concentration 
(mg/L) [mM] 
CPO Ni 
Cisplatin 
concentration 
(mg/L) [mM] 
UiO66 
Cisplatin 
concentration 
(mg/L) [mM] 
UiO66-NH2 
Cisplatin 
concentration 
(mg/L) [mM] 
0.5 (12.0) [0.02] (6.6) [0.02] (33.8) [0.11] (50.0) [0.17] 
0.9 (23.0) [0.04] (12.6) [0.04] (64.5) [0.22] (95.5) [0.32] 
1.3 (33.0) [0.11] (18.1) [0.06] (92.6) [0.31] (137.0) [0.46] 
1.7 (42.2) [0.14] (23.2) [0.08] (118.3) [0.39] (175.0) [0.58] 
2.0 (50.6) [0.17] (27.8) [0.09] (142.0) [0.47] (210.0) [0.70] 
Table 4-10 Concentration of cisplatin (mg/L) and (mM), stimulated THP-1 
cells. 
This indicates that formulation UiO66-NH2 with its high drug loading, in the dose, 
that is introduced in the cell media and brings in slightly more cisplatin in the 
well, should have the same or higher efficacy as 1 mg/ml cisplatin solution and 
the viability should be same after treatment with cisplatin solution and by 
stimulation with Zr-MOF. 
 
Figure 4-18 Viability results by Flow Cytometry, THP-1 stimulation over 24 
h exposure. Fluorescent staining allows to recognise the cell death 
mechanism. The error bars are SD (standard deviation) of results taken from 
duplicates. Concentration of MOF stimulant 2 g/L (500 μg/250 μL). 
Nevertheless, the results do not seem to support this (Figure 4-18). There is no 
significant difference between the viability of the cells stimulated with UiO66-
NH2 and the MOF containing cisplatin. This, may be connected with the retention 
of cisplatin in the MOF framework due to the interaction of amine group with Pt 
in the cisplatin and also the imperfection of a suspension as is not homogeneous. 
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UiO66 does not effects the viability of cells (97 %) and when loaded with a anti-
cancer drug cargo decreases cells’ survival (86 %). CPO Ni shows surprisingly 
high viability (89 %), and when encapsulated with cisplatin this viability will be 
decreased (76 %), same is observed for CPO Mg (82 %), however here, the % 
surviving cells is significantly lower ca. 50 % when cells are treated with the 
MOF carrying a drug cargo. Results depend on the homogeneity of the suspension 
as well as the condition of the cells used in the experiment (passage number). 
Below an example of a FACS cell viability analysis performed on cells of lower 
passage number (Figure 4-19) is presented. Unfortunately, the instrument got 
clotted and it was not possible to unblock it to finish the run including all the test 
samples in duplicate, that is why only those that were measured in duplicate are 
shown. Once the cells have been stimulated and the fluorescent dyes added there 
is a small time window for performing the analysis and the material cannot be 
preserved in the e.g. fridge for further investigations. 
 
Figure 4-19 FACS analysis of THP-1 cell viability performed on lower 
passage number. The error bars are SD (standard deviation) of results taken 
from duplicates. 24h stimulation. Concentration of MOF stimulant 2 g/L (500 
μg/250 μL). 
We can see that viability of the cells treated with pure UiO66 MOF is not 
compromised and is dramatically lower when treated with cisplatin-loaded 
UiO66, its efficacy is very high and is comparable to cisplatin, which could be 
concluded from the calculations of a dose being used to stimulate cell material 
(see Table 4-10).  
Chapter 4 MOFs as drug delivery carriers for cisplatin 
 
80 
 
Let’s take a look at the results obtained by stimulation of a different cell culture, 
A549 lung cancer, where cisplatin finds its application in various therapies
1, 39, 40
.  
The stimulation of cells was carried out for 24 h and 48 h and the results are 
depicted below (Figure 4-20) and (Figure 4-21). The number of the cell passage 
used for these experiment was 36 in case of 24 h and 37 in case for 48 h 
stimulations. The data shown come from two independent experiments (two well 
plates), in duplicate for each formulation. For each of the experiment, there was a 
viability calibration curve run along with the stimulations allowing to assess the 
viability. The standard curve was constructed as follows: fluorescence of 
untreated cells corresponded to 100 % and 0 % cells (RPMI media alone) to 0 % 
viability, with additional calibration points at 75 %, 50 % and 25 %. The amount 
of aliquots used for this experiment are listed in Table 4-9. The results show that 
after 24 h cancer cells stimulation with CPO Mg with encapsulated cisplatin, the 
cell viability drops, however there is no significant difference if this MOF 
contained cisplatin or not. To contrary, when stimulated with CPO Ni, the drop in 
viability for MOF carrying cisplatin cargo is noticeable. 
 
Figure 4-20 A549 cells viability testing, CPO Mg and CPO Ni used as a 
stimulant with/without encapsulated cisplatin a.) 24 hours and b.) 48 hours 
exposure. Concentration depicted in the legend refers to the quantity of 
added MOF in the aliquot. Please refer to Table 4-8, 4-9 and 4-10. 
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The situation changes for stimulations carried out for a longer time of 48 h. Here, 
we can see that viability of cells drops to 0 when CPO-27 Ni containing cisplatin 
is used. For CPO-27 Mg, there is a noticeable drop in cell viability after 
stimulation with the MOF containing cisplatin, which may be elucidated with the 
fact of delayed cisplatin release or the lack of homogeneity of the formulation. 
Particles size of CPO-27 Mg is 10 μm and CPO-27 Ni is 500-600 nm and this 
may be too big to migrate into the cell to release the cargo (see Figure 4-3). 
In case of Zr-MOF, the results show that viability of cells treated with UiO66 
containing cisplatin drops rapidly and at the same time the pure MOF is not 
cytotoxic to the cells when exposure is 24h. For UiO66-NH2, there is a slight 
decrease of the viability (drug carrier), however, pure MOF is not harmless to 
cells. The cisplatin loading is the highest achieved in this group of MOFs but the 
expected high cytotoxic effect is not observable. This is caused by interaction of 
amine group in the aromatic carbon ring of the framework with Pt of cisplatin. If 
the exposure time is increased to 48 hours, UiO66 is showing higher cytotoxicity 
towards the cells, however the UiO66 loaded with cisplatin does not kill the cells 
completely, which would be an indication that the cargo carried by the MOF has 
been released within 24 hours after stimulation. 
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Figure 4-21 A549 cells viability test, UiO66 and UiO66-NH2 used as a 
stimulant with/without encapsulated cisplatin a.) 24 hours b.) 48 hours 
exposure. Concentration depicted in the legend refers to the quantity of 
added MOF in the aliquot. Please refer to Table 4-8, 4-9 and 4-10. 
It can be concluded based on viability tests performed that the best candidate for 
the MOF-based drug delivery system prepared in the encapsulation route, is 
UiO66. The dose of cisplatin typically used in anti-cancer therapy is 20 mg/m
2
 per 
day for 5 days in case of testicular cancer, and 75 – 100 mg/m2 administered once 
every 4 weeks for ovarian cancer
41
. According to the Boyd formula
42
, an average 
male of 175 cm weighing 80 kg has a body surface area of 1.99 m
2
 Applying the 
same formula to an average female of 165 cm weighing 58 kg results in 1.63 m
2
. 
This would mean that in order to use the cisplatin-loaded MOFs in these therapies, 
an amount of ca. 1.7 g – 2.3 g (4 week treatment) would be necessary to treat 
ovarian cancer, and approx. 0.56 g for testicular cancer (a day).  
4.3.4 NPs of metallic Platinum as a result of one – pot synthesis. 
A synthesis aiming at cisplatin encapsulation in the one-step route in the variety 
of MOFs: CPO Mg and Ni as well as Zr-MOFs: UiO66 and UiO66-NH2, resulted 
in formation of metallic nanoparticles of Pt incorporated in the MOF framework. 
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This is quite an interesting aspect because it can open up the new potential 
application in photo catalysis and catalysis
43-45
. Some attempts have been made to 
immobilise nanoparticles of Pt in the voids of the UiO66-NH2 cages to use it as a 
platform for a catalyst
46
. The average size of the particles obtained in a one-step 
synthesis, was estimated to be 80 Å based on X-ray pattern analysis and 
application of the Scherrer equation
47
, see Eq. 4-3, where k is a constant, 
wavelength of radiation (λ), width at half maximum of the peak (β) and the Bragg 
angle (θ) in radians at which x-rays are scattered from the crystal lattice.  
  
  
     
       4-3 
The calculations were confirmed for UiO66 by TEM, Figure 4-22. Unfortunately, 
the MOF framework had been destroyed during this process and only the Pt can 
be seen here.  
 
Figure 4-22 TEM of the UiO66 with Pt particles inside. 
Incorporation of metallic Pt occurred during the microwave and autoclave routes 
of synthesis of UiO66 and UiO66-NH2. A comparison of the PXRD patterns of 
the pure MOF powders and those containing Pt nanoparticles are shown below in 
Figure 4-23. The broad peaks coming from metallic Pt can be seen in the PXRD 
pattern at 2θ of 39.76° (111) and 46.23° (200) with d of 2.265 Å and 1.962 Å 
respectively. These peaks have the highest intensities and thus are characteristic to 
Pt
48, 49
. In case of CPO Ni, the Pt is not noticable in the PXRD pattern, in case of 
CPO Mg, there are two broad peaks coming at the stated above 2θ values. 
However, when compared with a PXRD pattern of a pure MOF, these peaks are 
there too. It might lead to a conclusion that the peaks from Pt crystal latice and 
CPO-27 crystal lattices overlap.  
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Figure 4-23: PXRD of Zr-MOFs, phase pure UiO66 (red) and UiO66-NH2 
(blue) and containing Pt nanoparticles – UiO66 (green) and UiO66-NH2 
(purple). 
 
Figure 4-24 PXRD of CPO-27 MOFs, phase pure CPO Mg (green) and CPO 
Ni (gray) and after one-step synthesis with cisplatin CPO Mg (red) and CPO 
Ni (blue). 
The reaction temperatures used (120 °C and 220 °C for UiO66NH2 and UiO66 
respectively and 110 °C for CPO-27) which is much lower than the cisplatin 
decomposition temperature (270 °C), it is assumed that the reduction of the 
cisplatin to metallic platinum is driven either by the increased pressure in the 
sealed reaction vessel, or by reaction with acetic acid or formaldehyde produced 
by thermal decomposition of DMF. EDX shows that the Pt nanoparticles are 
homogeneously distributed throughout the MOF powders, with Zr : Pt ratios of 
1:2.6 and 1 : 1.5 (% Atomic) for UiO66 and UiO-NH2 respectively. For CPO Ni 
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EDX analysis is showing Pt : Ni ratio to be 1 : 115 (% Atomic), and for CPO Mg 
this relation is 1 to 29. The EDX analysis supports the argument that metallic Pt 
particles are entrapped in the CPO Mg structure.  
TGA measurements showed that nanoparticles of Pt in the structure do not 
significantly influence the robustness of the network, the decomposition 
temperature of the UiO66-NH2 remains effectively unchanged whilst that of the 
UiO66 decreases from 420 °C to approx. 400 °C upon inclusion of the Pt 
nanoparticles. The Pt-content, made on the basis of TGA, is estimated at the level 
of 9 % for both MOFs UiO66 and UiO66-NH2, see Figure 4-25. 
 
Figure 4-25 TGA analysis of Zr-MOFs with metallic Pt particles. 
4.4. Conclusions and Summary 
This chapter illustrated different synthesis strategies of the potential drug delivery 
systems for cisplatin and investigated potential usefulness of four MOFs for this 
purpose: CPO Ni, CPO Mg, UiO66 and UiO66-NH2. In case of the latter MOF, a 
conjugation technique of the Pt-prodrug (obtained by cisplatin modification) to 
the amine group by activating a formation of a peptide bond was researched. 
Results show that efficacy of such a drug carrier is better when compared with the 
system utilising the same MOF but prepared in the encapsulation route.  
The encapsulation route allowed for preparation a drug delivery systems that is a 
strong candidate – UiO66. This Zr-MOF releases cisplatin successfully and as 
consequence decreases the viability of the cancer cells. The experiments showed 
that the viability of cells decreased to 86% for THP-1 and 5% when performed on 
the lower passage number which can be compared with cisplatin efficacy (blood 
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cancer). Viability of A549 cells (lung cancer) when stimulated with UiO66 MOF 
dropped to 25% after the 24h exposure to drug delivery system and 16% after 48h 
exposure. This was the best result achieved in the group of MOFs being tested. 
This may be due to large pores in the structure of the UiO66 MOF. High porosity 
is also one of the properties of UiO66-NH2, however here, there is another 
mechanism coming to fore – an interaction of cisplatin with amine groups in the 
structure of this MOF. As a consequence, high loading of 10.46 wt% of cisplatin 
does not give rise to increased efficacy and UiO66 appears to be a better candidate 
with only 7.07 wt% cisplatin loading. Such a comparison is viable for both MOFs 
show very similar molecular weights. 
When comparing two cisplatin – loaded CPO-27 MOFs, according to the obtained 
results the efficacy of CPO Mg measured as a function of cell viability (lung and 
blood cancer cells) is higher than shown by cisplatin – loaded CPO Ni, and CPO 
Mg is considered as a non-toxic MOF in contrary to CPO Ni which contains Ni. 
However, if we only compared results obtained from viability assays performed 
on the lung cancer, it becomes obvious that after 48h exposure to the drug being 
released over time from CPO Ni system, the cell viability is less than 3%. It is 
worth mentioning that MOF powder showed tendency to form aggregates when 
suspended in the growth media during formulation preparations that were unable 
to break into smaller pieces, the pipetting of the given doses of stimulants is not 
error – free. In order to prevent this, a more optimised way of stimulants aliquots 
must be designed. 
 The one-pot synthesis for preparation of MOFs with incorporated cisplatin did 
not lead to a formation of drug delivery systems, however, allowed to prepare 
MOFs (UiO66 and UiO66NH2) with metallic particles of nano – Pt trapped in 
their pores. This might be an interesting method of synthesis of a subnano-
catalytic system with a MOF serving here as a carrier platform. 
TGA measurements proved to be not the best route to assess the cisplatin content. 
This may be caused by the presence of water molecules in the material that in the 
due course of cisplatin encapsulation are exchanged with cisplatin which is much 
heavier. Even though, the known amounts of MOF powders were used for 
encapsulation and concentration solution used for encapsulation and its volume 
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was also known, it proved not to give a precise cisplatin content in the loaded 
material but only an indication that there was a change of mass.  
The EDX method was used for crude estimates of cisplatin content, again the lack 
of knowledge on the exact molecular weight of material and operating only with 
approximation allowed for qualitative analysis and determination of regions in the 
sample with higher concentration of Pt. The method of choice when it comes to Pt 
content analysis should be ICP-AES/ICP-MP or MP-AES as these can give 
precise results for element content in the material as long as it is straight forward 
to perform mineralisation of the sample, which in the case of Zr-MOFs proved to 
be a complicated task and aqua regia solution was not able to dissolve the MOF 
structure. It was believed that this strong acid could allow for extraction of Pt 
from the pores of the material, however, once the microwave – based laser 
method, developed at the University of Warsaw in the group of Prof. Ewa Bulska, 
was applied to perform the dissolution of Zr-MOFs, the ICP –MP analysis 
returned higher Pt content. 
It was hypothesised that encapsulation of anti – cancer drugs in the delivery 
system may increase the efficacy of the anti – cancer therapy. The MOFs were 
thought to be a good candidate for a host with their large pores and availability of 
variety of structures. Nevertheless, it seems to be very hard to control the release 
of the drug that is loaded in the carrier system and remotely navigate the cargo to 
the tumour lesions sparing the healthy cells. As it was showed in this chapter, the 
high drug loading and release do not guarantee high efficacy and selectivity that is 
needed to fight the cancer. The author believes that another solution for anti – 
cancer therapies will emerge and this will be based on personalised medicine 
route
50
, relying on the cancer immunology of the human body
51
 employing 
monoclonal antibodies
52
 as drug carriers and exploring targets in cancer 
metabolism to design better delivery systems.  
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Chapter 5. MOFs as a drug delivery carrier for 
Fluorouracil (5-FU). 
5.1. Aims 
5-Fluorouracil (5-FU) is used to treat solid tumours administered either as an 
injection/infusion
1
 or topical as an ointment to treat skin cancers
2
, it is classified 
as anti-metabolite, which disrupts bioprocesses. The mechanism of action arises 
from the ability to inhibit thymidylate synthase (interfering with pyrimidine 
metabolic pathway) and the intercalation of fluoronucleotides in DNA and RNA 
chains which efficiently stops their synthesis that would lead to p53 dependent 
apoptotic death of a cancer cell
3, 4
. Such a treatment can cause several unpleasant 
symptoms when administered, just to name a few: nausea, vomiting and 
dermatological toxic effects, as it leads to a rapid absorption of the drugs through 
the cells. 5-FU has very short biological half-life of 8-14 minutes
5
, that is why 
there is a need for a carrier that could transport the drug through the body
6
 and 
release it after reaching its destination. There are some concepts of utilizing 
polymeric materials as the drug carriers
7-9
. Also, fluorouracil is not easily soluble 
in water which makes it challenging when it comes to preparation of drug 
formulations and high efficacy achieved by them. 5-FU can be easily dissolved in 
acids and basic solutions. Also high solubility is achieved in organic solvents like 
DMSO or DMF, these, however, are toxic and would be of hazard for bio-
applications. Metal organic frameworks with their high porosity and large pores 
able to accommodate guest molecules, came to interest as potential drug delivery 
systems for 5-FU encapsulation. There are some ongoing trials for incorporation 
of the drug, utilizing metal organic frameworks, serving as a host and carrier for 
the drug
10, 11
, liposomes are also used to serve this purpose
12
 as well as 
polymers
13
.  
In this chapter, two routes of encapsulations were investigated, one in methanol 
and the other in a solution comprising 50/50 v/v Methanol/Formic acid 
(MeOH/FA) to enhance the solubility of 5-FU and to increase amount of drug in 
the solution used for encapsulation. Four MOFs have been tested for their 
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retention and release of the drug: CPO-27 – Mg and Ni and Zr-MOFs – UiO66 
and UiO66-NH2. In order to assess efficacy of the obtained systems, biological 
testing was performed to evaluate viability of the cells that were treated with 
formulations as well as the type of death they induce. The released quantities and 
the achieved loading were measured using HPLC with a UV detector.  
5.2. Encapsulation MOFs with 5-FU (UiO66, UiO66-NH2, CPO 
Mg, CPO Ni) 
Physical encapsulation, also called impregnation, is one of the commonly used 
technique for incorporation of drugs into porous structures
14-18
. Based on this, it 
has been chosen for the investigation of its potential for 5-Fluorouracil. For these 
encapsulations, the MOFs previously synthesised for the cisplatin encapsulation 
were used Zr-MOFs and CPO-27. The details of their synthesis are described in 
Chapter 3. 
Two encapsulation solutions were prepared, one was pure methanol and the other 
was a mix v/v 50/50 of formic acid and methanol. The concentration of 5-FU in 
each of the solutions was adjusted according to the solubility data and kept at the 
level of 80% of max. solubility that could be achieved for that solvent. This gave 
the following limits: 40 mg/ml for Fluorouracil dissolved in Formic Acid and  
0.8 mg/ml for Methanol. The data was acquired from product specification sheet 
by one of the manufacturers
19
. The volume of the encapsulation solution was set 
to be 5 mL for each of the routes, and the amount of MOF powder was ca.  
100 ±5% mg in case of MeOH and 200 ± 5% mg in case of the 50/50 mix. The 
max amount of 5-FU in MeOH solutions was 4 mg, and 102 mg in 50/50 
solutions. Hence, the maximal achievable drug loading in this encapsulation was 
3.8 wt%[ 
 
     
 ] for the former and 33.8 wt% [
   
       
] for the latter case. The 
amounts of MOF powder were chosen based on the fact that some MOF quantities 
could be lost due to the centrifugation procedure and dissolving in the 
encapsulation media. The MOF powders were kept in the encapsulation solution 
under stirring for a period of 48h and recovered by centrifugation and left to dry. 
The experiment was prepared in duplicate. 
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5.3. Results 
5.3.1. MOF framework stability – X-ray of 5-FU encapsulated powders. 
The MOF’s stability was tested in a 50/50 v/v solution containing MeOH and 
formic acid (FA) to test if the framework can endure such a treatment. The 
duration of immersion under stirring was set to be 48 hours to recreate the 
conditions of drug encapsulation. 
The x-ray diffraction patterns recorded by the author, show that in case of UiO66-
NH2 the framework is kept intact. A presence of a new phase is observed for 
CPO-27 Ni which may be due to structure collapse or these extra peaks would 
signal the presence of 5-FU at the surface and not in the pores of material. In the 
case of the CPO-27 Mg, the peaks shift towards higher theta values that indicates 
the crystal lattice contraction, some peaks disappeared from the x-ray pattern 
which may indicate that this structure is digested over time by formic acid. For 
reference, the simulated x-ray diffraction pattern of 5-FU can be found in 
Appendix 2 p.170. After immersion in the solution, it was noticeable that some 
peaks disappeared from the x-ray pattern of UiO66. Here, due to the number of 
peaks missing, it is not possible to say which way they might have shifted. The x-
ray diffraction patterns are depicted in Figure 5-1 and Figure 5-2.  
 
Figure 5-1 X-ray diffraction patterns of CPO Mg and CPO Ni, untreated and 
after immersion in the solution of MeOH/FA. 
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Figure 5-2 X-ray diffraction patterns of UiO66 and UiO66-NH2, untreated 
and after immersion in the solution of MeOH/FA. 
After 5-FU encapsulation, the MOF structures were characterised by PXRD, in 
order to assess the integrity of the frameworks and the recorded x-ray patterns 
showed that the peaks were shifting. Cell parameter refinement was performed, 
using the CELREF software. The CIF files of the previously synthesised and 
reported MOFs were used as models for indexing the peaks of the MOF-powders 
that were used in the encapsulation experiment. This allowed to compensate for 
any changes in the cell parameters between the powders used and the CIF files. 
Based on this, an indexed framework of CPO-27 Ni, CPO-27 Mg and UiO66 were 
created and indexation operation was repeated using these indexed structures to 
determine the parameters of the cell that underwent encapsulation. It was expected 
that the cell unit should become slightly bigger, to accommodate the 5-FU 
molecules. This property has already been noticed in the case of MIL MOFs and 
described as a “breathing effect” and is connected with the expansion of the cell 
parameters to accommodate the guest molecules making MOFs potential 
candidates for drug encapsulation e.g. ibuprofen
15, 20-22
. This effect can be huge 
for MILs
22, 23
 but it is seemingly much smaller in the case of the MOFs author has 
chosen for 5-FU encapsulation. The peak indexing operation allowed to confirm 
that peaks are shifting, and the results of the cell parameters refinement are shown 
in Table 5-1 below. 
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CPO Ni 
R-3, α=β=90° ɣ=120°, a=b ≠c 
Pure 
V=3893 Å3 
5-FU in MeOH 
V=3966 Å3 
5FU (FA/MeOH) 
V=3893 Å3 
a=b 25.9279 26.1189 25.9234 
c 6.6881 6.7130 6.6894 
CPO Mg 
R-3, α=β=90° ɣ=120°, a=b ≠c 
Pure 
V=3957 Å3 
5-FU in MeOH 
V= 4018 Å3 
5FU (FA/MeOH) 
V= 4083 Å3 
a=b 25.9997 26.1296 26.2902 
c 6.7597 6.7966 6.8214 
UiO66 
FM-3M, α=β= ɣ= 90°, a=b=c 
Pure 
V= 8881 Å3 
5-FU in MeOH 
V=9106 Å3 
5FU (FA/MeOH) 
V=8889 Å3 
a=b=c 20.7089 20.8825 20.7156 
Table 5-1 Cell parameters refinement results obtained in CELREF software. 
Peaks coming from 5-FU were subtracted from the diffraction patterns of 
encapsulated powders by indexing 5-FU peaks based on its CIF file.  
Interestingly, the crystal lattice parameters expand when the encapsulation is 
performed in methanol (MeOH), and in case of MeOH/FA solution, this effect is 
only observed for CPO Mg. However, this cell parameter refinement is based on 4 
peaks that could be associated with the MOF framework, as other peaks are 
coming from 5-FU, indicating that the MOF framework did not kept intact. The 
peaks associated with 5-FU presence are showing up in the x-ray pattern, some 
already in MeOH encapsulation, though 5-FU peaks are especially noticeable in 
MeOH/FA encapsulation route. Each unit cell of 5-FU contains 8 molecules of the 
drug (Z=8 in the CIF file that was used)
24
, meaning that each molecule takes up 
125 Å3,  at the same time the pore volume per unit in CPO Mg based on CCDC 
668974 (Z=18) is 2843.18 Å3 which when recalculated per each individual Mg 
gives ca. 158 Å3. This leads to a conclusion that per each Mg atom, 1.26 5-FU 
molecules can be successfully encapsulated. During the encapsulation in MeOH, 
the unit cell volume of CPO Mg expands by 61 Å3 which would maximally allow 
ca. 1.29 5-FU per each Mg atom (2.4% increase), in case of MeOH/FA this 
expansion is bigger and maximum molecule load is thus ca. 1.32 5-FU molecules 
per each Mg atom (5% increase). In case of UiO66, the pore volume per unit cell 
equals 7845 Å3, which corresponds to 2.6 5-FU molecules per each Zr atom (24 of 
these in the unit cell). With changing cell parameters during MeOH encapsulation 
process this ratio will increase up to 2.7 (ca. 4% increase). UiO66-NH2 peaks 
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were not indexed due to the fact of a missing CIF file of the crystallographic 
structure. All the refined cell parameters are filed in Appendix 1 of this Thesis. 
Below, the x-ray patterns of the loaded/unloaded MOF materials (Figure 5-3, 
Figure 5-4) are depicted. At around 28° (2θ), in case of CPO Mg, CPO Ni and 
UiO66, there is a peak which is very characteristic for 5-FU presence in the 
structure. It has been observed that the peaks after the encapsulation with 5-FU in 
MeOH are shifting to the left, and that the encapsulation in FA/MeOH was quite 
detrimental for some of the MOFs, as not all of the peaks are present in the pattern 
(CPO Mg, UiO66) with the only MOF that “survived” encapsulation UiO66NH2 
as its structure remained intact. 
 
Figure 5-3 X-ray diffraction pattern of CPO Mg and CPO Ni, 
unloaded/loaded with 5-FU encapsulated  in MeOH or MeOH/FA. 
 
Figure 5-4 X-ray diffraction pattern of UiO66 and UiO66NH2, 
unloaded/loaded with 5-FU encapsulated  in MeOH or MeOH/FA. 
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The shift into lower angles is an indication that the cell parameters are changing 
and the crystal unit expanding to accommodate the drug in the MOF framework 
and we observe a slight “breathing effect”. 
5.3.2. Presence of 5FU in the pores of MOFs 
5.3.2.1. Changing BET 
The TRISTAR surface area and porosity analyser was employed to measure the 
pore volume as well as the BET surface area in order to compare these properties 
of the drug  loaded and unloaded MOFs. 
MOF/encapsulation 
route 
Evacuation 
temp [°C] 
Pore Volume BJH 
Desorption [cm³/g] 
Surface area BET 
m2/g 
UiO66-NH2 140 0.257 559.6 ± 13.4 
in MeOH 100 0.187 690.1 ± 17.2 
in MeOH/FA 100 0.186 284.2  ± 6.5 
UiO66 120 0.058 852.2 ± 3.8 
in MeOH 100 0.044 818.9 ± 22.3 
in MeOH/FA 100 0.008 1.6 ± 0.01 
CPO Mg 140 0.058 18.4 ± 0.23 
in MeOH 100 0.064 17.5 ± 0.23 
in MeOH/FA 100 0.007 2.9 ± 0.023 
CPO Ni 140 0.178 274.4 ± 6.8 
in MeOH 100 0.135 103.1 ± 2.4 
in MeOH/FA 100 0.027 4.2 ± 0.04 
Table 5-2 Adsorption properties of MOFs, BET, pores volume, pore size. 
The evacuation temperature was a bit higher for the pure MOFs because there was 
a concern that the 5-FU encapsulated in the pores may be destroyed by exposure 
to higher temperature under vacuum. This may lead to inaccuracies when the 
comparisons are made, for the surface area of the pure MOFs and their pore 
volume, as it was proven that these properties are highly dependent on the 
evacuation temperature
25
. On the other hand, if the evacuation temperature of the 
pure MOF, would match the one with the encapsulated drug, then the host (DMF, 
H2O) could still be in the pores leading to misleading results. The BET surface 
areas are decreasing for almost all MOFs tested, for the MeOH/FA encapsulation 
BET areas are dramatically low, which may be the effect of the partially destroyed 
structure depicted by x-ray diffraction patterns.  
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UiO66-NH2 structure according to x-ray patterns is perfectly intact, for MeOH/FA 
encapsulation there is a decrease of BET from 559 m
2
/g (pure MOF) to 284 m
2
/g, 
which is a loss of ca. 50%. The difference in the BET for 5-FU encapsulated in 
MeOH method (690 m
2
/g) and MeOH/FA method is huge, almost 3-fold, and it 
must be noted that in this case the evacuation temperatures were the same for both 
cases, 100°C. 
In CPO Ni, the specific pore volume of the pure MOF is 0.178 cm
3
/g measured at 
140°C. If we compared this with the unit cell parameters from CIF file, CCDC 
28847 comprising of 18 Ni Z=18 which corresponds to 2 molecules, we find the 
void area be 2809.6 Å3. Per each molecule it would be 312.2 Å3, and 156 Å3 per 
each Ni. It seems that “a guest” is taking up 0.043 cm3/g in MeOH encapsulation, 
5-FU molecule takes up 125 Å3 which corresponds to 344•1018 Fluorouracil 
molecules per gram of the powder, likewise 0.151 cm
3
/g drop (MeOH/FA) takes it 
to 1208•1018 5-FU molecules. Incorporating the Avogadro’s number to calculate 
the mol quantities, we get 0.057 mmol (7.41 mg) and 0.2 mmol (26 mg) for the 
second case for a gram of the powder. 
In UiO66, we find 0.058 cm
3
/g in the pure material, dropping to 0.044 cm
3
/g for 
the MeOH route and to 0.008 cm
3
/g for MeOH/FA route. In a CIF file CCDC 
73358, we have 54 Zr atoms which corresponds to 9 molecules comprising 6 Zr 
atoms each, for this unit cell the void area is 7845.3 Å3 which gives per molecule 
871.7 Å3 and 145 Å3 per each Zr. Again, the void volume drop of 0.016 cm3/g 
(MeOH) may correspond to 128•1018 molecules of 5-FU, and 0.05 cm3/g 
(MeOH/FA) to 400•1018 5-FU molecules. In moles quantities, we find here 0.021 
mmol (2.7 mg) and 0.066 mmol (8.6 mg) respectively, per each gram of the 
powder. These calculations may only be taken as the first approximation of the  
5-FU content and for a final confirmation another analytical technique should be 
involved, e.g. HPLC. 
5.3.2.2. FTIR spectra (ATR) 
The MOF powders were analysed using FTIR (ATR): Attenuated Total 
Reflectance method, because it offers a relatively straightforward and easy way 
for the sample analyses and eliminates the preparation of KBr discs. 5-FU 
structure is presented in Figure 5-5 . 
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Figure 5-5 Structure of 5-Fluorouracil. 
The recorded spectra, 5-FU and pure MOFs can be compared with the ones of the 
MOFs loaded with 5-FU in two encapsulation routes.  
The broad band 3300-2700 cm
-1
 can be assign to NH-stretching vibrations in 5-
FU and the stretching at 1647 cm
-1 
attributed to carbonyl group stretching (C=O), 
the peak at 1242 cm
-1
 arises from C-F bond stretching. These peaks can be found 
in the spectra of UiO66-NH2 encapsulated with 5-FU in MeOH/FA route, which 
can be seen in Figure 5-6. In case of  5-FU loaded UiO66, the peak coming at  
748 cm
-1
 in both of encapsulation routes that overlaps with stretching in the 5-FU 
spectra can serve as a proof of drug presence in the MOF framework (Figure 5-7). 
 
Figure 5-6 FTIR ATR spectra of UiO66NH2, 5-FU unloaded/loaded in two 
encapsulation routes. Red-marked is pure MOF. 
 
Chapter 5 MOFs as a drug delivery carrier for Fluorouracil (5-FU) 
101 
 
 
Figure 5-7 FTIR ATR spectra of UiO66, 5-FU unloaded/loaded in two 
encapsulation routes. Red-marked is pure MOF. 
In case of CPO Mg, the spectra analysis concluded that MeOH encapsulation was 
not as efficient as the one aided with addition of formic acid. 
The spectra of a 5-FU loaded MOF bears similar features  to the spectra of the 
drug (Figure 5-8). 
 
Figure 5-8 FTIR ATR spectra of CPO Mg, 5-FU unloaded/loaded in two 
encapsulation routes. Red-marked is pure MOF. 
 
Figure 5-9 FTIR ATR spectra of CPO Ni, 5-FU unloaded/loaded in two 
encapsulation routes. Red marked is pure MOF. 
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The spectra of MOFs prepared in MeOH/FA encapsulation route seem to show 
the stretching bands similar to the ones in the 5-FU spectra. Especially the bands 
at 725-817 cm
-1
 indicating the vibrations of CF=CH group. 
5.3.2.3. Drug release and challenges to measure it ( HPLC/UV-VIS) 
For the determination of the 5-FU quantities and its release profile encapsulated in 
the MOFs, HPLC method was applied. 5-FU calibration curve 0-250 μg/ml was 
constructed, based on 9 points, each measured 3 times (Figure 5-10). 
 
Figure 5-10 Calibration plot of 5-FU in a range 0-250 μg/mL. 
The aliquots (0.5 mL) were harvested during the 48h release experiment (time 
points 0.25, 0.5, 1, 2, 3, 4, 24 and 48h) and then diluted 5x and then filtered with a 
0.22 μm Micropore filter and transferred to the HPLC brown-coloured vials in 
order to keep them light-protected. Dilution was applied to perform a UV-VIS 
measurements for 5-FU quantities in a 2.5 mL cuvette. However, the spectra were 
masked by the MOFs inner-absorbance and another method of separation had to 
be applied. HPLC was the most appropriate. 
The CPO- Mg and Ni based samples (ca. 18 mg) were digested in a concentrated 
HCl (0.8 mL, 37%wt) and left overnight. Zr-based MOFs proved to be very robust 
and the digestion was not performed based on the previous experience with 
cisplatin. The following 5-FU quantities were found in the MOF powders: 
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MOF MeOH/FA encapsulation 
[μg 5-FU/mg powder] 
MeOH encapsulation 
[μg 5-FU/mg powder] 
CPO Mg 115.2 ± 1.4% (11.5 wt%) 10.8 ± 0.4% (1.08 wt%) 
CPO Ni 151.4 ± 0.3% (15.1wt%) 21.1 ± 21.1% (2.1 wt%) 
Table 5-3 Quantities of 5-FU determined with HPLC UV-detector 266 nm, in 
drug-loaded MOF powders: CPO Mg and CPO Ni. 
It has been observed that CPO Ni has a higher loading capacity of the 
encapsulated drug. Taking into account the amounts of 5-FU introduced in the 
solutions used for the two encapsulation routes that were followed, 4 mg (MeOH) 
and 102 mg (MeOH/FA), hence the theoretical loading was 3.8wt% and 33.8wt% 
respectively, and for CPO Mg was achieved in 28% (MeOH) and 34% 
(MeOH/FA), for CPO Ni to 55% and 45% respectively. The HPLC was used to 
quantify the amount of 5-FU in the aliquots (Figure 5-11). 
 
Figure 5-11 Release profiles for 5-FU [μg/mg MOF] encapsulated in MOFs 
(CPO Ni, CPO Mg, UiO66, UiO66NH2) in two encapsulation routes a). 
MeOH and b). MeOH/FA. 
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All the MOFs do not show a drug retention and the release is observable almost 
immediately. This may be due to the fact that the 5-FU was only adsorbed at the 
surface and did not penetrate the pores of the material. Only UiO66-NH2 in 
MeOH encapsulation releases the cargo gradually. It must be noted that some 
peaks arising from MOF itself could be wrongly assigned to 5-FU, with retention 
time is ca. 3.098 min detected at 266 nm, even though all the aliquots were 
filtered before the measurement to avoid recording the signal from MOF and to 
prevent the column from clogging.  
UV-VIS was initially applied to estimate the content of absorbed 5-FU during the 
encapsulation process. The aliquots were taken from the encapsulation mixture, 
just before the end of the encapsulation – 48 h, 50 μL from MeOH solutions and  
3 μL from MeOH/FA encapsulation solution, and diluted 60 and 1000 times 
respectively to match the Absorbance not exceeding 1. The concentration of 
remaining 5-FU in the encapsulation solution was calculated based on Absorbance 
UV-VIS measurements, and the amount absorbed was calculated as a difference 
between the remaining 5-FU and the concentration of encapsulation solution 
prepared that was 21.018 mg/mL for MeOH/FA and 0.788 mg/mL for MeOH. 
Based on these calculations the % of absorbed available drug was calculated 
(Table 5-4). 
Encapsulation solution/48 hours CPO Mg CPO Ni UiO66 UiO66NH2 
MeOH (% of absorbed 5-FU) 42.0 41.1 44.5 40.2 
MeOH/FA (% of absorbed 5-FU) 19.7 56.6 43.4 41.9 
 Table 5-4 % of absorbed 5-FU from the encapsulation solution after the 
process was stopped after 48 h. 
The results obtained are not far off the ones obtained from the HPLC 
measurements of the two MOFs: CPO Mg and CPO Ni. 
The release experiment was performed and aliquots harvested in order to perform 
UV-VIS analysis. This proved to be unsuccessful due to the absorbance coming 
from the MOF powders. The figure 5-12 a.) depicts the measured absorbance 
from the release experiment from CPO Mg in MeOH/FA, formic acid spectra and 
5-FU own spectra are also included. The CPO Mg own absorbance is masking the 
one arising from 5-FU. The sample was diluted 3 – 100 times and the recorded 
spectra still did not allow for quantification of 5-FU content. Figure 5-12 b.) 
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shows the Absorbance spectra from the aliquot harvested after 24 hours for MOFs 
encapsulated in MeOH/FA and after 48 hours in case of MeOH.  The 266 nm 
absorbance is marked with a line. The result is the same, MOFs inner absorbance 
at 266 nm overlaps with absorbance arising from 5-FU which eliminates this 
method as a quantifier of 5-FU content (Figure 5-12). 
 
 
Figure 5-12 Absorbance spectra recorded in UV-VIS method. Fig. a.) shows 
CPO Mg spectra recorded in different time points, encapsulation was 
performed in MeOH/FA. Fig. b.) shows recorded UV-VIS spectra for MOFs 
in one particular time point, 24 hours (MeOH/FA –dotted line) and 48 hours 
(MeOH –solid line). 
HPLC was selected to be the method that would troubleshoot the above 
mentioned challenging issue. 
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5.3.2.4. Traces of 5-FU in the NMR spectra 
Another technique that was utilized in order to verify the presence of 5-FU in the 
MOF powders was liquid NMR (Bruker 500 MHz), a 4 min 
1
H scan was 
performed. The powder samples ca. 20 mg were suspended in 10 ml of PBS  and 
the aliquots were taken after 48h (CPO Mg, UiO66) and 24h (CPO Ni, 
UiO66NH2), and control sample was a 0.75 mg/ml solution of pure 5-FU. The 
NMR chemical shifts are shown in Figure 5-13.  
 
Figure 5-13 NMR chemical shifts acquired @500MHz Bruker, aliquots in 
D2O solvent, harvested after 24h/48h release. MOF encapsulated in 
MeOH/FA. From the bottom – 5-FU, UiO66NH2, UiOO66, CPO Mg and top 
is CPO Ni. 
The same procedure was repeated after leaving the samples for a week to release 
5-FU, here as a control sample a 0.253 mg/ml 5-FU solution was used. D2O was 
used as an NMR solvent. The NMR shifts are shown in Figure 5-14. In both cases, 
there is a peak with the chemical shift at 7.59 ppm coming from the 
1
H proton, 
that is bound to a carbon. ChemDraw Professional program predicts the 
1
H signal 
coming from the 
1
H (between –F and –NH groups) at 7.01 in DMSO and for the 
other two 
1
H protons bound to N atom should give a doublet at 11.32 ppm and 
11.01, this signal is much weaker though and was not observed. Prediction of 
chemical shifts  in D2O was not in ChemDraw database. 
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Figure 5-14 NMR shifts acquired @500 MHz Bruker, aliquots in D2O 
solvent, harvested after 1 week release –test 2. MOFs encapsulated in MeOH. 
From the top – 5-FU, UiO66NH2, CPO Mg, UiO66 and bottom is CPO Ni. 
Results show that only UiO66NH2 encapsulated in MeOH shows some traces of 
5-FU in the released aliquot, the remaining MOFs do not show any traces when 
detected on NMR. MOF powders that were encapsulated with the drug in 
MeOH/FA solution show presence of 5-FU in the released aliquots. This confirms 
the FTIR results. 
5.3.3. Biological testing: Viability and Efficacy 
Alamar Blue (rezasurin) and Flow Cytometry (FACS) assays were prepared to 
assess the efficacy of stimulation of cancer cells with MOF powders loaded with 
5-FU. Flow cytometry allowed to test the drug formulation on the THP-1 cells in 
terms of cell viability and type of cell death mechanism (necrosis or apoptosis), 
assay based on resazurin allowed for testing the same formulations on A549 lung 
cancer cell line. It must be mentioned that as A549 cells are the adherent type of 
cells, the well surface is important for their proliferation and growth. The MOF 
drug carrier systems could deposit on that surface when falling on the well 
bottom, thus not permitting for the cells’ growth. The Alamar Blue assay was 
constructed to test the cells’ viability after 28h and 48h drug exposure, FACS – 
24h, apoptosis can be measured up until 24h after stimulation, later it is only late 
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apoptosis. This experiment was prepared in duplicate (two wells). There was an 
attempt to run 2 independent experiments, however, the instrument got blocked 
and only recorded measurements from one of the wells. MOF powders prepared 
as a formulation in suspension with RPMI or PBS form clots that FACS is very 
sensitive to. In order to keep the instrument unblocked, a “hot bleach” rinsing 
technique must be applied after each 2 samples to prevent clogging. The cell 
culture preparation and the overview of the techniques are described in the 
Chapter 3, Experimental Methods. 
 
Figure 5-15 FACS measurements to test the cell viability and type of cell 
death measured after the 24 h exposure to the drug formulations. Error bars 
are SD, results from duplicates. 
The dose of drug formulations used for cell stimulations was 50 μL per well. This 
corresponded to 500 μL of loaded/unloaded MOF sample, with a concentration 
reaching 2 g/L as the cell suspension volume was 200 μL per well,. The control 
stimulant with a concentration of 0.73 mg/mL 5-FU (36.5 ug in 50 μL, 0.146 g/L 
or 1.1 mM) was adjusted to support the idea that the 5-FU loading in the MOFs 
may be reaching ca. 7 wt%. The results showed high cell viability when the cells 
were stimulated with UiO66 and CPO Ni (96% and 89% respectively) and slightly 
lower if stimulated with CPO Mg and UiO66-NH2 (82% and 78% respectively), 
the control sample (untreated cells) showed viability at the level of 90%. Cells 
stimulated with 5-FU 0.73 mg/mL solution showed viability of 71%. The cell 
viability drops to 84% when stimulated with UiO66 loaded with 5-FU in methanol 
and further to 68% if the cells are exposed to UiO66 loaded with 5-FU in a 
MeOH/FA route, where theoretical loading was higher per gram of MOF. Also 
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the dominating mechanism of cell death is apoptosis, and ca. 30% cells would 
undergo this type of death (16% early +14% late apoptosis). It is worth 
mentioning that the % of cells that underwent necrosis is very low and can be 
neglected. The stimulation with 5-FU loaded CPO Ni has effect on cells and their 
viability drops to 85% (MeOH) and 61% (MeOH/FA) which by far shows the best 
efficacy for the tested range of MOFs. For stimulations performed with CPO Mg 
and UiO66-NH2, the results are not showing any particular trend, stimulation with 
5-FU loaded UiO66-NH2 gives 80% viability (MeOH) and 87% (MeOH/FA), 
likewise 5-FU loaded CPO Mg shows cell viabilities at the levels 68% (MeOH) 
and 81% (MeOH/FA). These values are very close to the ones obtained after 
stimulation with the pure MOF. This may lead to a conclusion that the amount of 
5-FU stored in the MOF material is not enough to dramatically lower viability, 
also 5-FU is a drug whose efficacy is reported to increase over time and only the 
exposure times of 48-72 h would allow to spot the difference.  
The further testing was performed on A549 cell line, applying Alamar Blue 
viability assay. The drug exposure time was 28h and 48h, two doses were used, 
either 10 μL (containing 100 ug MOF) or 50 μL (containing 500 ug MOF). Cell 
suspension of 100 μL per well was normalized with 2% RPMI growth media to 
150 μL after stimulation and incubated for the given time, after which Alamar 
Blue solution was added (15 μL, 10% per volume, per well) and the plates were 
incubated for another 4 hours after which the fluorescence at EX/EM 555/585 nm 
was recorded. The 5-FU dose of 10 μL per well corresponded to 0.16 g/L  
(1.23 mM) concentration and 50 μL to 0.032 g/L (0.25 mM). This corresponded to 
drug loading of 8 wt% (8 μg per 100 μg, and 40 μg per 500 μg). Two independent 
experiments were prepared (2 plates) for each of the exposure times, each well 
was prepared in duplicate. Figure 5-16 shows results of a 24h-stimulation of A549 
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cells with two different doses, 100 μg and 500 ug of MOFs (10 and 50 μL).
 
Figure 5-16 Results of  lung cancer cells stimulation for 24h with MOFs and 
5-FU control solution. Error bars are SEM (standard error of mean) from 
the 2 independent experiments each in duplicate. 
The results are showing quite a high deviation from the average values and the SD 
(standard deviations) are high, so it might be that the stimulation dose of 10 μL 
may be too small for the accurate administration. Nevertheless, the trend can be 
identified for almost all of the MOFs (apart from UiO66-MeOH, UiO66 pure). 
With addition of more formulation to the cell suspension, the cell proliferation 
and growth is visibly inhibited and cell viability drops. The MOF powders has the 
tendency to deposit at the bottom of the well and may block the available surface 
for cells’ growth. MOF powders suspended in RPMI are unfortunately not a 
perfectly homogenous suspension comprising of nano particles (200-500 nm) and 
some form aggregates and these could have been injected in the cell suspension 
without a proper dose control resulting in a higher stimulation dose. With a higher 
dose of 50 μL, the SDs are much smaller, however, loaded UiO66-NH2 does not 
seem to act any different to the pure MOF, the same holds for CPO Mg. There is a 
noticeable decrease in cell viability, when comparing UiO66 pure and 5-FU 
loaded in MeOH/FA and the same can be observed for CPO Ni. Surprisingly, 
CPO Ni should be toxic to the cells on its own due to the presence of Ni metal in 
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its structure, the results show that it is less cytotoxic to THP-1 and A549 than e.g. 
CPO Mg. 
Below, Figure 5-17 shows the results of cells’ stimulation with MOFs, with a drug 
exposure of 48 hours.  
 
Figure 5-17 Results of 48h lung cancer cells stimulation with MOFs and 5-FU 
control solution. Resazurin assay. Error bars are SEM (standard error of 
mean) from the 2 independent experiments each in duplicate. 
The cells stimulated with formulation containing 5-FU at the concentration of 
0.37 mM (10 μL) and 1.87 mM (50 μL) in the well (150 μL), showed the 
decreased viability when compared with the 24 h drug exposure, from 68% down 
to 46% and from 62% to 18% respectively. From the results obtained the 
conclusion can be derived that the efficacy of the drug delivery system prepared in 
MeOH/FA encapsulation method is higher than the MeOH, which may be due to 
the fact that the 5-FU concentration in the encapsulation solution was much 
higher. Also, it cannot be excluded that some amounts of Formic acid could retain 
in the MOF pores/ structure and thus be toxic to the cells. The MOF powders after 
encapsulation were centrifuged and not rinsed with H2O in order to prevent the 
drug being pushed out from the pores of the material. It was also noticed that 
results are dose-dependent only in some cases(10 μL vs 50 μL). This may be due 
to the inaccuracy of the pipetting of a non-homogeneous suspension containing 
MOF’s aggregates. Some attempts were made to resolve this issue: by grinding 
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the MOF materials and by exposing the prepared suspensions to ultrasound 
vibrations. 
5.4. Conclusions 
5-FU is one of the anti-cancer drugs that has been used in formulations to treat 
various cancers e.g. colon, breast, pancreas, ovarian and head
4, 26
 and lung 
cancer
27
. However, it is causing severe side effects if administered in bigger 
quantities and that is why there is a need to design a drug delivery system that 
would capture the drug and slowly release it in the patient’s organism. It has been 
reported that 5-FU encapsulation was successfully performed using MOF material 
Zn-BDC
28
, however no cytotoxic studies were performed, only release studies. 
Viability studies are very important in assessing efficacy of MOFs as potential 
drug delivery systems. The loading and release may be low but still sufficient to 
decrease the viability of the cancer cells. Hence, the attempt to run these tests for 
the purpose of this thesis. This included the viability testing for determination of 
viability and the type of death cells undergo – apoptosis or necrosis (FACS), and 
AlamarBlue assay based on redox potential and equilibrium between Resazurin 
and Resorufin. The results of the examination show that there is a potential to 
utilize the MOFs as delivery system for 5-FU. The encapsulation that was 
performed in MeOH showed that the MOF frameworks stayed intact when 
compared to formic acid route, however the achieved loading was much lower due 
to the low solubility of 5-FU in polar solvents. Generally, viability studies showed 
that cancer cell stimulation (lung cancer A549) with MOFs with encapsulated 
drug cargo was more efficient than of these stimulated with 5-FU only. In case of 
THP-1, the induced apoptotic death was observed to be higher than triggered by 
5-FU only when the stimulations were performed with CPO Ni and UiO66 for 
encapsulation in MeOH/FA and for CPO Mg, for encapsulation route in MeOH 
(see Figure 5-15). Frameworks have the ability to encapsulate the drug and release 
it, however more research is needed to learn how to control the drug release better 
and also to investigate some other encapsulation techniques to achieve higher 
drug loading. The next step could be to unify the size of the MOF particles used 
for preparation of suspensions. 
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Chapter 6. MOFs as potential vaccine adjuvants 
6.1. Aims 
This research work aimed at opening an avenue for novel potential applications 
for MOFs, as  adjuvants – an important part of a vaccine. In this section, I would 
like to recap on the topic of vaccines and immunology in a more detailed way to 
help the reader follow this chapter. The brief introduction into this topic was given 
in Chapter 1.  
Vaccination is the most effective medical intervention ever developed saving 
some millions lives per year
1
 by preparing an individual to develop effective 
biological defence mechanisms (immunity) against “danger” thanks to pattern 
recognition receptors able to recognise pathogens – infectious agents and thus to 
protect against an infectious disease
2
 and has been used for more than 100 years
3
. 
Vaccine is also considered as a potential protection against cancer and this 
direction of development is also increasingly targeted
4
. A vaccine contains a small 
amount of a material which resembles a disease – causing agent (the “antigen” – a 
viral, microbial or tumour component). The antigen comprises of a subunit or an 
inactivated form of the pathogen, and hence should not itself cause infection. The 
vaccine stimulates the body's immune system to recognize the antigen as 
unwanted and destroy it, but also to generate memory in cells which can rapidly 
respond to a subsequent infection, thereby conferring effective immunity against 
the pathogen. In order to ensure that robust immunity is inoculated, an “adjuvant” 
is usually added to vaccines to mimic the danger signals that naturally trigger 
immune responses. At present, inorganic compounds known as ‘alums’ (usually 
either AlO(OH) or amorphous aluminium hydroxyphosphate) are used as 
adjuvants in the majority of cases. “Alum” can lead to strong immunity to 
microbes and larger parasites, but does not provoke the necessary immune 
response to overcome viral infections or the majority of cancers. Only alum and a 
new adjuvant containing alum (AS04) are currently licensed by the FDA
5
. These 
often do not provoke the precise pattern of immune responses needed to most 
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effectively target a particular disease, which has led to problems in developing 
vaccines against, for instance, malaria
6
. 
The Alum adjuvant that is an Al-based mixture of hydroxides or phosphates has 
been doing the trick of boosting the immune response; however, its action is 
limited to inducing Th2 responses
7
. In immunology, there are two types of 
immune responses recognized, one is Th1 type, which is a cell – mediated 
response, and could kill intracellular bacterium and viruses, whereas Th2 response 
(induced by pathogen) stimulates a humoral immunity leading to production of 
antibodies, and as such to elimination of extracellular bacterial infections
8
. Up 
until now, the mechanism of how adjuvants are working has not been fully 
explained. And some empirical tests identified their ability to stimulate the 
immune response when administered along with an antigen
9
. 
Hence, there is a need to develop more powerful adjuvant material that would 
hopefully outperform alum and hopefully leading to elucidation of the mechanism 
of action of adjuvants, which is unknown. 
A total of 9 MOFs were tested for their ability stimulate to dendritic cells (DCs) to 
maturation and secretion of cytokines. This feature was assessed in terms of 
cytokine secretion (IL-6 and TNF-α), and the expression of the surface markers 
CD1a, CD40 and CD86 on dendritic cells. Dendritic cells (DCs) are capable to 
detect and recognise antigens and present them through MHC (major 
histocompatibility complex to helper T cells (T-cell receptors) which activate a 
specific immune response against the particular pathogen that the antigen came 
from 
10
. Once the antigen has been recognise, DCs would move towards the 
lymph nodes. At this point DCs are mature, and lose their ability for antigen 
uptake and only can express the co-stimulatory molecules
11
. By monitoring the 
response from the stimulated DCs, we can get an idea how effectively DCs will 
activate T cells to respond to pathogen.  
Briefly, cytokines are small peptides that are released by cells in order to induce 
an immune response and enable for communication between the cells. Mainly, 
they are secreted by macrophages or T cells. The measuring of secreted cytokines 
level responsible for pro-inflammatory action like IL-6 and TNF-α could allow for 
screening of the potential candidates for the novel adjuvants in new anti-cancer 
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prevention programmes. Also, the screening of the cell viability level after the 
stimulation allow to eliminate the toxic compounds. There is a variety of 
cytokines and for the purpose of this research, the testing was performed on the 
secretion of interleukin family (IL-6) and tumour necrosis factor family (TNF-α), 
the former one can promote different actions dependent on the interleukin and the 
role of the latter is to regulate inflammatory and immune responses
12
. 
Surface markers CD1a, CD40 and CD86, are expressed on the surface of the 
antigen – presenting cells like DCs. CD1a is a cell surface glycoprotein13, related 
to presenting a lipid antigen to T cells, CD40 (cluster of differentiation) is a 
protein that belongs to TNF-receptor family, and is expressed by B cells, DCs, 
and macrophages
14
, which are the antigen-presenting cells but it is also expressed 
on cancer cells (bladder, ovary, cervix). The antigens are presented to T cells. 
CD86 is a protein and activation marker for antibody producing cells (B cells), 
and DCs stimulated with chemical allergens would respond by increased level of 
co-stimulatory molecule
15
. The wider description of the key cells in immunity is 
given in Chapter 1, Section 1.4.  
This chapter is a continuation of a concept presented by Dr Gareth Williams and 
aims to investigate other materials than double layered hydroxides (LDHs) as 
these showed promising results to be the candidate to replace alum and potent 
enough to be taken into consideration
16
 . As such, research extends over the range 
of MOFs to be explored as adjuvants. Based on these results, it was proposed that 
MOFs could be even better candidates due to the fact of their wide range of 
structures, quite high surfaces areas and pores and these can be used for hosting of 
an antigen, a variety of different linkers used and metal anions which gives almost 
limitless number of combinations, that can be tested for immune response, 
catalogued and leading to establishment of a model of the optimally working 
adjuvant. The target of this concept, is to develop an adjuvant model, that would 
allow to predict the immune response triggered by the material based on its 
property – this however, it is not the aim of this thesis. 
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6.2. Synthesis  
The Zr-MOF powders assessed to have potential for a possible application as 
adjuvants for novel vaccines were synthesised according to the procedures found 
in the literature
17, 18
. Briefly, these synthesis routes are to be found in Chapter 4, in 
the section 4.2, dedicated to synthesis.  
The Al-MOFs were chosen based on the simplicity of the synthesis procedures 
found in the literature and the fact that they have Al-metal in their frameworks, 
and thus can be compared with the commercially used Al-containing “alum” 
adjuvants.  There was a hypothesis that MOF materials with Al-cation may over 
perform alum for its stimulation of cytokines secretion, especially TNF-α and IL-
6, given the fact that the organic linker may also contribute to the immunologic 
stimulation. Also, in scope of this research was a bold idea to investigate if it 
would be possible to control the immune response by changing the metal/linker, 
thus giving us a wide range of tuneable adjuvant candidates. These results could 
be a foundation for a data base to develop an adjuvant model and then to design 
an adjuvant with the desired properties as to inducing the desired immune 
responses. 
The following MOFs were chosen: Al-MIL 53, Al-MIL 53_NH2, MIL 96, DUT 5, 
MIL 120, MIL 122, MIL 101_NH2.  
MIL-53 AL 
A mixture of terephthalic acid (288 mg, 1 mmol) and metal salt Al(NO3)3·9H2O 
(1.3 g, 0.5 mmol) were dissolved in a solution of distilled water (5 ml) and left 
under stirring for 30 min. The mixture was then transferred to a Teflon-lined 
autoclave (23 ml) sealed, and placed in the oven for 72 hours at 220 °C. The 
product was collected by filtration as a white substance, ca. 370 mg was obtained. 
This synthesis followed the protocol found in the literature
19
. 
MIL-101 Al-NH2 
AlCl3·6H2O (514 mg, 1 mmol) was dissolved in DMF (30 ml) in a 50 ml Teflon 
liner. Under stirring 2-aminoterephthalic acid (562 mg, 1.5 mmol) was added and 
the mixture was stirred for 30 min. Then the liner was placed in an autoclave), 
sealed and placed in the oven for 72 hours at 130°C. The collected powder was 
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yellowish and the yield was 845 mg. The procedure was in accordance to the one 
in literature
20
,
21
. 
MIL-96 and  MIL-96 (“pure phase”) 
The synthesis route was exactly the same as mentioned in the literature
22
. Two 
MOFs were synthesised, one reported as MIL-96 and the other as MIL-96 “pure 
phase” by the scientific paper that established the synthesis route. Briefly, for this 
“pure phase” synthesis Al(NO3)3·9H2O (1.314 g, 3.5 mmol) was dissolved in 
distilled water (5 ml) and to this solution, trimethylbenzenetricarboxylate was 
added (0.44 g, 1.75 mmol). The organic linker is quite powdery and it was 
challenging to disperse it in water as it floated on its surface. The autoclave was 
sealed and placed in the oven for 24 hours at 210°C. The collected powder was 
white and the yield was 549 mg. For MIL-96 which is not noted as “phase pure” 
by literature
22
, the only difference was the linker being used, and in this case it 
was trimesic acid. The synthesis conditions were same as for the “pure phase” 
with only different amounts of reagents: Al(NO3)3·9H2O (1.314 g, 3.5 mmol) was 
dissolved in distilled water (5 ml) and to this solution trimesic acid (105 mg,  
0.5 mmol) was added. Yield: 205 mg  
MIL-120 
Al(NO3)3·9H2O (3.2 g, 8.5 mmol) was dissolved in 20 ml of distilled H2O and left 
under stirring. Pyromellitic acid (benzene-1,2,4,5-tetracarboxylic acid, 0.5 g,  
2 mmol) was dissolved in 4M NaOH (3.4 ml, 13.6 mmol) and left under stirring. 
The two solutions were transferred into a Teflon-lined autoclave (50 ml) and 
stirred for 30 min before being placed in the oven for 24 hours at 210°C. The 
collected white powder was washed with H2O under reflux for 10 hours at 100°C. 
Yield: 189 mg. The synthesis procedure can be found in literature
23
. 
MIL-122 
Al(NO3)3·9H2O was dissolved in 5 ml of distilled water (342 mg, 0.9 mmol) and 
left under stirring. Then 276 mg (0.9 mmol) of the organic linker 1,4,5,8-
naphthalenetetracarboxylic acid was added to the metal salt solution. The Teflon-
lined autoclave (50 ml) was then sealed and placed in an oven for 24 hours at 
210°C. The product was collected by filtration and the yield was 149 mg. The 
synthesis route followed the protocol
24
. 
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DUT-5  
A mixture of Al(NO3)3·9H2O (0.52 g, 1.4 mmol) was dissolved in 30 ml DMF. 
4,4-biphenyldicarboxylic acid (0.26 g, 1.07 mmol) was added and the reagents 
were left under stirring for 30 min, then the solution was transferred to an 
autoclave (50 ml) and placed in the oven for 24 hours at 120°C. The product was 
a white powder that was washed with DMF 3 times. The yield was 443 mg. The 
method can be found in the literature
25
. 
These MOFs all contained Al- or Zr-cation in their structure and the linker was 
different every time (see Table 6-1). The linkers used are characterised in the table 
below. This allowed to spot different patterns for immune responses and in the 
next step would help to build a model. This, however, was not the aim of this 
thesis. 
MOF Linker Linker Structure Metal cation 
UiO66 Terephthalic acid 
 
Zr 
MIL 53 Al 
UiO66-NH2 2-aminoterephthalic acid 
 
 
Zr 
MIL-101-
NH2 
Al 
MIL-96 Trimesic acid 
 
Al 
MIL-96 
“pure 
phase” 
trimethyl 
benzenetricarboxylate 
 
Al 
MIL-120 pyromellitic acid 
 
Al 
MIL-122 1,4,5,8-
napthalenetetracarboxylic 
acid  
Al 
DUT-5 biphenyldicarboxilic acid 
 
Al 
Table 6-1 Organic linkers used for the MOFs synthesis. 
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6.3. Results 
6.3.1.X-ray patterns 
The characterisation was performed by X-ray on RIGUKU and by comparing the 
location of the peaks from crystal lattices. The X-ray diffraction patterns are to be 
found in Appendix 2. All of the 7 Al-containing MOFs were successfully 
synthesised and the peak patterns compared to these from the literature.  
6.3.2.Immune responses measured by ELISA 
The immune responses induced by the presence of MOF particles in macrophages 
and dendritic cells were measured with ELISA and flow cytometry (FACS). The 
principles of the two methods are described in the Experimental Section 3.5, 
Chapter 3. FACS was performed to verify the quantity of the receptors activated 
on the dendritic cells surfaces, with CD40, CD86 and CD1a quantified. ELISA 
was a pivotal experiment to measure the secretion of two cytokines IL-6 and 
TNF-α. They regulate the body temperature to stop infections and relaxing blood 
vessels in order to allow leucocytes to permeate to the centre of infection. It is 
stipulated that they may play a vital role in fighting the cancer by making healthy 
cells immune to tumour-genesis and tumour-proliferation. 
IL-6 is secreted by macrophages or T cells to give rise to immune response. It has 
been recently associated with presence of cancer in human tissues as elevated 
concentrations of this cytokine are found in human blood diagnosed with an 
advanced cancer. It is stipulated that the higher levels of IL-6 cytokines can fight 
the cancer cells. It can be released in response to microbial molecules/pathogens.  
The main role of TNF-alpha (tumour necrosis factor alpha)is to regulate the 
immune cells and induce inflammation in order to reduce the viral replication and 
cancer growth. 
Macrophages were obtained through the THP-1 cells differentiation, and dendritic 
cells from the differentiation of primary human monocytes, as detailed in Chapter 
3, Section 3.5.3. The levels of secreted cytokines were compared with the ones 
induced by a commercial alum: ALHYDROGEL (Aluminium Hydrohide Gel, 
CAS No. 21645-51-2, Al content 10mg/ml) and Adju – Phos (Aluminimum 
Phosphate Gel, AlPO4 content 2%, CAS No. 7784-30-7), both purchased from 
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Brenntag, Denmark, which is commonly used for variety of vaccines. It must be 
pinpointed that “alum” does not have a defined structure or composition and 
immunologists refer to all of the adjuvants containing Aluminium in the gel as 
“alum”. Chemists, however, refer to materials having a formula 
KAl(SO4)2•12H2O and alternatively NH3(aq)Al(SO4)2, as “alum” which causes a 
lot of uncertainty and definitely has its influence on the possibility to compare the 
properties of variety of alums. In the immunology world, AlO(OH) “alum” is a 
crystalline layered material in a suspension and Al(OH)x(PO4)y is an amorphous 
material containing hydroxyl and phosphate groups
26
.  
Three independent experiments with at least three replicates in each experiment, 
were performed for each of the parameters and the results obtained averaged. Al-
MOFs’ performance as the potential adjuvant were assessed against the 
commercial alum, and results were compared within all of the tested MOFs 
containing Al-cation in the network. Another experiment was performed to test 
the performance of the two Zr-MOFs against the two commercial alums: 
Aluminium-phosphate and Aluminium-hydroxite containing commercial alums. 
LPS (bacterial lipopolysaccharide), which is an endotoxin was used as a positive 
control since it is known to induce a strong immune response. The differentiation 
of THP-1 cells to macrophages was performed to enable secreting cytokines. Such 
an approach has been demonstrated in literature
27
.  
6.3.2.1.Immune response: Al-MOFs 
 
Figure 6-1 TNF-α levels secreted by macrophages (THP-1) after 24h 
stimulation with Al-MOFs and alum, measured by ELISA. The error bars 
refer to SEM (standard error of mean). 
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Figure 6-1 shows the quantities of TNF-α secreted (tumour necrotic factor α). 
TNF-α regulates immune cells and induces inflammation in order to reduce viral 
replication and cancer growth
28
. Hence, it is hypothesised that it may play a vital 
role in anti-cancer therapies, including vaccines
4, 29
.  
Obtained results (Figure 6-2) show that some MOFs perform better than alum, 
MIL-96 and MIL-120 and MIL-96 “pure” lead to concentrations of TNF-α three 
times greater than induced by stimulation with alum. MIL-53 Al induces similar 
levels of secretion of TNF-α to alum. The levels of another cytokine, IL-6 
(interleukin-6), were also quantified.  
 
Figure 6-2 IL-6 levels secreted by macrophages (THP-1) after 24h 
stimulation with Al-MOFs and alum, measured by ELISA. The error bars 
refer to SEM (standard error of mean). 
In terms of the amount of secreted cytokine IL-6 by the stimulated macrophages, 
commercially available alum performs better than MIL-122 and MIL-101-NH2, 
other tested Al-MOFs show more promising results though. MIL-96 and MIL120, 
followed by MIL-96 “pure phase” and DUT 5 and MIL-53 Al show increased 
levels of IL-6. This could be a result of the contribution of the linkers to the 
enhancement of immune response triggered. Also morphology of the samples and 
the size of the particles may play a role here. However, the latter is more 
challenging to claim, as upon introduction of the MOF powder into the PBS 
(phosphate buffered saline) in order to prepare a suspension for cell stimulation, 
the MOF particles tend to clamp and form aggregates that are very difficult to 
disintegrate. PBS was used as a carrier phase due to the fact that it is neutral to 
viability and cytokine’ secretion. To address this issue, a method for preparation 
of the homogeneous suspension with similar particle sizes should be further 
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investigated. If successful, this could lead to commercialisation of new adjuvants 
for novel vaccines. 
Figure 6-3 depicts the SEM image taken of the two MOFs prepared with different 
linkers, these are both MIL-96 structures. The shape of the particles is different, 
which may have a tremendous effect on the ability of the MOF powder to induce 
the immunological signal in the cells. 
 
Figure 6-3 SEM image of MIL-96 (left) and MIL-96 “pure phase” (right). 
The difference in the morphology of the samples is noticeable. 
6.3.2.2. Immune response: Zr-MOFs 
The ELISA tests were performed to investigate the ability of Zr-MOFs (UiO66 
and UiO66-NH2) for secretion of cytokines TNF-α and IL-6. This was done in 
two independent experiments and each condition within was done in triplicate. 
The obtained results are presented below, TNF-α (Figure 6-4) and IL-6 (Figure 
6-5). 
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Figure 6-4 TNF-α levels secreted by macrophages THP-1 after 24h 
stimulation with Zr-MOFs and alums, measured by ELISA. Two 
independent experiments (grey and purple columns), error bars are a 
standard deviation (SD) between results, in triplicates. 
 
Figure 6-5 IL-6 levels secreted by macrophages THP-1 after 24h stimulation 
with Zr-MOFs and alums, measured by ELISA. Two independent 
experiments (red and green columns), error bars are a standard deviation 
(SD) between results, in triplicates. 
Based on the results obtained, we can assume that the performance of Zr-MOFs is 
only slightly better when compared to AlO(OH) alum and achieving the same 
results when compared to AlPO4 (aluminium hydroxyphosphate). Macrophages 
stimulated with LPS show elevated levels of secreted cytokines, while untreated 
cells produce only low levels.  
There was an attempt to investigate the correlation of the induced immune-
response (IL-6) with the amount of the stimulant added to the cell suspension. The 
following quantities were chosen 10μL (476 μg MOF/ml), 20 (910 μg/ml)and 
30μL (1300 μg/ml). 
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The amount of IL-6 secretion slightly increased with the increased quantities of 
Zr-MOFs added, but remained rather stable in case of alums. This is an important 
finding, as the quantity of adjuvant must be adjusted to its optimum depending on 
the material being used to boost the immune response.  
 
Figure 6-6 IL-6 concentration secreted by macrophages THP-1 after 24h 
stimulation with Zr-MOFs and alums, measured by ELISA. Increasing 
concentration of stimulants Zr-MOFs and alums, LPS concentration 100 
ng/ml (yellow) and 200 ng/ml (fair green).Results based on experiment from 
one plate in duplicates. Error bars refer to standard deviation (SD) between 
the results measured from two wells. 
As shown by the results, the highest levels of IL-6 were obtained when stimulated 
with the highest dose of Zr-MOFs, however in case of alums the dose seemed not 
to play a crucial role. This could stipulate that a higher concentration of MOF 
powder is potentially needed in order to induce much more pronounced immune 
response. For alums, there is no special trend being observed and it looks like  
910 mg/ml dose induces lower immune response. 
To summarise the ELISA experiments, we can conclude that Al-MOFs look more 
promising than Zr-MOFs to be candidates for the novel adjuvants. 
6.3.3.Immune responses measured by Flow Cytometry 
Flow Cytometry equipment was used to measure the concentration of the surface 
proteins on the dendritic cells following exposure to the MOFs. The dendritic 
cells were kindly provided by Dr Ilona Kubajewska. 
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The activity of three receptors on cell surface of dendritic cells (DCs) were 
measured when stimulated with Al-MOFs, these were: CD40, CD1a and CD86.  
 
Figure 6-7 CD1a expression on dendritic cells after 24h stimulation with Al-
MOFs and alum, measured by FACS. Error bars are SEM (standard error of 
mean) from three independent experiments.  
The above results (Figure 6-7) show that MIL-101-NH2 is the best candidate to 
successfully activate the CD1a receptor, with MIL-96 “pure phase” followed by 
MIL-120 and MIL-53-Al in terms of the percentage of cells expressing this co 
stimulatory molecule.  
 
Figure 6-8 CD40 expression on dendritic cells after 24h stimulation with Al-
MOFs and Alum, measured by FACS. Error bars refer to SEM (standard 
error mean), experiments performed over 3 plates, each in duplicates. FACS 
measurement performed by and courtesy of Dr Kubajewska. 
Again, as we can see (Figure 6-8), MIL-101-NH2 is the best performing MOF 
when it comes to activation of the CD40 receptor, followed by MIL-122. Based 
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on the results obtained, MOFs are showing better ability to induce higher immune 
response than alum. This opens door to further investigations to test the 
performance of MOF powders, in order to assess their efficiency in vivo.  
 
Figure 6-9 CD86 expression on dendritic cells after 24h stimulation with Al-
MOFs and Alum, measured by FACS, courtesy of Dr Kubajewska. Error 
bars refer to SEM (standard error of mean), results obtained over 3 
independent experiments with duplicates. 
In terms of CD86 expression (Figure 6-9), alum shows low levels of expression 
and MIL-96 “pure phase” stimulation is leading to the production of more CD86 
receptors in a comparison made over all the tested MOFs. MIL-53-Al, which also 
leads to up – regulated expression of CD86 receptor, could also be taken into 
account as a candidate for a new adjuvant. 
To summarise, different MOFs can up-regulate expression of the surface markers, 
what was observed in case of MIL-96”pure” for CD86 (outperformed alum), 
however, when CD40 expression was monitored, this MOF did not induce a 
significant level of response and MIL-122 and MIL-101-NH2 took the lead. The 
MOF, which gives the best results over the data sets obtained is MIL-96 “pure”. It 
is not always the best in its class, however, the response induced for secretion of 
TNF-α, and elevated levels of expressions CD1a and CD86, gives it the lead and 
as such this MOF should be taken for further experiments in vitro as well as in 
vivo. 
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6.3.4.Viability tests - Dendritic Cells and THP-1 differentiated 
macrophages 
It is vital to assess the viability of the cells when these are stimulated with a 
certain substance. It is important to observe elevated signal from the receptors, 
and elevated cytokine expression, however, the potential adjuvant cannot be too 
toxic because the cells would be terminated which is not desired, some cell death 
is not a bad outcome though as it sends signals and stimulates the immune 
response. The viability testing was performed with Alamar Blue assay for Zr-
MOFs, and by FACS for Al-MOFs. 
 
Figure 6-10 Viability of dendritic cells after exposure to Al-MOFs and alum 
for 24h, measured by FACS based on Annexin V/PI staining. Results were 
averaged based on 3 independent experiments, courtesy of Dr Kubajewska. 
Error bars are SEM (standard mean of error). 
Based on the results obtained (Figure 6-10) for the viability screening, almost all 
the MOFs, except MIL-101-NH2 can be regarded as non-toxic and do not 
compromise the safety of the living system - the cells. MIL-101-NH2 decreases 
viability to70 % and when compared with different tested MOFs, may show 
higher toxicity, due to the presence of amine group. Alum shows the viability at 
the level of 80%.  
Similar experiments were performed to measure the viability of macrophages 
when stimulated with Zr-MOFs. After the 24-hour simulation was completed, the 
aliquots of cells suspension containing secreted cytokines were harvested. Please 
refer to Chapter 3 Section 3.5.2. for a detailed description of the procedure.  
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Figure 6-11 Viability of macrophages (THP-1 cells) after 24-hour stimulation 
with Zr-MOFs and alums AlOOH and ALPO4, measured by Alamar Blue 
assay. Error bars refer to SEM (standard error of mean), results from 2 
independent experiments, each in duplicate. 
The viability results show that the stimulation with Zr-MOFs did not compromise 
the cell viability,  as opposed to the alum samples (AlO(OH) and ALPO4), which 
decreased the number of live cells down to 84-85%. Control wells, stimulated 
with PBS solution or LPS (100 ng/ml) show that LPS decreases the viability 
slightly, PBS stimulation does not harm the cells. The results obtained, viability 
testing on dendritic cells and macrophages, show that Zr-MOF and Al-MOF, apart 
from MIL-101-NH2, are non-toxic to the cells and could be potentially used as 
adjuvants. The obtained results show that generally MOFs do not compromise 
cells’ viability. This property of MOFs combined with the data showing the 
induction of higher immune responses based on the levels of IL-6 and TNF- 
cytokines and the expression of cell receptors on the dendritic cells responsible for 
the stimulation of T cells, suggests that MOFs might be strong candidates for 
novel adjuvants in vaccines. Recently, some attempts were made to synthesise 
biocompatible MOFs with lower toxicity, especially the ones containing Fe in 
their framework
30-32
, the MOFs containing Cr and Co cations in their framework 
show the highest toxicity
33, 34
, but still can be used as drug carriers for anti-cancer 
drugs as the latter are very toxic anyway. 
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6.4. Conclusions 
The concept of providing a more potent adjuvant to replace alum was the 
foundation of this research project. It is strongly believed that Al (Aluminium) 
may be the key to triggering the immune responses
3
, and with the new class of 
MOF materials allowing to play around with variety of their structures and linkers 
with an exact composition, showed a promising route to follow as MOFs are seen 
as potential candidates for variety of applications, with some in medicine
35-37
. 
There have been a lot of vaccines invented over the years for variety of diseases, 
with the idea to immunize the organism with the pathogen’s subunit and induce 
specific immune response against it. Likewise, the idea that links the immune 
system with the cancer prevention emerged, and there were some trials made to 
design a vaccine for cervical cancer that led to Gardasil invention
38
.  
In this chapter, a series of Al- and Zr-containing MOFs were synthesised and their 
immunogencity explored in the in vitro studies. Experiments were performed to 
probe the maturation of macrophages and dendritic cells, looking at the levels of 
cytokines secreted by the macrophages and surface protein expression by the 
dendritic cells. The results show that MOFs containing Al-metal in their 
framework were more potent in provoking cytokine secretion than a commercially 
used alum or MOFs with a Zr-metal, and leading to increased concentrations of 
TNF-α and IL-6. The cell viability levels were also higher in the case of Al-
MOFs, than those measured for alum, and it may be concluded that alum led to 
decreased viability. Upon stimulation with Al-MOFs, higher percentages of 
dendritic cells (DCs) expressed signal from CD40, CD86 and CD1a receptors and 
thus are expected to be able to activate T-cells more effectively than alum
39
. The 
results obtained with Zr-MOFs showed the levels of cytokines secreted were only 
slightly higher than these obtained after stimulation with alum. The viability 
studies showed that Zr-MOFs are non-toxic to the cells and the viability levels are 
sustained at nearly 100%.  
Overall, the data collected indicated that Al-containing MOFs could be potent 
vaccine adjuvants. To prove this, further studies must be performed to link 
different parameters of the substances e.g. shape of grains, size of particles, zeta-
potential, distances between Metal-carbon chemistry of the compounds to their 
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immunogenic properties. This would allow to build an adjuvant model and predict 
the potentially best match for an adjuvant. Such modelling was performed by Dr 
Williams showing promising results for LDH (layered double hydroxides) to link 
their chemistry to their performance as adjuvants
16
. The in vivo results were 
promising. However, in case of MOFs, in order to prove the model, some more in 
vitro studies are needed and ultimately some in vivo, also taking into 
consideration further MOF structures.  
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Chapter 7. MOFs as multifunctional drug delivery 
systems – nitric oxide release 
7.1. Aims 
This chapter explores the possibilities of utilizing MOFs as multifunctional drug 
delivery systems. MOFs were encapsulated with selected anti-cancer drugs: 
cisplatin or 5-FU, and engaging the open metal sites as well as available amine 
sites to serve as the capture point for NO absorption was investigated. In case of 
cisplatin treatment, anticancer therapy may lead to thrombosis
1-3
 – the formation 
of blood clots that may cause hypoxia and in extreme cases tissue death, heart 
attacks and strokes. Entrapment of nitric oxide (NO) – known for its anti-
thrombosis, anti-inflammatory and anti-bacterial effects
4-6
 – in the cisplatin-
loaded MOFs, could mitigate this risk. Previous studies have shown that NO can 
be stored and released on demand by the MOFs HKUST-1, CPO-27-Mg and 
CPO-27-Ni
7-9
. It must be mentioned that nitric oxide itself has also been reported 
to cause cancer cell death
10
. Thus, preparing MOFs loaded with cisplatin and NO 
should permit the production of dual-functionality systems mitigating the risk of 
thrombosis as well as maximising the anti-cancer efficacy, and when co-loaded 
with 5FU also maximising anti-cancer treatment results. 
7.2. Nitric Oxide loading  
7.2.1 MOFs encapsulated with 5FU or Cisplatin 
All four MOFs: CPO-27 Mg CPO-27 Ni and UiO66 and UiO66-NH2 loaded 
either with cisplatin or with 5FU were previously examined. Because MOFs have 
a strong affinity and high capacity for NO, the release experiments can take a very 
long time until the NO concentration drops below biologically active levels, time 
constraints meant, the experiments could only be done in duplicate. The amount 
of released NO from the MOF containing anticancer drug was compared against 
the amount in the pure MOF, which was also run in duplicate. The NO loading 
was performed using the procedure described in Chapter 3 of this thesis and was 
applied for all the samples tested. 
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7.2.2 Zr-MOF with a conjugated prodrug 
The aim of this section was to investigate if the conjugation of the cisplatin 
prodrug to the amine group of UiO66NH2 would affect the release of NO and the 
storage capacity for this gas. 
7.3. Results 
During the previous experiments with CPO-27 MOFs, it has been discovered that 
due to the presence of open metal sites in the structure, so-called “unsaturated 
metal sites”, NO entrapment is possible as these sites are able to chemically retain 
NO and release it in a controllable way
5, 11
. To trigger this “on demand” process, a 
replacement of nitric oxide molecule by another is necessary. It is done by placing 
the MOF powder in an environment of a controlled moisture level so that the H2O 
will compete with NO for the open metal site occupancy and as a result will 
trigger NO release
7, 8, 12
. UiO66 shows poor NO release, although its porosity is 
high as the structure lacks of NO binding sites. On the other hand, the presence of 
the cisplatin and fluorouracil in the pores of the material enhances the NO release. 
This indicates that the presence of the unsaturated sites like amine groups or 
nitrogen in the aliphatic chain is crucial when it comes to gas storage by 
chemisorptions and prolonged release. It might well be that concentration of NO 
in the pores is quite high initially, but is released too quickly for NO to be 
measured. For the targeted application, the property is not very useful. UiO66-
NH2 shows better results for NO release, due to the presence of the NH2 group 
which can form the diazeniumdiolate group (NONOate)
13
 in combination with the 
NO. 
7.3.1 NO release: UiO66-NH2 with a conjugated prodrug. 
The release of NO was measured from the pure UiO66-NH2 and with a 
conjugated cisplatin prodrug in order to check if the presence of a prodrug 
affected the release profile. The amounts of NO released are quite high and 
similar, this would prove that functionalisation of the amine group with a prodrug 
of cisplatin in amide-coupling reaction did not affect the ability of UiO66-NH2 for 
NO storage and release. Conversely, UiO66, showed very poor ability to release 
NO over time. This shows the difference between two sorption processes, the 
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physisorbed NO in UiO66 versus chemisorbed in UiO66-NH2. There are no 
anchor points in the big voids of the UiO66 material for NO, hence immediately 
after the vial was cracked NO was released very quickly and by the time the probe 
was introduced in the analyser the amounts were very low and the release was 
completed within 100 sec.  
 
Figure 7-1 Total NO released monitored over time. Blue line indicates pure 
MOF UiO66-NH2 whereas green the same MOF with conjugated prodrug. In 
the inset, there is a depiction of a NO release profile registered for UiO66. 
The vertical axis has same units as the main Y axis. 
The plot above shows registered total NO release, it is worth noting that the 
conjugation did not influence the amount of NO that is released which can serve 
as a proof for a successful double functionalisation of the drug carrier. The Table 
7-1 below shows the Total quantities of NO that were measured to be released by 
Zr-MOFs. 
MOF UiO66-NH2 pure UiO66-NH2-
conjugated 
UiO66 pure 
Total NO release 
[μmoles] 
13.2 ± 3.22 7.69 ± 0.43 0.01 ± 0.0019 
Table 7-1 Total NO released by different Zr-MOFs containing in the ring a 
conjugated  prodrug, amine group or no functional group at all. 
The difference between the amount of the released NO from UiO66-NH2 in a pure 
or in its conjugated form does not vary a lot. The monitoring for NO release was 
carried out up until the moment NO concentration detected by analyser was  
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20 ppb (cut – off point). The concentration at that level is still biologically active 
and stays active down to the values of ca. 2-3 ppb. However, as the NO release 
measurements are a time consuming process taking a long time to achieve the NO 
parts drop down to that concentration, the cut-off was set to be 20 ppb. This way, 
it was still possible to compare obtained results. 
It has been stipulated that the elevated concentration of NO in tumours makes 
them more susceptible to therapies (radio and chemo) and what is more, be able to 
induce apoptotic death in cancer cells
4, 14
. Recent studies performed on lung 
fibroblast cells investigated the relation between NO concentration and cisplatin 
cytotoxicity, concluding that NO enhances the action of the latter on the tumour 
cells
15
. 
7.3.2 NO release from Mg-MOFs encapsulated with cisplatin and 
fluorouracil drugs. 
The two drugs were chosen to be encapsulated in the CPO-27 Mg-MOF carriers 
as they are both used in anti-cancer treatments, however, both have some 
shortcomings. The multifunctional carrier action was identified as interesting for 
investigations and some attempts were made to load the MOFs, previously 
encapsulated with drugs, with nitric oxide (NO). CPO-27 Mg, has been known for 
its ability to entrap NO and to allow for a controlled release
16
 that is triggered by 
the H2O molecules that are contained in the moisture saturated nitrogen /air flow. 
The plot below shows the result of the release experiment. 
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Figure 7-2 Total NO released from CPO-27 Mg MOF, pure (red), 
encapsulated with fluorouracil in Methanol (green) and encapsulated with 
cisplatin (purple).  
Results show that the encapsulation with 5-FU of the pores of CPO-27 Mg in 
methanol solution, does not compromise the ability of the MOF to entrap NO on 
its open metal sites, and the capacity for NO loading remains at the same level as 
it seems 5-FU does not block the open metal sites. This may be elucidated with 
the presence of N-groups in the 5-FU drug that have a potential to (2 unpaired 
electrons) chemically bind NO and hence prolong its release. The quantity of the 
drug in the pores of MOF structure was not very high, please refer to Chapter 5. 
Another explanation for this, would be that 5-FU is not migrating into the pores of 
material and stays at the surface which allows for binding of NO to metal open 
sites. The other route for encapsulation was investigated, utilising 50/50 v/v 
solution of formic acid and methanol in which 5-FU was diluted reaching 80% of 
saturation. CPO-27 Mg structure was not fully intact, showing some evidence of 
damage, the total released NO was measured to be 0.21 μmol/g. The value for 
CPO-27 Mg encapsulated with cisplatin was 2.05 μmol/g, and 13.5 μmol/g for the 
amount of NO being released from CPO-27 Mg encapsulated with 5-FU in 
methanol and for the pure MOF it was measured to be 16.7 μmol/g. The presence 
of cisplatin in the pores dramatically decreased the release of nitric oxide, it might 
be due to the fact that two amine groups on cisplatin block the open metal sites 
Chapter 7 MOFs as multifunctional drug delivery systems – nitric oxide release 
 
142 
 
and this mechanism makes them unavailable to NO entrapment, reducing the 
release of the gas 8 x when compared to the release that is achieved with the pure 
MOF. 
7.3.3. NO release from Ni-MOFs encapsulated with cisplatin and 
fluorouracil drugs. 
CPO-27 Ni proved to be one of the MOFs with very high NO release which is 
triggered upon exposure to moisture reaching the delivery of ca. 7 mmol/g of 
material
8
. This feature would make it a good candidate for a multifunctional 
carrier as the results in Chapter 4 showed its high capacity and ability for cisplatin 
release. Below, in the Figure 7-3, the total NO release from CPO-27 Ni is 
depicted. Extraordinary behaviour of CPO-27 Ni to entrap nitric oxide for its 
prolonged release is partially compromised by the presence of 5-FU drug in the 
pores of the material, this is further impaired when cisplatin is encapsulated, 
similar as in case of CPO-27 Mg.  
 
Figure 7-3 Total NO released from CPO-27 Ni MOF, pure (red), 
encapsulated with fluorouracil in Methanol (green) and encapsulated with 
cisplatin (purple). 
The average release of nitric oxide from CPO-27 Ni was measured to be  
6.09 ± 0.1 mmol/g, based on two samples. The average amount released from 
CPO-27 Ni with encapsulated 5-FU showed 5.15 ± 0.1 mmol/g, and with cisplatin 
only 2.61 ± 0.11 mmol/g. These amount, even though lower than in case of the 
pure MOF are still significant to provide desired level of NO concentration. The 
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mechanism behind this causing such a drop in the released amount of nitric oxide 
is similar that is observed for CPO-27 Mg and must be due to the interaction 
between amine groups of cisplatin and open metal sites of Ni in the MOF 
structure. It should be mentioned that such a nitric oxide cargo would still play its 
role in preventing thrombosis in patients under anti-cancer treatment. 
7.3.4. NO release from Zr-MOFs encapsulated with cisplatin and 
fluorouracil drugs. 
It was observed that encapsulating UiO66-NH2 with cisplatin increases the 
amount of NO being released. This is due to the presence of additional amine 
groups on the cisplatin that can entrap NO.  
 
Figure 7-4 Total NO released from UiO66-NH2, pure (red), encapsulated with 
5FU in Methanol (green) and encapsulated with cisplatin (purple). 
UiO66-NH2 with encapsulated fluorouracil (5-FU) performs slightly worse than 
the pure MOF and the MOF encapsulated with cisplatin. This may be due to the 
interaction between amine groups on the functionalised organic linker of the MOF 
and the 5-FU molecule. The measured released quantity (cut-off concentration for 
NO at 20 ppm) was 13.2±3.2 μmol/g and for encapsulated cisplatin this was 
22.7±1.45 μmol/g and finally for MOF with encapsulated 5-FU was 11.8±1.5 
μmol/g, see Figure 7-4. The experiment that aimed at achieving higher loading of 
5-FU in the MOF with encapsulation in a solution of 50/50 v/v MeOH and Formic 
acid, resulted in obtaining a MOF sample with NO release to be 1.88±0.04 
μmol/g. This low result obtained for NO release can be elucidated by the fact of 
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partial MOF structure collapse during the encapsulation, or affecting the amine 
groups on the linker that were not able to support the NO entrapment. 
UiO66 ability to retain and then release NO is rather poor, and this can be 
explained by the fact that there are no open sites for NO to form a bond. The MOF 
with encapsulated 5-FU shows almost the same results for NO release as the 
quantity of 5-FU in the pores is low. This is then dramatically different if the 
encapsulation of 5-FU is done in 50/50 v/v solution MeOH/Formic acid saturated 
with fluorouracil. Here, the main vehicle for NO capturing is 5-FU itself. The 
amount of the released NO measured for UiO66 is 0.013 μmol/g and goes up to 
0.45 μmol/g for UiO66 encapsulated with 5-FU in MeOH/Formic acid solution. 
This is a 400-fold increase. The NO release curves are depicted in Figure 7-5.  
The evidence shows that cisplatin increases release of NO in UiO66 but not in 
CPO-27, we can thus conclude that open metal sites play an important role in the 
NO storage and release mechanism. We can conclude that by introducing cisplatin 
in the pores of the MOF material without any open metal sites, the NO release 
will be enhanced when compared with the pure MOF e.g. UiO66. 
 
Figure 7-5 Total NO released from UiO66, pure (red), encapsulated with 5FU 
in MeOH (green) and encapsulated with 5FU in 50/50 v/v MeOH/Formic A. 
(purple). 
For clarity, as the amount of NO released from UiO66 encapsulated with cisplatin 
was measured to be much higher than from the unloaded MOF, this is depicted on 
the separate plot, see Figure 7-6. Again, the reason behind is assigned to the 
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presence of cisplatin in the pores of the material and the interaction between NO 
and amine groups of cisplatin. The amount of nitric oxide measured was  
16.5±4.2 μmol/g which is almost as high as the results obtained for UiO66-NH2 
encapsulated with cisplatin and can be attributed to the presence of cisplatin. 
 
Figure 7-6 Total NO released from UiO66 Zr MOF, encapsulated with 
cisplatin. 
This result shows that not only the MOF should necessarily show the ability to 
entrap NO but also there is a possibility for increased NO uptake if the 
encapsulated drug will have open sites. 
7.4. Conclusions 
The performed experiments were to investigate the possibilities for co-entrapment 
of two therapeutic agents, an anti-cancer drug and nitric oxide to capitalize on 
anti-tumor properties and to utilize NO anti- thrombotic properties. Thrombosis 
can be a threat during anti-cancer therapies offered to the patients. The results 
show that CPO-27 Ni has the superior properties when it comes to entrapping NO 
and then releasing it on demand. Ni in the MOF, however, is toxic and may be 
questioned for its choice. All of the anti cancer drugs and therapies, however, are 
far more toxic than Ni, and as such CPO-27 Ni application as a drug delivery 
system for cisplatin and 5-FU with the entrapped nitric oxide can be justified. 
CPO-27 Mg performs worse than CPO-27 Ni in terms of its entrapment ability for 
nitric oxide, but on the other hand, its toxicity is very low. Still, CPO-27 Mg 
loaded with cisplatin seems to release less nitric oxide, which is due to the fact 
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that the open metal sites were occupied by the electron pair from the amine group 
coming from cisplatin blocking it to accessible by nitric oxide. This is also the 
mechanism for CPO-27 Ni. UiO66, when encapsulated with cisplatin shows a 
pronounced surge in the amount of a released nitric oxide thanks to its interaction 
with amine groups on the anti-cancer drug. When unloaded, UiO66 ability to 
retain the gas in its structure was negligible. The quantities of cisplatin that could 
be stored and then released leading to the decreased viability of the cancer cells 
were quite substantial. This would make UiO66 the best candidate for the 
multifunctional drug delivery systems. As for UiO66-NH2, the nitric oxide uptake 
is still the same for the MOF with a conjugated prodrug, where cytotoxicity can 
be switched on demand when in the proximity of tumour environment. The 
conjugated moiety did not completely block the amine group interaction but also 
offered the amine groups on the prodrug to compensate for the amine groups on 
the linker engaged in the peptide bond and hence inactive for nitric oxide 
capturing. The unloaded MOF has the ability to entrap nitric oxide, to contrary to 
its non-functionalised form UiO66 thanks to the amine groups able to interact 
with nitrogen of nitric oxide. 
To conclude, MOFs with big pores and cages could make excellent drug delivery 
systems for anti-cancer drugs as they can be host drug molecules. The nitric oxide 
loading of these MOFs, which do not necessary offer metal open sites, can be 
increased and optimized by encapsulation of drugs that could offer open sites for 
nitric oxide to bind to and then be released in a controlled process. This can be 
observed for cisplatin-loaded UiO66, in which the released amount of nitric oxide 
measured is 16.5 μmol/g and is by far 1000 times higher than for the unloaded 
MOF. 
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Chapter 8. Further Work 
The research depicted in this thesis covers a wide spectrum of potential biological 
applications where metal organic frameworks could be successfully implemented. 
This includes the investigation of possible MOF applications in medicine as drug 
delivery systems for two anti-cancer drugs: cisplatin and fluorouracil as well as 
new adjuvants for novel vaccines. It is worth noting that many aspects of 
chemistry and biochemistry have been addressed ranging from material synthesis, 
characterisation to immune response testing and conducting the viability studies in 
order to assess chosen MOFs in terms of their efficiency. 
Not every aspect could have been addressed in this thesis due to the time 
constraints as well as the wide variety of MOF structures available and thus there 
is a potential for continuation of the work described. 
First of all, for cisplatin encapsulation, some other MOFs with huge pores and 
ideally without unsaturated metal sites, as it has been observed that this feature 
prevents the cisplatin cargo from being released with the drug remaining trapped 
in the pores. The other MOFs could be tested for their loading and release of 
cisplatin e.g. MIL-1251. The interesting idea recently being researched is to 
encapsulate cisplatin in a protein called ferritin in one of the nanocages as it is 
biocompatible and capable of cisplatin delivery to targeted sites2. As a potential 
candidate for prodrug conjugation platform MIL-53-NH2, MIL-101-NH2 and 
MIL-125-NH2 could be good candidates due to their availability of amine group 
in the structure. Also, in order to double the amount of cargo, a synthesis of a 
MOF structure with 2,5-diaminoterephthalic acid as a linker would be suitable, 
e.g. UiO66-(NH2)23. Once the prodrug of cisplatin will be incorporated in the 
MOF structure, it might be used for co-encapsulation of 5-Fluorouracil, creating a 
multifunctional drug delivery system. Cisplatin prodrug would not take up the 
space in the material voids, anchored to the amine functional groups and allowing 
for such a double co-encapsulation.  
The cytotoxicity tests to assess the efficacy of the prepared formulations, were 
only performed on A549 lung cancer cells, and THP-1 human leukaemia and 
author’s wish would be to perform some more tests on HeLa cell line (cervical 
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cancer cells) for cisplatin and colorectal cancer e.g. HCA-7 Colony 29 for  
5-Fluorouracil.  
Some other drugs like heparin could be loaded in the MOF structure, ideally in the 
MOF with unsaturated metal sites to allow for a nitric oxide co-loading to top up 
the potential release of antithrombotic cargo available. The MOF/heparin/NO 
formulation could be used as a patch offered to women on birth control pills as it 
is commonly known that it poses a higher risk of platelets clotting that may lead 
to heart attack, especially for those who smoke. The risk of arterial thrombosis 
was 1.6 times higher for women on oral contraceptive pill when compared to 
those not using this form of birth control4. 
In case of Fluorouracil encapsulation, the further investigation may follow to 
optimise the encapsulation route, which would require a set-up of other 
encapsulation system, different to the one used in this thesis (MeOH or 
MeOH/formic acid) that would increase 5-FU solubility without compromising 
the MOF structure during encapsulation. Other MOFs as candidates for these 
encapsulation routes should be tested, e.g. MIL materials used for ibuprofen 
loading – MIL-53-Fe with ca. 20% wt, and MIL-101-Fe with ca. 1.4 g ibuprofen/g 
of material released after 6 days, or MIL-88 with its impressive pore sizes of 6 to 
16 Å and showing a breathing effect of 85-230% in volume5.  
New routes are being followed to investigate other options for drug delivery 
systems, just to name a few: electrospun - nanofibers obtained in an 
electrospinning process6 containing 5-Fluorouracil7 or 3D printing for 
personalised medicine8, or different proteins and antibodies9. With the amount of 
research conducted into various potential drug delivery systems, MOFs may not 
be seen as the first league candidates due to the fact that there is an issue with 
biocompatibility and excretion from the human body. 
From the perspective of this thesis, the most hopes still lie in taking further steps 
to explore the efficiency of MOFs as novel adjuvants, as this area has never been 
researched before and for the first time it has been disclosed in this thesis. Metal 
oxides10, 11 and double layered hydroxides (LDHs)12 proved to have a potential to 
outperform alum in their ability to stimulate cells to secrete elevated concentration 
of cytokines. It is worth mentioning that still little is known about the mechanism 
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behind the immunisation by adjuvants and it is not yet fully understood13, hence 
researchers perform screening of many materials for their immune response 
inducing properties without knowing what triggers this mechanism.  
In the group of tested MOFs, some showed great potential in inducing the immune 
response, these were Al-containing MOFs. Hence, it is recommended to undertake 
some further studies in vitro, investigating the levels of other cytokines being 
secreted and also expression of the receptors on dendritic cells and finally a move 
towards in vivo testing should be made. Some other MOFs like CPO-27: Mg, Ni, 
Co and Zn were also qualified as potential candidates, and the tests are on-going 
but not in the scope of this thesis. The next steps would involve a set-up of some 
immuno-assays for MOFs having in their structure different metal ions and the 
same linker, and then performing the same experiment for MOFs with the same 
metal ion in the building unit, it was done in the case of Al, and different linkers. 
The data collection and analysis would allow for modelling of properties, which 
would lead to defining  a model for a super-adjuvant.  
This work however, would require a tandem of skills of an immunologist and a 
chemist in order to perform necessary synthesis, powder characterisation and 
investigation of biological properties – cytokines secretion, surface cell receptors 
and in vivo response and these involving a design of immuno-assays aided by 
FACS, ELISA, and also multiplex Luminex that allows to simultaneously detect 
and quantify the concentration of multiple cytokines in just one experiment, which 
is a great help to speed up the screening process.  Author would see that help from 
a mathematician would also be necessary in order to run some computer 
simulations and build a model. 
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List of Abbreviations used in this Thesis 
MOF metal-organic frameworks 
UiO66 Universitetet i Oslo (University of Oslo) 
CPO Coordination polymer of Oslo 
5-FU 5-Fluorouracil 
ELISA enzyme-linked immunosorbent assay 
PMA phorbol myristate acetate 
HRP horseradish peroxidase 
TMB 3,3′,5,5′-Tetramethylbenzidine 
IL-6 interleukin 6 (cytokine) 
TNF-α tumor necrosis factor (cytokine) 
NO nitric oxide 
XRD X-ray diffraction 
PXRD powder X-ray diffraction 
FTIR Fourier Transform Infra red 
NMR Nuclear Magnetic Resonance 
THF Tetrahydrofuran 
DMF Dimethylformamide 
BET Brunauer, Emmett and Teller (surface area) 
THP-1 cancer cell line human leukemia 
A549 cancer cell line lung cancer 
HPLC High-pressure Liquid Chromatography 
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Appendix 1 ChekCELL cell refinement program 
Refinements performed on MOF cells, that were used in the 5-Fluorouracil 
encapsulation in order to monitor the MOF “breathing effect”: CPO Ni, CPO Mg, 
UiO66, UiO66-NH2. 
The conclusions derived from these cell refinements are described in Chapter 5. 
CHEKCELL is a modified version of CELREF for analysing the solutions given by the 
CRYSFIREprogram. The cell parameters refinement program from powder diffraction 
diagram was used, which is not as powerful as GSAS, however allows for cell 
refinement. The program was developed at the Laboratoire des Matériaux et du Génie 
Physique Ecole Nationale Supérieure de Physique de Grenoble (INPG) Domaine 
Universitaire by Jean Laugier and Bernard Bochu.       
The below results are the reports from the program with the refined parameters of the 
cell. 
5-Fluorouracil in UiO66 (encapsulation v/v 50/50 Formic 
acid/Methanol CELREF Version 3.  2/22/2016 6:13:32 PM 
-----------------------------------------------------------
----------- 
 
 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190   9.2200  12.6600  12.6700  89.70  43.90  
98.60   1000.08 
   0      0         1        1        1        1      1      
1 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    0   -1    1    13.3463      13.3463    13.4167    -
0.0704 
    2   0    2    19.5757      19.5757    19.4773     
0.0984 
    0   1    2    20.6263      20.6263    20.5770     
0.0493 
    2    1    2    21.6851      21.6851    21.7758    -
155 
 
0.0907 
   -1    2    1    24.4027      24.4027    24.3178     
0.0849 
    1    2    3    25.8509      25.8509    25.7929     
0.0580 
   -1    3    1    27.9826      27.9826    28.0211    -
0.0385 
    2    0    0    28.7143      28.7143    28.6356     
0.0787 
   -1   -2    1    29.7118      29.7118    29.6211     
0.0907 
    1   -3    3    32.7695      32.7695    32.7972    -
0.0277 
   -2    2    1    36.6889      36.6889    36.7654    -
0.0765 
    2    1    5    36.8779      36.8779    36.8898    -
0.0119 
    3    3    4    39.7359      39.7359    39.7325     
0.0034 
    3   -3    5    41.6667      41.6667    41.6773    -
0.0106 
    4   -2    2    44.5520      44.5520    44.5180     
0.0340 
    4    1    6    45.7554      45.7554    45.7207     
0.0347 
    3    3    1    46.8101      46.8101    46.7944     
0.0157 
   -1   -5    1    47.5812      47.5812    47.6173    -
0.0361 
    5   -1    5    49.4351      49.4351    49.4305     
0.0046 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.0694 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.0574 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190   9.2170  12.6874  12.6627  89.74  43.87  
98.67   1000.51 
  0.0000 0.00000   0.0276   0.0318   0.0348   0.292  0.083  
0.185    5.295 
 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    0   -1    1    13.3463      13.3463    13.4201    -
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0.0738 
    2    0    2    19.5757      19.5757    19.4873     
0.0884 
    0    1    2    20.6263      20.6263    20.5960     
0.0303 
    2    1    2    21.6851      21.6851    21.7866    -
0.1015 
   -1    2    1    24.4027      24.4027    24.3212     
0.0815 
    1    2    3    25.8509      25.8509    25.7979     
0.0530 
   -1    3    1    27.9826      27.9826    28.0019    -
0.0193 
    2    0    0    28.7143      28.7143    28.6695     
0.0448 
   -1   -2    1    29.7118      29.7118    29.6381     
0.0737 
    1   -3    3    32.7695      32.7695    32.7795    -
0.0100 
   -2    2    1    36.6889      36.6889    36.7923    -
0.1034 
    2    1    5    36.8779      36.8779    36.9187    -
0.0408 
    3    3    4    39.7359      39.7359    39.7344     
0.0015 
    3   -3    5    41.6667      41.6667    41.6561     
0.0106 
    4   -2    2    44.5520      44.5520    44.5360     
0.0160 
    4    1    6    45.7554      45.7554    45.7443     
0.0111 
    3    3    1    46.8101      46.8101    46.8211    -
0.0110 
   -1   -5    1    47.5812      47.5812    47.5869    -
0.0057 
    5   -1    5    49.4351      49.4351    49.4479    -
0.0128 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.0650 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.0538 
 
CELREF Version 3.  2/22/2016 5:34:55 PM 
-----------------------------------------------------------
----------- 
 
CPO Mg MeOH peaks omitted 5FU.dif 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
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  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  25.9997  25.9997   6.7597  90.00  90.00 
120.00   3957.26 
   0      0         1        0        1        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.6070       6.6070     6.7998    -
0.1928 
    3    0    0    11.6520      11.6520    11.7915    -
0.1395 
    1    0    1    13.6740      13.6740    13.6780    -
0.0040 
    0    2    1    15.0890      15.0890    15.2894    -
0.2004 
    2    1    1    16.6520      16.6520    16.7499    -
0.0979 
    1    3    1    19.1960      19.1960    19.3514    -
0.1554 
    3    3    0    20.3570      20.3570    20.4965    -
0.1395 
    3    2    1    21.3840      21.3840    21.6530    -
0.2690 
    5    2    0    24.5090      24.5090    24.6933    -
0.1843 
    1    2    2    28.1700      28.1700    28.4147    -
0.2447 
    7    1    0    29.6880      29.6880    29.9624    -
0.2744 
    7    1    0    29.8210      29.8210    29.9624    -
0.1414 
    5    4    1    33.7500      33.7500    33.8026    -
0.0526 
    9    0    0    35.7140      35.7140    35.8962    -
0.1822 
    8    2    0    36.3390      36.3390    36.5780    -
0.2390 
    0    0    3    39.8660      39.8660    40.0162    -
0.1502 
    6    5    1    40.4460      40.4460    40.4812    -
0.0352 
    6    6    0    41.6520      41.6520    41.6883    -
0.0363 
    5    7    1    43.7950      43.7950    44.0763    -
0.2813 
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Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.1892 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.1790 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  26.1296  26.1296   6.7966  90.00  90.00 
120.00   4018.73 
  0.0000 0.00000   0.0359   0.0000   0.0042   0.000  0.000  
0.000    6.058 
 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.6070       6.6070     6.7660    -
0.1590 
    3    0    0    11.6520      11.6520    11.7327    -
0.0807 
    1    0    1    13.6740      13.6740    13.6038     
0.0702 
    0    2    1    15.0890      15.0890    15.2077    -
0.1187 
    2    1    1    16.6520      16.6520    16.6612    -
0.0092 
    1    3    1    19.1960      19.1960    19.2502    -
0.0542 
    3    3    0    20.3570      20.3570    20.3935    -
0.0365 
    3    2    1    21.3840      21.3840    21.5403    -
0.1563 
    5    2    0    24.5090      24.5090    24.5686    -
0.0596 
    1    2    2    28.1700      28.1700    28.2589    -
0.0889 
    7    1    0    29.6880      29.6880    29.8101    -
0.1221 
    7    1    0    29.8210      29.8210    29.8101     
0.0109 
    5    4    1    33.7500      33.7500    33.6271     
0.1229 
    9    0    0    35.7140      35.7140    35.7118     
0.0022 
    8    2    0    36.3390      36.3390    36.3898    -
0.0508 
    0    0    3    39.8660      39.8660    39.7895     
0.0765 
    6    5    1    40.4460      40.4460    40.2692     
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0.1768 
    6    6    0    41.6520      41.6520    41.4715     
0.1805 
    5    7    1    43.7950      43.7950    43.8438    -
0.0488 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.1073 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.1015 
 
CELREF Version 3.  2/13/2016 12:26:05 PM 
-----------------------------------------------------------
----------- 
CPO Mg encapsulated in Formic acid/MeOH with 5-FU 
 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  25.9997  25.9997   6.7597  90.00  90.00 
120.00   3957.26 
   0      0         1        0        1        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    3    1    18.7054      18.7054    19.3514    -
0.6460 
    3    2    1    21.2946      21.2946    21.6530    -
0.3584 
    1    2    2    28.3482      28.3482    28.4147    -
0.0665 
    9    0    0    35.5357      35.5357    35.8962    -
0.3605 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.5832 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.4124 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  26.2902  26.2902   6.8214  90.00  90.00 
120.00   4083.15 
  0.0000 0.00000   0.2539   0.0000   0.0553   0.000  0.000  
0.000   51.474 
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    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    3    1    18.7054      18.7054    19.1536    -
0.4482 
    3    2    1    21.2946      21.2946    21.4270    -
0.1324 
    1    2    2    28.3482      28.3482    28.1443     
0.2039 
    9    0    0    35.5357      35.5357    35.4862     
0.0495 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.3622 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.2561 
 
CELREF Version 3.  2/22/2016 5:06:57 PM 
-----------------------------------------------------------
----------- 
 
CPO Ni encapsulation in Formic acid/MeOH with 5-FU 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  25.9279  25.9279   6.6881  90.00  90.00 
120.00   3893.75 
   0      0         1        0        1        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.8816       6.8816     6.8186     
0.0630 
    3    0    0    11.8766      11.8766    11.8242     
0.0524 
    2    2    0    13.7179      13.7179    13.6616     
0.0563 
    0    2    1    15.4925      15.4925    15.4219     
0.0706 
    2    1    1    16.9236      16.9236    16.8788     
0.0448 
    4    1    0    18.1153      18.1153    18.1050     
0.0103 
    1    3    1    19.5374      19.5374    19.4771     
0.0603 
    3    2    1    21.7841      21.7841    21.7779     
0.0062 
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    0    5    1    23.8398      23.8398    23.8676    -
0.0278 
    2    4    1    24.8576      24.8576    24.8502     
0.0074 
    5    1    1    25.8196      25.8196    25.7977     
0.0219 
    4    3    1    27.6024      27.6024    27.6016     
0.0008 
    1    2    2    28.7286      28.7286    28.6941     
0.0345 
    7    1    0    30.0520      30.0520    30.0474     
0.0046 
    6    2    1    31.7176      31.7176    31.6985     
0.0191 
    4    2    2    34.0606      34.0606    34.1385    -
0.0779 
    1    5    2    34.8541      34.8541    34.8540     
0.0001 
    2    7    1    35.3250      35.3250    35.3672    -
0.0422 
    4    6    1    37.4271      37.4271    37.4164     
0.0107 
    0    7    2    38.9210      38.9210    38.9065     
0.0145 
    4    5    2    41.4015      41.4015    41.4200    -
0.0185 
    3    0    3    42.3006      42.3006    42.3023    -
0.0017 
    7    2    2    42.6224      42.6224    42.6307    -
0.0083 
    9    2    1    43.0421      43.0421    43.0647    -
0.0226 
    1    8    2    43.7618      43.7618    43.8143    -
0.0525 
    6    4    2    44.3946      44.3946    44.3966    -
0.0020 
    2   10    1    47.1140      47.1140    47.0726     
0.0414 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.0385 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.0371 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  25.9234  25.9234   6.6894  90.00  90.00 
120.00   3893.16 
  0.0000 0.00000   0.0157   0.0000   0.0009   0.000  0.000  
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0.000    2.423 
 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.8816       6.8816     6.8198     
0.0618 
    3    0    0    11.8766      11.8766    11.8263     
0.0503 
    2    2    0    13.7179      13.7179    13.6640     
0.0539 
    0    2    1    15.4925      15.4925    15.4203     
0.0722 
    2    1    1    16.9236      16.9236    16.8779     
0.0457 
    4    1    0    18.1153      18.1153    18.1082     
0.0071 
    1    3    1    19.5374      19.5374    19.4771     
0.0603 
    3    2    1    21.7841      21.7841    21.7787     
0.0054 
    0    5    1    23.8398      23.8398    23.8691    -
0.0293 
    2    4    1    24.8576      24.8576    24.8519     
0.0057 
    5    1    1    25.8196      25.8196    25.7997     
0.0199 
    4    3    1    27.6024      27.6024    27.6041    -
0.0017 
    1    2    2    28.7286      28.7286    28.6898     
0.0388 
    7    1    0    30.0520      30.0520    30.0527    -
0.0007 
    6    2    1    31.7176      31.7176    31.7020     
0.0156 
    4    2    2    34.0606      34.0606    34.1365    -
0.0759 
    1    5    2    34.8541      34.8541    34.8524     
0.0017 
    2    7    1    35.3250      35.3250    35.3716    -
0.0466 
    4    6    1    37.4271      37.4271    37.4213     
0.0058 
    0    7    2    38.9210      38.9210    38.9063     
0.0147 
    4    5    2    41.4015      41.4015    41.4207    -
0.0192 
    3    0    3    42.3006      42.3006    42.2949     
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0.0057 
    7    2    2    42.6224      42.6224    42.6318    -
0.0094 
    9    2    1    43.0421      43.0421    43.0710    -
0.0289 
    1    8    2    43.7618      43.7618    43.8158    -
0.0540 
    6    4    2    44.3946      44.3946    44.3982    -
0.0036 
    2   10    1    47.1140      47.1140    47.0798     
0.0342 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.0384 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.0370 
 
CELREF Version 3.  2/22/2016 5:20:16 PM 
-----------------------------------------------------------
----------- 
 
CPO Ni encapsulated in MeOH with 5-FU, indexed omitted 5FU 
peaks.lst 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  25.9279  25.9279   6.6881  90.00  90.00 
120.00   3893.75 
   0      0         1        0        1        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.5110       6.5110     6.8186    -
0.3076 
    3    0    0    11.2550      11.2550    11.8242    -
0.5692 
    0    2    1    15.0500      15.0500    15.4219    -
0.3719 
    4    1    0    17.7730      17.7730    18.1050    -
0.3320 
    1    3    1    19.1340      19.1340    19.4771    -
0.3431 
    3    2    1    21.8570      21.8570    21.7779     
0.0791 
    2    4    1    24.5380      24.5380    24.8502    -
0.3122 
    5    1    1    25.4460      25.4460    25.7977    -
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0.3517 
    1    2    2    28.2920      28.2920    28.6941    -
0.4021 
    1    6    1    28.8290      28.8290    29.3029    -
0.4739 
    7    1    0    29.4480      29.4480    30.0474    -
0.5994 
    3    1    2    30.4380      30.4380    30.3393     
0.0987 
    3    1    2    30.4380      30.4380    30.3393     
0.0987 
    0    4    2    31.1390      31.1390    31.1323     
0.0067 
    5    5    0    34.2330      34.2330    34.5963    -
0.3633 
    1    5    2    34.4390      34.4390    34.8540    -
0.4150 
    8    2    0    36.4190      36.4190    36.6829    -
0.2639 
    1    1    3    40.7100      40.7100    41.0837    -
0.3737 
    6    6    0    41.6170      41.6170    41.8091    -
0.1921 
    7    2    2    42.3180      42.3180    42.6307    -
0.3127 
    9    2    1    42.9790      42.9790    43.0647    -
0.0857 
    3    7    2    44.8760      44.8760    44.9729    -
0.0969 
    3    3    3    45.7620      45.7620    45.8000    -
0.0380 
    0   11    1    46.3950      46.3950    46.5166    -
0.1216 
    7    7    0    49.1140      49.1140    49.2001    -
0.0861 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.3274 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.3141 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  26.1189  26.1189   6.7130  90.00  90.00 
120.00   3966.03 
  0.0000 0.00000   0.0858   0.0000   0.0042   0.000  0.000  
0.000   13.264 
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    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    1    1    0     6.5110       6.5110     6.7687    -
0.2577 
    3    0    0    11.2550      11.2550    11.7375    -
0.4825 
    0    2    1    15.0500      15.0500    15.3497    -
0.2997 
    4    1    0    17.7730      17.7730    17.9715    -
0.1985 
    1    3    1    19.1340      19.1340    19.3662    -
0.2322 
    3    2    1    21.8570      21.8570    21.6464     
0.2106 
    2    4    1    24.5380      24.5380    24.6918    -
0.1538 
    5    1    1    25.4460      25.4460    25.6311    -
0.1851 
    1    2    2    28.2920      28.2920    28.5713    -
0.2793 
    1    6    1    28.8290      28.8290    29.1064    -
0.2774 
    7    1    0    29.4480      29.4480    29.8226    -
0.3746 
    3    1    2    30.4380      30.4380    30.1991     
0.2389 
    3    1    2    30.4380      30.4380    30.1991     
0.2389 
    0    4    2    31.1390      31.1390    30.9838     
0.1552 
    5    5    0    34.2330      34.2330    34.3354    -
0.1024 
    1    5    2    34.4390      34.4390    34.6679    -
0.2289 
    8    2    0    36.4190      36.4190    36.4052     
0.0138 
    1    1    3    40.7100      40.7100    40.9201    -
0.2101 
    6    6    0    41.6170      41.6170    41.4893     
0.1277 
    7    2    2    42.3180      42.3180    42.3688    -
0.0508 
    9    2    1    42.9790      42.9790    42.7504     
0.2286 
    3    7    2    44.8760      44.8760    44.6883     
0.1877 
    3    3    3    45.7620      45.7620    45.5839     
0.1781 
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    0   11    1    46.3950      46.3950    46.1719     
0.2231 
    7    7    0    49.1140      49.1140    48.8168     
0.2972 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.2469 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.2368 
 
CELREF Version 3.  2/5/2016 3:27:49 PM 
-----------------------------------------------------------
----------- 
UiO66 encapsulation in Formic acid/MeOH with 5-FU 
indexed peaks UiO66 FA MeOH 5FU eliminated.lst 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  20.7089  20.7089  20.7089  90.00  90.00  
90.00   8881.19 
   0      0         1        0        0        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    0    0    4    17.4420      17.4420    17.1277     
0.3143 
    3    1    3    18.5750      18.5750    18.6777    -
0.1027 
    2    2    4    20.8860      20.8860    21.0167    -
0.1307 
    1    1    5    22.3820      22.3820    22.3075     
0.0745 
    1    3    5    25.2820      25.2820    25.4467    -
0.1647 
    2    4    4    25.7800      25.7800    25.8138    -
0.0338 
    3    3    5    28.3180      28.3180    28.2597     
0.0583 
    4    4    4    29.8140      29.8140    29.8937    -
0.0797 
    7    3    3    35.5690      35.5690    35.4831     
0.0859 
    5    1    7    37.6530      37.6530    37.6167     
0.0363 
    2    6    6    38.0610      38.0610    37.8761     
0.1849 
    4    0    8    38.9680      38.9680    38.8991     
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0.0689 
    6    4    6    40.7350      40.7350    40.8803    -
0.1453 
    3    1    9    41.4600      41.4600    41.6031    -
0.1431 
    6    6    6    45.4480      45.4480    45.5215    -
0.0735 
    0    4   10    47.3510      47.3510    47.2761     
0.0749 
    4    2   10    48.2120      48.2120    48.1349     
0.0771 
    0    8    8    49.7990      49.7990    49.8190    -
0.0200 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.1275 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.1240 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  20.7156  20.7156  20.7156  90.00  90.00  
90.00   8889.75 
  0.0000 0.00000   0.0622   0.0000   0.0000   0.000  0.000  
0.000   26.709 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    0    0    4    17.4420      17.4420    17.1222     
0.3198 
    3    1    3    18.5750      18.5750    18.6716    -
0.0966 
    2    2    4    20.8860      20.8860    21.0099    -
0.1239 
    1    1    5    22.3820      22.3820    22.3002     
0.0818 
    1    3    5    25.2820      25.2820    25.4384    -
0.1564 
    2    4    4    25.7800      25.7800    25.8054    -
0.0254 
    3    3    5    28.3180      28.3180    28.2504     
0.0676 
    4    4    4    29.8140      29.8140    29.8839    -
0.0699 
    7    3    3    35.5690      35.5690    35.4713     
0.0977 
    5    1    7    37.6530      37.6530    37.6042     
0.0488 
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    2    6    6    38.0610      38.0610    37.8635     
0.1975 
    4    0    8    38.9680      38.9680    38.8861     
0.0819 
    6    4    6    40.7350      40.7350    40.8666    -
0.1316 
    3    1    9    41.4600      41.4600    41.5891    -
0.1291 
    6    6    6    45.4480      45.4480    45.5061    -
0.0581 
    0    4   10    47.3510      47.3510    47.2600     
0.0910 
    4    2   10    48.2120      48.2120    48.1185     
0.0935 
    0    8    8    49.7990      49.7990    49.8019    -
0.0029 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.1284 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.1248 
 
CELREF Version 3.  2/22/2016 5:47:08 PM 
--------------------------------------------------------- 
UiO66 encapsulation in MeOH with 5-FU 
peaks_uio66_MeOH_eliminated 5FU.lst 
 
Initial values    : (Refinement keys on 2nd line) 
--------------    : 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  20.7089  20.7089  20.7089  90.00  90.00  
90.00   8881.19 
   0      0         1        0        0        0      0      
0 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
 
    0    0    2     8.2245       8.2245     8.5399    -
0.3154 
    0    2    2    11.8297      11.8297    12.0885    -
0.2588 
    2    2    2    14.5786      14.5786    14.8192    -
0.2406 
    0    0    4    17.0572      17.0572    17.1277    -
0.0705 
    3    1    3    18.3640      18.3640    18.6777    -
0.3137 
    0    2    4    18.9949      18.9949    19.1674    -
0.1725 
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    1    3    5    25.3490      25.3490    25.4467    -
0.0977 
    2    4    4    25.6645      25.6645    25.8138    -
0.1493 
    2    4    6    32.1087      32.1087    32.3520    -
0.2433 
    1    3    7    33.2804      33.2804    33.2317     
0.0487 
    6    0    6    36.5701      36.5701    36.8291    -
0.2590 
 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.2276 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.2170 
 
Final values      : (Standard errors on 2nd line) 
------------ 
  Zero    Lambda      a       b       c      alpha  beta   
gamma   volume 
   0.000 1.54190  20.8825  20.8825  20.8825  90.00  90.00  
90.00   9106.44 
  0.0000 0.00000   0.1552   0.0000   0.0000   0.000  0.000  
0.000   67.686 
 
    H    K    L    2Th(obs) 2Th_obs-shift 2Th(Calc)    
diff. 
    0    0    2     8.2245       8.2245     8.4688    -
0.2443 
    0    2    2    11.8297      11.8297    11.9876    -
0.1579 
    2    2    2    14.5786      14.5786    14.6953    -
0.1167 
    0    0    4    17.0572      17.0572    16.9843     
0.0729 
    3    1    3    18.3640      18.3640    18.5210    -
0.1570 
    0    2    4    18.9949      18.9949    19.0066    -
0.0117 
    1    3    5    25.3490      25.3490    25.2316     
0.1174 
    2    4    4    25.6645      25.6645    25.5955     
0.0690 
    2    4    6    32.1087      32.1087    32.0757     
0.0330 
    1    3    7    33.2804      33.2804    32.9475     
0.3329 
    6    0    6    36.5701      36.5701    36.5120     
0.0581 
Sqrt(Sum(2Th O-C)**2)/(Nref-Npar)) : 0.1619 
Sqrt(Sum(2Th O-C)**2)/Nref       ) : 0.1544 
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Appendix 2 X-ray pattern of 5-Fluorouracil/Chapter 5 
X-ray diffraction pattern of 5-FU, generated from the CIF file, Crystal maker. 
{Hulme et al., JACS, 2005, 127, 1116} 
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Appendix 3 X-ray patterns of Al-MOFs/Adjuvants/Chapter 6 
X-ray diffraction patterns of the Al-MOFs that were synthesised for the Adjuvant project. 
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